

# Cancer

PRESENTED BY AMERICA'S PHARMACEUTICAL RESEARCH COMPANIES

## More Than 800 Medicines and Vaccines in Testing Offer Hope in the Fight Against Cancer

Few things cause patients more fear and uncertainty than a cancer diagnosis. But today—because of a steady stream of new and improved medicines and treatments—cancer increasingly can be managed and even beaten. President Obama has called for a cancer cure in our lifetime, patients and their families are looking for more and better treatments, and America's pharmaceutical research and biotechnology companies are responding.


Pharmaceutical researchers are now working on 861 medicines for cancer. Many are high-tech weapons to fight the disease, while some involve innovative research on using existing medicines in new ways.

The medicines in development—all in either clinical trials or under Food and Drug Administration review—include 122 for lung cancer, the leading cause of cancer death in the United States; 106 for breast cancer, which is expected to strike more than 180,000 American women each year; 103 for prostate cancer, which is expected to kill more than 28,000 American men each year; and 70 for colorectal cancer, the third most common cancer in both men and women in this country. Additional medicines target brain cancer, kidney cancer, leukemia, ovarian cancer, pancreatic cancer, skin cancer, and others. In addition, companies are working on medicines to improve the quality of life for cancer patients.

This commitment to patients and research is at the core of the remarkable progress made in the past decade fighting cancer that has led to declines in both cancer cases and cancer deaths. Death rates for eight of the top 10 cancers remained level or declined during the 1990s, according to a Journal of the National Cancer Institute report.

America's pharmaceutical research companies are working on many new cutting edge approaches to fight cancer. They include:

- A medicine that inhibits production of a protein that may interfere with the effectiveness of chemotherapy.
- A drug that delivers a synthetic version of a substance derived from scorpions directly to brain tumor cells.
- A medicine designed to induce a powerful immune response to melanoma.

**MEDICINES IN DEVELOPMENT FOR CANCER\***

\*Some medicines are listed in more than one category.

- A potential first-line treatment (meaning it's given to patients before any other treatment) and first-in-class medicine designed to target specific cancer cells and kill them, then activate the patient's general immune system to destroy any remaining cancer cells.
- One therapy in development uses new nanotechnology that enhances the delivery of medicine to the patient, overcoming obstacles in existing treatments.

Despite progress, cancer remains the second leading cause of death by disease in the United States, exceeded only by heart disease. In 2008, some 565,650 Americans were expected to die of cancer—more than 1,500 people a day. The hundreds of new medicines to treat cancer now being developed by the pharmaceutical research industry demonstrate our commitment to meeting patient needs. They are our best hope for stemming the toll of cancer-related deaths.

Billy Tauzin  
President and CEO  
PhRMA

# Medicines in Development for Cancer

## BLADDER CANCER

Product Name	Sponsor	Indication	Development Status*
<b>Advexin</b> <sup>®</sup> contusugene ladenovec	Introgen Therapeutics <i>Austin, TX</i>	(see also brain, breast, head/neck, lung, ovarian, prostate, stomach)	Phase I (512) 708-9310
BC-819	BioCancell Therapeutics <i>Jerusalem, Israel</i>		Phase II
belinostat	Topo Target USA <i>Rockaway, NJ</i>	combination therapy (see also colorectal, leukemia, liver, lung, lymphoma, ovarian)	Phase II (973) 895-6900
CDX-1307	Celldex Therapeutics <i>Needham, MA</i>	(see also breast, colorectal, ovarian, pancreatic)	Phase I (781) 433-0771
<b>Celebrex</b> <sup>®</sup> celecoxib	Pfizer <i>New York, NY</i>	(see also prostate)	Phase III (860) 732-5156
CG0070	Cell Genesys <i>South San Francisco, CA</i> Novartis Pharmaceuticals <i>East Hanover, NJ</i>		Phase I (650) 266-3000 (888) 669-6682
<b>Chemophase</b> <sup>™</sup> hyaluronidase	Halozyme Therapeutics <i>San Diego, CA</i>	superficial bladder cancer	Phase I/II (858) 794-8889
<b>EOquin</b> <sup>®</sup> apaziquone	Spectrum Pharmaceuticals <i>Irvine, CA</i>		Phase III (949) 788-6700
<b>Erbix</b> <sup>®</sup> cetuximab	Bristol-Myers Squibb <i>Princeton, NJ</i> Eli Lilly <i>Indianapolis, IN</i> ImClone Systems <i>New York, NY</i>	(see also colorectal, head/neck, lung, prostate, stomach)	Phase II (212) 546-4000 (800) 545-5979 (212) 645-1405
<b>Hexiv</b> <sup>®</sup> hexyl aminolevulinate	GE Healthcare <i>Waukesha, WI</i>	diagnostic imaging of bladder cancer	application submitted
<b>Iressa</b> <sup>®</sup> gefitinib	AstraZeneca <i>Wilmington, DE</i>	(see also brain)	Phase II (800) 236-9933
larotaxel (XRP9881)	sanofi-aventis <i>Bridgewater, NJ</i>	(see also pancreatic)	Phase III (800) 633-1810
<b>Levulan</b> <sup>®</sup> PD aminolevulinic acid	DUSA Pharmaceuticals <i>Wilmington, MA</i>	(see also cervical, colorectal, lung, stomach)	Phase I/II (978) 657-7500
MCC/HA	Bioniche Life Sciences <i>Belleville, Canada</i>	second-line therapy	Phase III (800) 265-5464
OGX-427	Oncogenex Pharmaceuticals <i>Bothell, WA</i>	(see also breast, lung, ovarian, prostate)	Phase I (425) 686-1500

\* For more information about a specific medicine in this report, please call the telephone number listed.

## BLADDER CANCER

Product Name	Sponsor	Indication	Development Status
polyphenon E	Polyphenon Pharma New York, NY	superficial bladder cancer (see also leukemia, prostate)	Phase II (212) 661-0578
pralatrexate (PDX)	Allos Therapeutics Westminster, CO	(see also lung, lymphoma)	Phase II (303) 426-6262
SCH-58500 (p53 gene therapy)	Schering-Plough Kenilworth, NJ	(see also head/neck, liver, lung, cancer-related)	Phase I (908) 298-4000
SCH-721015	Schering-Plough Kenilworth, NJ		Phase I (908) 298-4000
<b>Tarceva</b> <sup>®</sup> erlotinib	Genentech South San Francisco, CA OSI Pharmaceuticals Melville, NY	neoadjuvant therapy (see also brain, breast, colorectal, head/neck, liver, lung, other)	Phase II (650) 224-1000 (800) 572-1932
<b>Valstar</b> <sup>®</sup> valrubicin	Indevus Pharmaceuticals Lexington, MA		application submitted (781) 861-8444
VB-4845	Viventia Biotech Mississauga, Canada	(see also head/neck)	Phase II (905) 361-8686
vinflunine	Pierre Fabre Pharmaceuticals Parsippany, NJ	(see also breast)	Phase II (973) 898-1042

## BRAIN CANCER

Product Name	Sponsor	Indication	Development Status
3F8 mAb	United Therapeutics Silver Spring, MD	neuroblastoma, leptomeningeal cancer (see also other)	Phase II (301) 608-9292
8H9 mAb	United Therapeutics Silver Spring, MD		Phase I (301) 608-9292
<b>Advexin</b> <sup>®</sup> contusugene ladenovec	Introgen Therapeutics Austin, TX	glioblastoma (see also bladder, breast, head/neck, lung, ovarian, prostate, stomach)	Phase I (512) 708-9310
AEE788	Novartis Pharmaceuticals East Hanover, NJ	glioblastoma multiforme (see also solid tumors)	Phase I (888) 669-6682
AMG 102	Amgen Thousand Oaks, CA	glioma (see also colorectal, kidney, lung, stomach)	Phase II (805) 447-1000
ANG-1005	AngioChem Montreal, Canada	metastatic brain cancer, metastatic glioblastoma	Phase I (514) 788-7800
<b>Armala</b> <sup>™</sup> pazopanib	GlaxoSmithKline Rsch. Triangle Park, NC	glioma (see also breast, cervical, kidney, liver, lung, ovarian, sarcoma, other)	Phase II (888) 825-5249

# BRAIN CANCER

Product Name	Sponsor	Indication	Development Status
<b>Avastin®</b> bevacizumab	Genentech <i>South San Francisco, CA</i>	glioblastoma (see also colorectal, head/neck, kidney, liver, lung, lymphoma, multiple myeloma, ovarian, pancreatic, prostate, stomach, other)	application submitted (650) 225-1000
		metastatic brain cancer from NSCLC	Phase II (650) 225-1000
<b>Azedra™</b> iodine-labeled metaiodobenzyl- guanidine	Molecular Insight Pharmaceuticals <i>Cambridge, MA</i>	neuroblastoma in children (see also other)	Phase II (617) 492-5554
<b>Azixa™</b> (MPC-6827)	Myriad Pharmaceuticals <i>Salt Lake City, UT</i>	glioblastoma, metastatic brain cancer (see also skin)	Phase II (801) 584-3600
banoxantrone	Transcept Pharmaceuticals <i>Pt. Richmond, CA</i>	glioblastoma	Phase I/II (510) 215-3500
berubicin <b>(Orphan Drug)</b>	Reata Pharmaceuticals <i>Dallas, TX</i>	brain metastases, recurrent primary brain cancer	Phase II (972) 865-2200
		glioma	Phase I (972) 865-2200
BIBW 2992	Boehringer Ingelheim Pharmaceuticals <i>Ridgefield, CT</i>	glioblastoma (see also breast, head/neck, lung)	Phase I/II (800) 243-0127
BMS-844203 (VEGF inhibitor- adnectin)	Bristol-Myers Squibb <i>Princeton, NJ</i>	glioblastoma (see also solid tumors)	Phase II (212) 546-4000
BSI-201	BiPar Sciences <i>Brisbane, CA</i>	glioblastoma (see also breast, ovarian, other)	Phase I/II (650) 635-6050
CC-8490	Celgene <i>Summit, NJ</i>	glioblastoma	Phase II (908) 673-9000
CDX-110 <b>(Orphan Drug)</b>	Celldex Therapeutics <i>Needham, MA</i> Pfizer <i>New York, NY</i>	newly diagnosed glioblastoma (see also solid tumors)	Phase II/III (781) 433-0771 (860) 732-5156
cilengitide <b>(Orphan Drug)</b>	EMD Serono <i>Rockland, MA</i>	newly diagnosed and recurrent glioblastoma (see also lymphoma, prostate, solid tumors)	Phase II (800) 283-8088
cintredekin besudotox	NeoPharm <i>Lake Bluff, IL</i>	glioblastoma	Phase III (847) 887-0800
<b>Cotara™</b> mAb TNT-1 <b>(Orphan Drug)</b>	Peregrine Pharmaceuticals <i>Tustin, CA</i>	glioblastoma	Phase I (714) 508-6000
<b>DCVax®-Brain®</b> brain cancer vaccine <b>(Orphan Drug)</b>	Northwest Biotherapeutics <i>Bothell, WA</i>	glioblastoma	Phase II (425) 608-3000

## BRAIN CANCER

Product Name	Sponsor	Indication	Development Status
EMD 273063	EMD Serono <i>Rockland, MA</i>	neuroblastoma (see also skin)	Phase II (800) 283-8088
enzastaurin (LY317615)	Eli Lilly <i>Indianapolis, IN</i>	glioblastoma (combination therapy) (see also breast, colorectal, lymphoma, multiple myeloma, ovarian, prostate)	Phase II (800) 545-5979
G 207 <b>(Orphan Drug)</b>	MediGene <i>San Diego, CA</i>	glioma	Phase I (858) 586-2240
gimatecan <b>(Orphan Drug)</b>	Novartis Pharmaceuticals <i>East Hanover, NJ</i>	glioma (see also leukemia)	Phase I/II (888) 669-6682
<b>GliAtak™</b> gene therapy	Advantagene <i>Boston, MA</i> <i>San Diego, CA</i>		Phase I/II (617) 916-5445 (760) 943-8981
ICT-107 (cancer vaccine)	ImmunoCellular Therapeutics <i>Woodland Hills, CA</i>	glioblastoma	Phase I (818) 992-2907
<b>Iressa®</b> gefitinib	AstraZeneca <i>Wilmington, DE</i>	glioblastoma (see also bladder)	Phase II (800) 236-9933
<b>Karenitecin®</b> cositecan	BioNumerik Pharmaceuticals <i>San Antonio, TX</i>	(see also lung, ovarian, skin)	Phase II completed (210) 614-1701
KRX-0402	Keryx Biopharmaceuticals <i>New York, NY</i>	brain cancer, glioblastoma (combination therapy), glioma (combination therapy) (see also colorectal, kidney, multiple myeloma, sarcoma)	Phase II (212) 531-5965
laromustine (VNP 40101M)	Vion Pharmaceuticals <i>New Haven, CT</i>	glioma (combination therapy) (see also leukemia)	Phase II (203) 498-4210
<b>Lucanix®</b> belagenpumatucel-L	NovaRx <i>San Diego, CA</i>	glioma (see also lung)	Phase I (858) 552-8600
lucanthone	Spectrum Pharmaceuticals <i>Irvine, CA</i>	glioma (combination therapy)	Phase I (949) 788-6700
MLN8237	Millennium Pharmaceuticals <i>Cambridge, MA</i>	neuroblastoma (see also leukemia, lymphoma, solid tumors)	Phase I/II (800) 390-5663
<b>Neuradiab™</b> anti-tenascin mAb 81C6-I-131 <b>(Orphan Drug)</b>	Bradmer Pharmaceuticals <i>Louisville, KY</i>	glioblastoma	Phase III (502) 657-6038
<b>OncoGel®</b>	Protherics <i>Brentwood, TN</i>	glioblastoma (see also pancreatic, stomach)	Phase I/II (615) 327-1027
<b>Oncophage®</b> vitespan	Antigenics <i>New York, NY</i>	glioma (see also colorectal, kidney, pancreatic, skin, stomach)	Phase II (866) 805-8994
panobinostat	Novartis Pharmaceuticals <i>East Hanover, NJ</i>	glioma (see also breast, leukemia, lymphoma, prostate)	Phase I/II (888) 669-6682

## BRAIN CANCER

Product Name	Sponsor	Indication	Development Status
patupilone (EPO906)	Novartis Pharmaceuticals <i>East Hanover, NJ</i>	(see also breast, colorectal, liver, lung, ovarian)	Phase II (888) 669-6682
perifosine	AEterna Zentaris <i>Montreal, Canada</i> Keryx Biopharmaceuticals <i>New York, NY</i>	glioma (see also head/neck, kidney, lymphoma, multiple myeloma, ovarian, sarcoma)	Phase II (212) 531-5965
PRX-321 <b>(Orphan Drug)</b>	Protox Therapeutics <i>Vancouver, Canada</i>	glioblastoma (see also solid tumors)	Phase II (604) 688-0199
<b>Reolysin</b> <sup>®</sup> reovirus	Oncolytics Biotech <i>Calgary, Canada</i>	glioma (see also head/neck, lung, sarcoma, skin)	Phase I/II (403) 670-7377
sagopilone	Bayer HealthCare Pharmaceuticals <i>Wayne, NJ</i>	(see also breast, ovarian, prostate)	Phase II (888) 842-2937
SBG	Biotec Pharmacon <i>Tromsø, Norway</i>	neuroblastoma (pediatric) (combination therapy)	Phase I/II www.biotec.no
systemic hedgehog antagonist	Genentech <i>South San Francisco, CA</i>	(see also colorectal, ovarian, skin)	Phase I (650) 224-1000
talampanel	Teva Pharmaceuticals <i>North Wales, PA</i>	newly diagnosed glioblastoma	Phase II (215) 591-3000
tandutinib (MLN0518)	Millennium Pharmaceuticals <i>Cambridge, MA</i>	glioma (see also prostate)	Phase II (800) 390-5663
		glioblastoma	Phase I/II (800) 390-5663
<b>Tarceva</b> <sup>®</sup> erlotinib <b>(Orphan Drug)</b>	Genentech <i>South San Francisco, CA</i> OSI Pharmaceuticals <i>Melville, NY</i>	glioblastoma (see also bladder, breast, colorectal, head/neck, liver, lung, other)	Phase II (650) 225-1000 (800) 572-1932
terameprocol	Erimos Pharmaceuticals <i>Houston, TX</i>	glioma (see also cervical, head/neck)	Phase I/II (713) 541-2000
<b>TheraCIM</b> <sup>™</sup> nimotuzumab <b>(Orphan Drug)</b>	YM Biosciences <i>Wayne, PA</i>	glioma (pediatric) (see also breast, prostate, stomach)	Phase II (610) 560-0600
TM-601 <b>(Orphan Drug)</b>	TransMolecular <i>Cambridge, MA</i>	recurrent high-grade glioma	Phase I (617) 995-3050
TM-601-I-131 <b>(Orphan Drug)</b>	TransMolecular <i>Cambridge, MA</i>	glioma (intracranial) (see also skin)	Phase II (617) 995-3050
		glioma (intravenous)	Phase I/II (617) 995-3050
<b>Trisenox</b> <sup>®</sup> arsenic trioxide	Cephalon <i>Frazer, PA</i>	glioma (see also leukemia, multiple myeloma)	Phase I (610) 344-0200
<b>Tykerb</b> <sup>®</sup> lapatinib	GlaxoSmithKline <i>Rsch. Triangle Park, NC</i>	brain metastases from breast cancer (see also head/neck, stomach)	Phase III (888) 825-5249

## BRAIN CANCER

Product Name	Sponsor	Indication	Development Status
VP101 (Orphan Drug)	Access Pharmaceuticals <i>Dallas, TX</i>	glioblastoma (see also colorectal, leukemia, prostate)	Phase II (214) 905-5100
Xcytrin® motexafin gadolinium	Pharmacyclics <i>Sunnyvale, CA</i>	brain metastases from non-small-cell lung cancer (see also kidney, leukemia, lung, lymphoma)	application submitted (408) 774-0330
		glioma (combination therapy)	Phase II (408) 774-0330
		glioblastoma (combination therapy)	Phase I (408) 774-0330
Xerecept® corticotropin (Orphan Drug)	Celtic Pharma <i>Hamilton, Bermuda</i>	peritumoral brain edema	Phase III (441) 299-7440
XL-184	Bristol-Myers Squibb <i>Princeton, NJ</i> Exelixis <i>South San Francisco, CA</i>	glioblastoma (see also other)	in clinical trials (212) 546-4000
XL-765	Exelixis <i>South San Francisco, CA</i>	glioma (see also solid tumors)	Phase I (650) 837-7000
Zactima® vandetanib	AstraZeneca <i>Wilmington, DE</i>	glioma (see also breast, lung, other)	Phase I (800) 236-9933
Zolinza® vorinostat	Merck <i>Whitehouse Station, NJ</i>	glioblastoma (see also breast, colorectal, kidney, leukemia, lung, lymphoma, multiple myeloma)	Phase II (800) 672-6372

## BREAST CANCER

Product Name	Sponsor	Indication	Development Status
ABI-008	Abraxis BioScience <i>Los Angeles, CA</i>	metastatic breast cancer (see also prostate)	Phase I/II (310) 883-1300
ABT-751	Abbott Laboratories <i>Abbott Park, IL</i>	(see also colorectal, kidney, lung)	Phase II (847) 937-6100
ABT-869	Abbott Laboratories <i>Abbott Park, IL</i> Genentech <i>South San Francisco, CA</i>	combination therapy (see also kidney, liver, lung)	Phase II (847) 937-6100 (650) 225-1000
aderbasib (INCB7839)	Incyte <i>Wilmington, DE</i>	combination therapy	Phase II (302) 498-6700
Advexin® contusogene ladenovec	Introgen Therapeutics <i>Austin, TX</i>	combination therapy (see also bladder, brain, head/neck, lung, ovarian, prostate, stomach)	Phase II (512) 708-9310

# BREAST CANCER

Product Name	Sponsor	Indication	Development Status
AE-37	Antigen Express Worcester, MA	(see also ovarian)	Phase II (508) 852-8783
AG-14699	Pfizer New York, NY	(see also ovarian)	Phase II (860) 732-5156
<b>Alimta</b> <sup>®</sup> pemetrexed	Eli Lilly Indianapolis, IN	(see also head/neck, lung, ovarian)	Phase II (800) 545-5979
AMG 386	Amgen Thousand Oaks, CA	(see also kidney, ovarian, stomach, other)	Phase II (805) 447-1000
AMG 479	Amgen Thousand Oaks, CA	(see also colorectal, lung, pancreatic, sarcoma)	Phase II (805) 447-1000
<b>Amplimexon</b> <sup>®</sup> imexon	AmpliMed Tucson, AZ	(see also lung, multiple myeloma, pancreatic, prostate, skin)	Phase I (520) 529-1000
anti-CD3 activated T-cells	TransTarget Hillsborough, CA	metastatic breast cancer	Phase I
anti-MUC1 mAb	Paladin Labs St. Laurent, Canada	(see also multiple myeloma, pancreatic)	Phase I completed (888) 376-7830
anti-PEM mAb	Access Pharmaceuticals Dallas, TX		Phase I/II (214) 905-5100
<b>Armala</b> <sup>™</sup> pazopanib	GlaxoSmithKline Rsch. Triangle Park, NC	combination therapy (see also brain, cervical, kidney, liver, lung, ovarian, sarcoma, other)	Phase III (888) 825-5249
<b>Aromasin</b> <sup>®</sup> exemestane	Pfizer New York, NY	breast cancer prevention	Phase III (860) 732-5156
ARRY-543	Array BioPharma Boulder, CO	combination therapy	Phase I/II (303) 381-6600
arzoxifene	Eli Lilly Indianapolis, IN	invasive breast cancer risk reduction	Phase III (800) 545-5979
AS-1402	Antisoma Cambridge, MA		Phase II (617) 225-0522
AVE1642 (anti-IGF-1R mAb)	sanofi-aventis Bridgewater, NJ	hormonal-sensitive breast cancer	Phase II (800) 633-1810
AZD2281	AstraZeneca Wilmington, DE	monotherapy (see also ovarian)	Phase II (800) 236-9933
		combination therapy	Phase I/II (800) 236-9933
AZD4992	AstraZeneca Wilmington, DE		Phase I (800) 236-9933
BIBW 2992	Boehringer Ingelheim Pharmaceuticals Ridgefield, CT	second-line therapy (see also brain, head/neck, lung)	Phase II (800) 243-0127
bleomycin (electrical pulse delivery)	Inovio Biomedical San Diego, CA	(see also head/neck)	Phase I (858) 597-6006
bosutinib	Wyeth Pharmaceuticals Collegeville, PA	(see also leukemia, solid tumors)	Phase II (800) 934-5556

# BREAST CANCER

Product Name	Sponsor	Indication	Development Status
breast cancer vaccine	Quantum Immunologics <i>Tampa, FL</i>		Phase I/II (866) 213-4594
BSI-201	BiPar Sciences <i>Brisbane, CA</i>	(see also brain, ovarian, other)	Phase II (650) 635-6050
BTSCAN	Molecular Targeting Technologies <i>West Chester, PA</i>	diagnosis of breast cancer	Phase I (610) 738-7938
BZL-101	Bionovo <i>Emeryville, CA</i>		Phase II (510) 601-2000
cancer vaccine	MabVax Therapeutics <i>San Diego, CA</i>	(see also sarcoma)	Phase I (858) 259-9405
<b>Capoxigem®</b> apricoxib	Tragara Pharmaceuticals <i>San Diego, CA</i>	combination therapy (see also lung, pancreatic)	Phase II (858) 350-6900
CDX-1307	Celldex Therapeutics <i>Needham, MA</i>	(see also bladder, colorectal, ovarian, pancreatic)	Phase I (781) 433-0771
cediranib	AstraZeneca <i>Wilmington, DE</i>	(see also kidney, leukemia)	Phase II (800) 236-9933
CNF-2024	Biogen Idec <i>Cambridge, MA</i>	(see also leukemia, solid tumors, stomach)	Phase I (617) 679-2000
CP-751871	Pfizer <i>New York, NY</i>	combination therapy (see also colorectal, lung, multiple myeloma, prostate, sarcoma)	Phase II (860) 732-5156
CR011-vcMMAE	CurGen <i>Branford, CT</i>	(see also skin)	Phase II (888) 436-6642
deforolimus (MK-8669)	ARIAD Pharmaceuticals <i>Cambridge, MA</i> Merck <i>Whitehouse Station, NJ</i>	combination therapy (see also lung, prostate, sarcoma, other)	Phase II (617) 494-0400 (800) 672-6372
<b>Doxil®</b> doxorubicin liposome injection	Ortho Biotech <i>Bridgewater, NJ</i>	combination therapy	application submitted (908) 541-4000
doxorubicin liposomal	Sopherion Therapeutics <i>Princeton, NJ</i>	combination therapy	Phase III (609) 986-2021
enzastaurin (LY317615)	Eli Lilly <i>Indianapolis, IN</i>	combination therapy (see also brain, colorectal, lymphoma, multiple myeloma, ovarian, prostate)	Phase II (800) 545-5979
eribulin mesylate (E7389)	Eisai <i>Woodcliff Lake, NJ</i>	metastatic breast cancer (see also head/neck, lung, ovarian, prostate, sarcoma, solid tumors)	Phase III (888) 422-4743
		advanced breast cancer	Phase II (888) 422-4743
<b>Genasense®</b> oblimersen	Genta <i>Berkeley Heights, NJ</i>	(see also leukemia, lung, lymphoma, skin, solid tumors)	Phase II completed (908) 286-9800

## BREAST CANCER

Product Name	Sponsor	Indication	Development Status
glufosfamide	Threshold Pharmaceuticals <i>Redwood City, CA</i>	(see also lung, pancreatic, sarcoma)	Phase II (650) 474-8200
GRN-163L	Geron <i>Menlo Park, CA</i>	combination therapy (see also leukemia, lung, multiple myeloma)	Phase I/II (650) 473-7700
HER2-antigen-specific cancer immunotherapeutic	Genentech <i>South San Francisco, CA</i>		Phase II (650) 224-1000
HER2/neu peptide vaccine	GlaxoSmithKline <i>Rsch. Triangle Park, NC</i>		Phase I/II (888) 825-5249
<b>Hycamtin</b> <sup>®</sup> topotecan	GlaxoSmithKline <i>Rsch. Triangle Park, NC</i>	(see also colorectal, head/neck, kidney, leukemia, lung, lymphoma, multiple myeloma, ovarian, pancreatic, prostate, stomach, other)	Phase II (888) 825-5249
IMC-1121B	Eli Lilly <i>Indianapolis, IN</i> ImClone Systems <i>New York, NY</i>	(see also colorectal, kidney, liver, lung, ovarian, prostate, skin)	Phase III (800) 545-5979 (212) 645-1405
IMC-A12	Eli Lilly <i>Indianapolis, IN</i> ImClone Systems <i>New York, NY</i>	(see also colorectal, head/neck, liver, lung, pancreatic, prostate, sarcoma, solid tumors)	Phase II (800) 545-5979 (212) 645-1045
IMT-1012	ImmunoVaccine Technologies <i>Halifax, Canada</i>	(see also ovarian)	Phase I (902) 492-1819
INGN 225 (p53 vaccine)	Introgen Therapeutics <i>Austin, TX</i>	(see also lung)	Phase I/II (512) 708-9310
ispinesib	CytoKinetics <i>South San Francisco, CA</i>	(see also colorectal, kidney, leukemia)	Phase II (650) 624-3000
<b>Ixempra</b> <sup>™</sup> ixabepilone	Bristol-Myers Squibb <i>Princeton, NJ</i>	early breast cancer (see also lung, pancreatic, prostate)	in clinical trials (212) 546-4000
lapuleucel-T	Dendreon <i>Seattle, WA</i>	(see also colorectal, ovarian)	Phase I completed (206) 256-4545
LEP-ETU	NeoPharm <i>Lake Bluff, IL</i>		Phase II (847) 887-0800
LOR-2040	Lorus Therapeutics <i>Toronto, Canada</i>	metastatic breast cancer (see also colorectal, kidney, leukemia)	Phase II (416) 798-1200
<b>Lymphoseek</b> <sup>™</sup>	Neoprobe <i>Dublin, OH</i>	diagnosis of breast cancer (see also skin)	Phase III (800) 793-0079
milataxel	Taxolog <i>Fairfield, NJ</i>	(see also colorectal, lung)	Phase II (877) 829-6564
MK-0646	Merck <i>Whitehouse Station, NJ</i>	(see also lung, pancreatic, other)	Phase I (800) 672-6372

## BREAST CANCER

Product Name	Sponsor	Indication	Development Status
MK-0752	Merck <i>Whitehouse Station, NJ</i>	(see also leukemia)	Phase I (800) 672-6372
MKC 1	EntreMed <i>Rockville, MD</i>	metastatic breast cancer (see also leukemia, lung, pancreatic)	Phase II completed (240) 864-2600
motesanib	Amgen <i>Thousand Oaks, CA</i> Millennium Pharmaceuticals <i>Cambridge, MA</i>	combination therapy (see also colorectal, lung, other)	Phase II (805) 447-1000 (800) 390-5663
NBI-42902	Neurocrine Biosciences <i>San Diego, CA</i>	(see also prostate, other)	Phase I (858) 617-7600
neratinib (HKI272)	Wyeth Pharmaceuticals <i>Collegeville, PA</i>	monotherapy (see also lung)	Phase III (800) 934-5556
		combination therapy	Phase I/II (800) 934-5556
<b>NeuVax™</b> E75 cancer vaccine	Apthera <i>Scottsdale, AZ</i>	(see also prostate)	Phase II (480) 882-8841
<b>Nexavar®</b> sorafenib	Bayer HealthCare Pharmaceuticals <i>Wayne, NJ</i> Onyx Pharmaceuticals <i>Emeryville, CA</i>	combination therapy (see also lung, skin)	Phase II (888) 842-2937 (510) 597-6500
NOV-002	Novelos Therapeutics <i>Newton, MA</i>	early-stage breast cancer (see also lung, ovarian)	Phase II (617) 244-1616
OBP-301	Oncolys Biopharma <i>Tokyo, Japan</i>	(see also head/neck, lung)	Phase I <a href="http://www.oncolys.com">www.oncolys.com</a>
OGX-427	Oncogenex Pharmaceuticals <i>Bothell, WA</i>	(see also bladder, lung, ovarian, prostate)	Phase I (425) 686-1500
OPT-22	Optimer Pharmaceuticals <i>San Diego, CA</i>		Phase I (858) 909-0736
panobinostat	Novartis Pharmaceuticals <i>East Hanover, NJ</i>	(see also brain, leukemia, lymphoma, prostate)	Phase I/II (888) 669-6682
patupilone (EPO906)	Novartis Pharmaceuticals <i>East Hanover, NJ</i>	(see also brain, colorectal, liver, lung, ovarian)	Phase II (888) 669-6682
PD-332991	Pfizer <i>New York, NY</i>	combination therapy, first-line therapy (see also lymphoma, multiple myeloma)	Phase I/II (860) 732-5156
pertuzumab	Genentech <i>South San Francisco, CA</i>	first-line therapy, metastatic breast cancer (see also ovarian)	Phase III (650) 224-1000
PTC-299	PTC Therapeutics <i>South Plainfield, NJ</i>	(see also skin)	Phase I/II (908) 222-7000

## BREAST CANCER

Product Name	Sponsor	Indication	Development Status
PX-1032 (HER2 breast cancer vaccine)	BN ImmunoTherapeutics <i>Mountain View, CA</i> Pharmexa <i>Horsholm, Denmark</i>		Phase I/II (650) 681-4660
<b>Quinamed®</b> amonafile	ChemGenex Pharmaceuticals <i>Menlo Park, CA</i>	(see also ovarian, prostate)	Phase II (650) 474-9800
R1507	Roche <i>Nutley, NJ</i>	combination therapy (see also lung, lymphoma, sarcoma)	Phase II (973) 235-5000
retaspimycin (IPI 504)	Infinity Pharmaceuticals <i>Cambridge, MA</i>	(see also lung, stomach)	Phase II (617) 453-1000
<b>Reximmune-C™</b>	Epeius Biotechnologies <i>San Marino, CA</i>		Phase I/II (626) 441-6695
<b>Rexin-G™</b> tumor-targeted gene therapy	Epeius Biotechnologies <i>San Marino, CA</i>	recurrent, refractory metastatic breast cancer (see also pancreatic, sarcoma)	Phase I/II (626) 441-6695
sagopilone	Bayer HealthCare Pharmaceuticals <i>Wayne, NJ</i>	(see also brain, ovarian, prostate)	Phase II (888) 842-2937
<b>Sarasar™</b> lonafarnib	Schering-Plough <i>Kenilworth, NJ</i>	(see also leukemia, pancreatic)	Phase II (908) 298-4000
satraplatin	Spectrum Pharmaceuticals <i>Irvine, CA</i>	metastatic breast cancer, second-line therapy (see also lung, prostate)	Phase II completed (949) 788-6700
SCH-727965	Schering-Plough <i>Kenilworth, NJ</i>	(see also leukemia, lung)	Phase II (908) 298-4000
SF1	SonneMed <i>Boston, MA</i>	advanced breast cancer	Phase I/II
SNDX-275	Syndax Pharmaceuticals <i>Waltham, MA</i>	(see also lung)	Phase II (781) 839-7301
SU-14813	Pfizer <i>New York, NY</i>		Phase II (860) 732-5156
<b>Sutent®</b> sunitinib	Pfizer <i>New York, NY</i>	(see also colorectal, liver, lung, pancreatic, prostate, sarcoma, stomach)	Phase III (860) 732-5156
<b>TamoGel™</b> afimoxifene	ASCEND Therapeutics <i>Herndon, VA</i>		Phase II (703) 471-4744
<b>Tarceva®</b> erlotinib	Genentech <i>South San Francisco, CA</i> OSI Pharmaceuticals <i>Melville, NY</i>	(see also bladder, brain, colorectal, head/neck, liver, lung, other)	Phase II (650) 224-1000 (800) 572-1932
TAS-108	Taiho Pharma USA <i>Princeton, NJ</i>		Phase II (609) 750-5300
<b>Telcyta™</b> canfosamide	Telik <i>Palo Alto, CA</i>	(see also colorectal, lung, ovarian)	Phase II completed (650) 845-7700

## BREAST CANCER

Product Name	Sponsor	Indication	Development Status
tesmilifene	YM BioSciences Wayne, PA	(see also prostate)	Phase III (610) 560-0600
<b>TheraCIM™</b> nimotuzumab	YM Biosciences Wayne, PA	adjunctive treatment (see also brain, prostate, stomach)	Phase I (610) 560-0600
<b>Thermodox™</b> LTSDEL	Celsion Columbia, MD	locally recurrent breast cancer (see also liver)	Phase I/II (410) 290-5390
trastuzumab-DM1	Genentech South San Francisco, CA ImmunoGen Waltham, MA	metastatic breast cancer (second-line therapy)	Phase III (650) 225-1000 (781) 895-0600
		metastatic breast cancer (first-line therapy, third-line therapy)	Phase II (650) 225-1000 (781) 895-0600
<b>Trelstar®</b> triptorelin	Watson Pharmaceuticals Corona, CA		Phase III (951) 493-5300
tremelimumab	Pfizer New York, NY	(see also colorectal, kidney, lung, prostate, skin)	Phase I (860) 732-5156
trilostane	Genzyme Cambridge, MA	(see also prostate)	in clinical trials (617) 252-7500
vinflunine	Pierre Fabre Pharmaceuticals Parsippany, NJ	advanced breast cancer (see also bladder)	Phase III (973) 898-1042
WX-671	Wilex Munich, Germany		Phase II www.wilex.com
<b>Yondelis®</b> trabectedin	Johnson & Johnson Pharmaceutical Research & Development Raritan, NJ	(see also ovarian, prostate, sarcoma, other)	Phase II (800) 817-5286
<b>Zactima®</b> vandetanib	AstraZeneca Wilmington, DE	(see also brain, lung, other)	Phase II (800) 236-9933
<b>Zolinza®</b> vorinostat	Merck Whitehouse Station, NJ	(see also brain, colorectal, kidney, leukemia, lung, lymphoma, multiple myeloma)	Phase II (800) 672-6372
ZYC300	Eisai Woodcliff Lake, NJ	(see also colorectal, kidney, ovarian, prostate)	Phase I (888) 422-4743

## CERVICAL CANCER

Product Name	Sponsor	Indication	Development Status
A-007	Tigris Pharmaceuticals Bonita Springs, FL	cervical intraepithelial neoplasia (see also colorectal)	Phase II completed (239) 444-5400
<b>Armala™</b> pazopanib	GlaxoSmithKline Rsch. Triangle Park, NC	(see also brain, breast, kidney, liver, lung, ovarian, sarcoma, other)	Phase II (888) 825-5249
<b>Camptosar®</b> irinotecan	Pfizer New York, NY	(see also lung, pancreatic, prostate)	application submitted (860) 732-5156

## CERVICAL CANCER

Product Name	Sponsor	Indication	Development Status
HspE7 (verpasep caltespen)	Nventa Biopharmaceuticals <i>San Diego, CA</i>	cervical intraepithelial neoplasia	Phase I completed (858) 202-4900
<b>Levulan® PD</b> aminolevulinic acid	DUSA Pharmaceuticals <i>Wilmington, DE</i>	cervical intraepithelial neoplasia (see also bladder, colorectal, lung, stomach)	Phase II (978) 657-7500
<b>Multikine®</b> leukocyte interleukin	CEL-SCI <i>Vienna, VA</i>	cervical cancer, cervical dysplasia (see also head/neck)	Phase I/II completed (703) 506-9460
PV701	Wellstat Biologics <i>Gaithersburg, MD</i>	(see also colorectal)	Phase II (240) 631-2500
R3484 (MVA-HPV-IL2 vaccine)	Roche <i>Nutley, NJ</i>	cervical intraepithelial neoplasia	Phase II (973) 235-5000
TAK-851	Millennium Pharmaceuticals <i>Cambridge, MA</i>	cervical dysplasia	Phase II (800) 390-5663
terameprocol	Erimos Pharmaceuticals <i>Houston, TX</i>	cervical intraepithelial neoplasia (see also brain, head/neck)	Phase II (713) 541-2000
tirapazamine	SRI International <i>Menlo Park, CA</i>		Phase III (650) 859-2000
V503	Merck <i>Whitehouse Station, NJ</i>	cervical cancer prevention (see also other)	Phase III (800) 672-6372
V505	Merck <i>Whitehouse Station, NJ</i>		Phase III (800) 672-6372

## COLORECTAL CANCER

Product Name	Sponsor	Indication	Development Status
1018 ISS	Dynavax Technologies <i>Berkeley, CA</i>	(see also lymphoma)	Phase I (510) 848-5100
A-007	Tigris Pharmaceuticals <i>Bonita Springs, FL</i>	anal intraepithelial neoplasia (see also cervical)	Phase I/II (239) 444-5400
ABT-751	Abbott Laboratories <i>Abbott Park, IL</i>	(see also breast, kidney, lung)	Phase II (847) 937-6100
aflibercept (VEGF-trap)	sanofi-aventis <i>Bridgewater, NJ</i> Regeneron Pharmaceuticals <i>Tarrytown, NY</i>	second-line metastatic colorectal cancer (combination therapy) (see also lung, pancreatic, prostate, other)	Phase III (800) 633-1610 (914) 345-7400
AMG 102	Amgen <i>Thousand Oaks, CA</i>	(see also brain, kidney, lung, stomach)	Phase I/II (805) 447-1000
AMG 479	Amgen <i>Thousand Oaks, CA</i>	(see also breast, lung, pancreatic, sarcoma)	Phase II (805) 447-1000

## COLORECTAL CANCER

Product Name	Sponsor	Indication	Development Status
AMG 951 (rhApo2L/TRAIL)	Amgen <i>Thousand Oaks, CA</i> Genentech <i>South San Francisco, CA</i>	(see also lymphoma)	Phase I (805) 447-1000 (650) 225-1000
apomab	Genentech <i>South San Francisco, CA</i>	(see also lung, lymphoma)	Phase I (650) 225-1000
AR-726	Antigenics <i>New York, NY</i>	(see also lymphoma)	Phase II (212) 994-8200
<b>Avastin®</b> bevacizumab	Genentech <i>South San Francisco, CA</i>	adjuvant treatment (see also brain, head/neck, kidney, liver, lung, lymphoma, multiple myeloma, ovarian, pancreatic, prostate, stomach, other)	Phase III (650) 225-1000
AVX701	AlphaVax <i>Rsch. Triangle Park, NC</i>	colorectal cancer prevention	Phase I/II (919) 595-0400
axitinib	Pfizer <i>New York, NY</i>	combination first-line therapy (see also kidney, lung, solid tumors, other)	Phase II (860) 732-5156
		----- metastatic colorectal cancer (combination second-line therapy)	Phase II (860) 732-5156
belinostat	TopoTarget USA <i>Rockaway, NJ</i>	(see also bladder, leukemia, liver, lung, lymphoma, ovarian)	Phase I (973) 895-6900
brivanib (VEGFR/FGFR kinase inhibitor)	Bristol-Myers Squibb <i>Princeton, NJ</i>	metastatic colorectal cancer (combination with cetuximab) (see also liver)	Phase III (212) 546-4000
CDX-1307	Celldex Therapeutics <i>Needham, MA</i>	(see also bladder, breast, ovarian, pancreatic)	Phase I (781) 433-0771
conatumumab	Amgen <i>Thousand Oaks, CA</i>	(see also lung, pancreatic, sarcoma)	Phase II (805) 447-1000
CP-751871	Pfizer <i>New York, NY</i>	(see also breast, lung, multiple myeloma, prostate, sarcoma)	Phase II (860) 732-5156
CPX-1	Celator Pharmaceuticals <i>Princeton, NJ</i>		Phase II (609) 243-0123
<b>Davanat™</b> galactomannan C	Pro-Pharmaceuticals <i>Newton, MA</i>	(see also solid tumors)	Phase II (617) 559-0033
denenicokin (IL-21)	ZymoGenetics <i>Seattle, WA</i>	combination therapy (see also kidney, lymphoma, ovarian, skin)	Phase I (206) 442-6600
edotecarin	Pfizer <i>New York, NY</i>		Phase III (860) 732-5156
enzastaurin (LY317615)	Eli Lilly <i>Indianapolis, IN</i>	combination therapy (see also brain, breast, lymphoma, multiple myeloma, ovarian, prostate)	Phase II (800) 545-5979

## COLORECTAL CANCER

Product Name	Sponsor	Indication	Development Status
<b>Erbix<sup>®</sup></b> cetuximab	Bristol-Myers Squibb <i>Princeton, NJ</i>	adjuvant, first-line, second-line colorectal cancer	Phase III (212) 546-4000 (800) 545-5979 (212) 645-1405
	Eli Lilly <i>Indianapolis, IN</i> ImClone Systems <i>New York, NY</i>	(see also bladder, head/neck, lung, prostate, stomach)	----- Phase II (212) 546-4000 (800) 545-5979 (212) 645-1405
<b>Fusilev<sup>™</sup></b> levoleucovorin for injection	Spectrum Pharmaceuticals <i>Irvine, CA</i>	(see also sarcoma)	application submitted (949) 788-6700
<b>Herceptin<sup>®</sup></b> trastuzumab	Genentech <i>South San Francisco, CA</i>	(see also ovarian, pancreatic, prostate, stomach, other)	Phase II (650) 225-1000
huA33	Life Science Pharmaceuticals <i>Greenwich, CT</i>		Phase I (203) 422-6500
<b>Hycamtin<sup>®</sup></b> topotecan	GlaxoSmithKline <i>Rsch. Triangle Park, NC</i>	(see also breast, head/neck, kidney, leukemia, lung, lymphoma, multiple myeloma, ovarian, pancreatic, prostate, stomach, other)	Phase II (888) 825-5249
IMC-1121B	Eli Lilly <i>Indianapolis, IN</i> ImClone Systems <i>New York, NY</i>	(see also breast, kidney, liver, lung, ovarian, prostate, skin)	Phase II (800) 545-5979 (212) 645-1405
IMC-A12	Eli Lilly <i>Indianapolis, IN</i> ImClone Systems <i>New York, NY</i>	(see also breast, head/neck, liver, lung, pancreatic, prostate, sarcoma, solid tumors)	Phase II (800) 545-5979 (212) 645-1405
IMO-2055	Idera Pharmaceuticals <i>Cambridge, MA</i>	combination therapy (see also kidney, lung)	Phase I (617) 679-5500
ispinesib	CytoKinetics <i>South San Francisco, CA</i>	(see also breast, kidney, leukemia)	Phase II (650) 624-3000
KRN-330	Kirin Pharma USA <i>La Jolla, CA</i>		Phase I (858) 952-7000
KRX-0402	Keryx Biopharmaceuticals <i>New York, NY</i>	(see also brain, kidney, multiple myeloma, sarcoma)	Phase I (212) 531-5965
lapuleucel-T	Dendreon <i>Seattle, WA</i>	(see also breast, ovarian)	Phase I completed (206) 256-4545
LE-SN38	NeoPharm <i>Lake Bluff, IL</i>	second-line therapy	Phase II (847) 887-0800
<b>Levulan<sup>®</sup> PD</b> aminolevulinic acid	DUSA Pharmaceuticals <i>Wilmington, MA</i>	(see also bladder, cervical, lung, stomach)	in clinical trials (978) 657-7500
<b>Litx<sup>™</sup></b> talaporfin	Light Sciences Oncology <i>Bellevue, WA</i>	metastatic colorectal cancer	Phase III (425) 957-8900
LOR-2040	Lorus Therapeutics <i>Toronto, Canada</i>	metastatic colorectal cancer (see also breast, kidney, leukemia)	Phase II (416) 798-1200

## COLORECTAL CANCER

Product Name	Sponsor	Indication	Development Status
milataxel	Taxolog <i>Fairfield, NJ</i>	(see also breast, lung)	Phase II (877) 829-6564
motesanib	Amgen <i>Thousand Oaks, CA</i> Millennium Pharmaceuticals <i>Cambridge, MA</i>	metastatic colorectal cancer (combination therapy) (see also breast, lung, other)	Phase I (805) 447-1000 (800) 390-5663
NKTR-102	Nektar Therapeutics <i>San Carlos, CA</i>	combination, second-line therapy (see also ovarian)	Phase II (650) 631-3100
<b>Oncophage®</b> vitespen	Antigenics <i>New York, NY</i>	(see also brain, kidney, pancreatic, skin, stomach)	Phase II (866) 805-8994
<b>OncoVAX®</b> cancer vaccine	Vaccinogen <i>Frederick, MD</i>	stage III colorectal cancer (combination therapy) (see also kidney, skin)	Phase II (301) 668-8400
		colorectal cancer	Phase I/II (301) 668-8400
patupilone (EPO906)	Novartis Pharmaceuticals <i>East Hanover, NJ</i>	(see also brain, breast, liver, lung, ovarian)	Phase I/II (888) 669-6682
pelitinib (EKB569)	Wyeth Pharmaceuticals <i>Collegeville, PA</i>	second-line therapy (see also lung)	Phase II (800) 934-5556
picoplatin	Poniard Pharmaceuticals <i>Seattle, WA</i>	(see also lung)	Phase II (206) 281-7001
PN401	Wellstat Therapeutics <i>Gaithersburg, MD</i>	(see also pancreatic, stomach)	Phase I (240) 631-2500
PV701	Wellstat Biologics <i>Gaithersburg, MD</i>	(see also cervical)	Phase II (240) 631-2500
<b>RIGScan® CR49</b> radiodiagnostic agent	Neoprobe <i>Dublin, OH</i>	diagnosis of colorectal cancer	Phase III (800) 793-0079
RM1812	Royalmount Pharmaceuticals <i>Montreal, Canada</i>		Phase I (514) 340-7849
robatumumab	Schering-Plough <i>Kenilworth, NJ</i>	(see also sarcoma)	Phase II (908) 298-4000
sibrotuzumab	Life Science Pharmaceuticals <i>Greenwich, CT</i>	(see also head/neck, lung)	Phase II (203) 422-6500
<b>Sutent®</b> sunitinib	Pfizer <i>New York, NY</i>	(see also breast, liver, lung, pancreatic, prostate, sarcoma, stomach)	Phase II (860) 732-5156
systemic hedgehog antagonist	Genentech <i>South San Francisco, CA</i>	first-line therapy (see also brain, ovarian, skin)	Phase II (650) 224-1000
<b>Tarceva®</b> erlotinib	Genentech <i>South San Francisco, CA</i> OSI Pharmaceuticals <i>Melville, NY</i>	combination therapy (see also bladder, brain, breast, head/neck, liver, lung, other)	Phase II (650) 224-1000 (800) 572-1932

## COLORECTAL CANCER

Product Name	Sponsor	Indication	Development Status
TAS-109	Taiho Pharma USA <i>Princeton, NJ</i>		Phase II (609) 750-5300
tegafur/uracil combination	EMD Serono <i>Rockland, MA</i>	(see also head/neck)	Phase III (800) 283-8088
<b>Telcyta™</b> canfosfamide	Telik <i>Palo Alto, CA</i>	(see also breast, lung, ovarian)	Phase II completed (650) 845-7700
tesetaxel	Genta <i>Berkeley Heights, NJ</i>	second-line therapy (see also stomach)	Phase II (908) 286-9800
tetrandrine	Millenia Hope <i>Montreal, Canada</i>		Phase III (514) 846-5757
<b>Thymitaq®</b> nolatrexed	YM BioSciences USA <i>Wayne, PA</i>	(see also head/neck, liver, lung, pancreatic, prostate)	Phase II (610) 560-0600
<b>TNFerade™</b>	GenVec <i>Gaithersburg, MD</i>	(see also head/neck, pancreatic, skin, stomach)	Phase II (240) 632-0740
<b>Torisel™</b> temsirolimus	Wyeth Pharmaceuticals <i>Collegeville, PA</i>	(see also kidney, lung, lymphoma, multiple myeloma, prostate)	Phase II (800) 934-5556
tremelimumab	Pfizer <i>New York, NY</i>	(see also breast, kidney, lung, prostate, skin)	Phase II (860) 732-5156
tucotuzumab celmoleukin	EMD Serono <i>Rockland, MA</i>	(see also lung, ovarian, prostate)	Phase II (800) 283-8088
<b>Urso Forte™</b> ursodeoxycholic acid	Axcan Pharma <i>Birmingham, AL</i>	(see also cancer-related)	Phase II (205) 991-8085
VP101	Access Pharmaceuticals <i>Dallas, TX</i>	(see also brain, leukemia, prostate)	Phase II (214) 905-5100
<b>Xeloda®</b> capecitabine	Roche <i>Nutley, NJ</i>	first-line metastatic colorectal cancer, second-line metastatic colorectal cancer (see also stomach)	application submitted (973) 235-5000
<b>Zolinza®</b> vorinostat	Merck <i>Whitehouse Station, NJ</i>	(see also brain, breast, kidney, leukemia, lung, lymphoma, multiple myeloma)	Phase I (800) 672-6372
ZYC300	Eisai <i>Woodcliff Lake, NJ</i>	colon cancer (see also breast, kidney, ovarian, prostate)	Phase I (888) 422-4743

## HEAD/NECK CANCER

Product Name	Sponsor	Indication	Development Status
<b>Abraxane™</b> albumin-bound paclitaxel	Abraxis BioScience <i>Los Angeles, CA</i>	(see also lung, ovarian, pancreatic, prostate, skin)	Phase I/II (310) 883-1300

# HEAD/NECK CANCER

Product Name	Sponsor	Indication	Development Status
<b>Advexin®</b> contusugene ladenovec <b>(Orphan Drug)</b>	Introgen Therapeutics <i>Austin, TX</i>	(see also bladder, brain, breast, lung, ovarian, prostate, stomach)	Phase III completed (512) 708-9310
<b>Alimta®</b> pemetrexed	Eli Lilly <i>Indianapolis, IN</i>	(see also breast, lung, ovarian)	Phase III (800) 545-5979
AP-5346	Access Pharmaceuticals <i>Dallas, TX</i>		Phase II (214) 905-5100
ARQ-501 (beta lapachone)	ArQule <i>Woburn, MA</i>	(see also pancreatic, solid tumors, other)	Phase II (781) 994-0300
<b>Avastin®</b> bevacizumab	Genentech <i>South San Francisco, CA</i>	combination therapy (see also brain, colorectal, kidney, liver, lung, lymphoma, multiple myeloma, ovarian, pancreatic, prostate, stomach, other)	Phase III (650) 225-1000
BIBW 2992	Boehringer Ingelheim Pharmaceuticals <i>Ridgefield, CT</i>	second-line therapy (see also brain, breast, lung)	Phase II (800) 243-0127
bleomycin (electrical pulse delivery)	Inovio Biomedical <i>San Diego, CA</i>	(see also breast)	Phase III (858) 597-6006
<b>Erbix®</b> cetuximab	Bristol-Myers Squibb <i>Princeton, NJ</i> Eli Lilly <i>Indianapolis, IN</i> ImClone Systems <i>New York, NY</i>	first-line (see also bladder, colorectal, lung, prostate, stomach)	application submitted (212) 546-4000 (800) 545-5979 (212) 645-1405
eribulin mesylate (E7389)	Eisai <i>Woodcliff Lake, NJ</i>	(see also breast, lung, ovarian, prostate, sarcoma, solid tumors)	Phase II (888) 422-4743
<b>Gemzar®</b> gemcitabine	Eli Lilly <i>Indianapolis, IN</i>	(see also lung, lymphoma, sarcoma)	Phase I (800) 545-5979
<b>Hycamtin®</b> topotecan	GlaxoSmithKline <i>Rsch. Triangle Park, NC</i>	(see also breast, colorectal, kidney, leukemia, lung, lymphoma, multiple myeloma, ovarian, pancreatic, prostate, stomach, other)	Phase II (888) 825-5249
IMC-A12	Eli Lilly <i>Indianapolis, IN</i> ImClone Systems <i>New York, NY</i>	(see also breast, colorectal, liver, lung, pancreatic, prostate, sarcoma, solid tumors)	Phase II (800) 545-5979 (212) 645-1405
ING 234 (mouthwash)	Colgate-Palmolive <i>New York, NY</i> Introgen Therapeutics <i>Austin, TX</i>	orofacial cancer (prevention)	Phase II (512) 708-9310
INGN 241 (mda-7)	Introgen Therapeutics <i>Austin, TX</i>	combination therapy (see also skin)	Phase III (512) 708-9310
IRX-2	IRX Therapeutics <i>New York, NY</i>		Phase II (212) 582-1199

# HEAD/NECK CANCER

Product Name	Sponsor	Indication	Development Status
<b>Multikine®</b> leukocyte interleukin	CEL-SCI Vienna, VA	(see also cervical)	Phase II (703) 506-9460
OBP-301	Oncolys Biopharma Tokyo, Japan	(see also breast, lung)	Phase I www.oncolys.com
perifosine	AEterna Zentaris Montreal, Canada Keryx Biopharmaceuticals New York, NY	(see also brain, kidney, lymphoma, multiple myeloma, ovarian, sarcoma)	Phase II (212) 531-5965
<b>Reolysin®</b> reovirus	Oncolytics Biotech Calgary, Canada	combination therapy (see also brain, lung, sarcoma, skin)	Phase II (403) 670-7377
SCH-58500 (p53 gene therapy)	Schering-Plough Kenilworth, NJ	(see also bladder, liver, lung, cancer-related)	Phase I (908) 298-4000
sibrotuzumab	Life Science Pharmaceuticals Greenwich, CT	(see also colorectal, lung)	Phase II (203) 422-6500
<b>Tarceva®</b> erlotinib	Genentech South San Francisco, CA OSI Pharmaceuticals Melville, NY	resected head/neck squamous cell cancer (see also bladder, brain, breast, colorectal, liver, lung, other)	Phase III (650) 224-1000 (800) 572-1932
TAS-106	Taiho Pharma USA Princeton, NJ		Phase II (609) 750-5300
tegafur/uracil combination	EMD Serono Rockland, MA	(see also colorectal)	Phase II (800) 283-8088
terameprocol	Erimos Pharmaceuticals Houston, TX	(see also brain, cervical)	Phase I (713) 541-2000
<b>Thymitaq®</b> nolatrexed	YM BioSciences Wayne, PA	(see also colorectal, liver, lung, pancreatic, prostate)	Phase II (610) 560-0600
<b>TNFerade™</b>	GenVec Gaithersburg, MD	(see also colorectal, pancreatic, skin, stomach)	Phase I/II (240) 632-0740
<b>Tykerb®</b> lapatinib	GlaxoSmithKline Rsch. Triangle Park, NC	(see also brain, stomach)	Phase III (888) 825-5249
VB-4845 <b>(Orphan Drug)</b>	Viventia Biotech Mississauga, Canada	(see also bladder)	Phase II (905) 361-8686
<b>Vectibix™</b> panitumumab	Amgen Thousand Oaks, CA	first-line therapy (see also lung)	Phase III (805) 447-1000
		second-line therapy	Phase II (805) 447-1000
XL-880	Exelixis South San Francisco, CA GlaxoSmithKline Rsch. Triangle Park, NC	(see also kidney, stomach)	Phase II (650) 837-7000 (888) 825-5249
zalutumumab	Genmab Princeton, NJ		Phase II (609) 430-2481

## HEAD/NECK CANCER

Product Name	Sponsor	Indication	Development Status
<b>Zybrestat™</b> fosbretabulin	OXiGENE Waltham, MA	(see also lung, ovarian, other)	Phase I/II (781) 547-5900

## KIDNEY CANCER

Product Name	Sponsor	Indication	Development Status
ABT-751	Abbott Laboratories Abbott Park, IL	(see also breast, colorectal, lung)	Phase II (847) 937-6100
ABT-869	Abbott Laboratories Abbott Park, IL Genentech South San Francisco, CA	(see also breast, liver, lung)	Phase II (847) 937-6100 (650) 225-1000
AGS-003	Argos Therapeutics Durham, NC	metastatic renal cancer	Phase II (919) 287-6300
AMG 102	Amgen Thousand Oaks, CA	(see also brain, colorectal, lung, stomach)	Phase II (805) 447-1000
AMG 386	Amgen Thousand Oaks, CA	(see also breast, ovarian, stomach, other)	Phase II (805) 447-1000
<b>Armala™</b> pazopanib	GlaxoSmithKline Rsch. Triangle Park, NC	late-stage metastatic kidney cancer (see also brain, breast, cervical, liver, lung, ovarian, sarcoma, other)	Phase III (888) 825-5249
AS-1411 <b>(Orphan Drug)</b>	Antisoma Cambridge, MA	(see also leukemia)	Phase II (617) 225-0522
AV-951	AVEO Pharmaceuticals Cambridge, MA	combination therapy (see also lung, stomach)	Phase I (617) 299-5000
<b>Avastin®</b> bevacizumab	Genentech South San Francisco, CA	first-line metastatic renal cell carcinoma (see also brain, colorectal, head/neck, liver, lung, lymphoma, multiple myeloma, ovarian, pancreatic, prostate, stomach, other)	application submitted (650) 225-1000
axitinib	Pfizer New York, NY	second-line therapy (see also colorectal, lung, solid tumors, other)	Phase III (860) 732-5156
BAY 73-4506	Bayer HealthCare Pharmaceuticals Wayne, NJ		Phase II (888) 842-2937
CA9-SCAN	Wilex Munich, Germany	diagnosis of kidney cancer	Phase III www.wilex.com
cediranib	AstraZeneca Wilmington, DE	(see also breast, leukemia)	Phase II (800) 236-9933
CNTO 328	Centocor Horsham, PA	(see also prostate)	Phase I (610) 651-6000
CYT-107	Cytheris Rockville, MD	(see also leukemia, skin, solid tumors)	Phase I/II (301) 231-0450

## KIDNEY CANCER

Product Name	Sponsor	Indication	Development Status
denenicokin (IL-21)	ZymoGenetics Seattle, WA	combination therapy (see also colorectal, lymphoma, ovarian, skin)	Phase II (206) 442-6600
dovitinib	Novartis Pharmaceuticals East Hanover, NJ	(see also skin)	Phase I/II (888) 669-6682
EC-17	Endocyte West Lafayette, IN	combination therapy	Phase II (765) 463-7175
everolimus	Novartis Pharmaceuticals East Hanover, NJ	(see also pancreatic, other)	application submitted (888) 669-6682
GC-1008	Genzyme Cambridge, MA	(see also skin)	Phase I (617) 252-7000
<b>Hycamtin®</b> topotecan	GlaxoSmithKline Rsch. Triangle Park, NC	(see also breast, colorectal, head/neck, leukemia, lung, lymphoma, multiple myeloma, ovarian, pancreatic, prostate, stomach, other)	Phase II (888) 825-5249
IMC-1121B	Eli Lilly Indianapolis, IN ImClone Systems New York, NY	metastatic kidney cancer (see also breast, colorectal, liver, lung, ovarian, prostate, skin)	Phase II (800) 545-5979 (212) 645-1405
IMO-2055	Idera Pharmaceuticals Cambridge, MA	(see also colorectal, lung)	Phase II completed (617) 679-5500
ispinesib	CytoKinetics South San Francisco, CA	(see also breast, colorectal, leukemia)	Phase II (650) 624-3000
KRX-0402	Keryx Biopharmaceuticals New York, NY	(see also brain, colorectal, multiple myeloma, sarcoma)	Phase I (212) 531-5965
LOR-2040 <b>(Orphan Drug)</b>	Lorus Therapeutics Toronto, Canada	metastatic kidney cancer (see also breast, colorectal, leukemia)	Phase II (416) 798-1200
MDX-1411	Medarex Princeton, NJ	clear-cell renal cell carcinoma	Phase I (609) 430-2880
naptumomab estafenatox	Active Biotech Lund, Sweden	(see also lung, pancreatic)	Phase I completed www.activebiotech.com
<b>Oncophage®</b> vitespen	Antigenics New York, NY	(see also brain, colorectal, pancreatic, skin, stomach)	Phase II (866) 805-8994
<b>OncoVAX®</b> cancer vaccine	Vaccinogen Frederick, MD	(see also colorectal, skin)	Phase I/II (301) 668-8400
ortataxel	Spectrum Pharmaceuticals Irvine, CA	(see also lymphoma)	Phase II (949) 788-6700
perifosine	AETerna Zentaris Montreal, Canada Keryx Biopharmaceuticals New York, NY	(see also brain, head/neck, lymphoma, multiple myeloma, ovarian, sarcoma)	Phase II (212) 531-5965
<b>Rencarex®</b> W-G250 <b>(Orphan Drug)</b>	Wilex Munich, Germany	non-metastatic, clear cell renal cell carcinoma	Phase III www.wilex.com

## KIDNEY CANCER

Product Name	Sponsor	Indication	Development Status
romidepsin	Gloucester Pharmaceuticals <i>Cambridge, MA</i>	(see also lymphoma, multiple myeloma, pancreatic, prostate)	Phase II completed (617) 583-1300
RX-0201 <b>(Orphan Drug)</b>	Rexahn Pharmaceuticals <i>Rockville, MD</i>	late-stage kidney cancer	Phase II (240) 268-5300
talactoferrin <b>(Orphan Drug)</b>	Agennix <i>Houston, TX</i>	(see also lung)	Phase II (713) 552-1091
<b>Torisel™</b> temsirolimus <b>(Orphan Drug)</b>	Wyeth Pharmaceuticals <i>Collegeville, PA</i>	first-line therapy, late-stage kidney cancer (see also colorectal, lung, lymphoma, multiple myeloma, prostate)	Phase III (800) 934-5556
tremelimumab	Pfizer <i>New York, NY</i>	(see also breast, colorectal, lung, prostate, skin)	Phase I (860) 732-5156
<b>TroVax®</b> (SAR109659)	BioMedica <i>San Diego, CA</i> sanofi-aventis <i>Bridgewater, NJ</i>		Phase III (858) 677-6500 (800) 633-1610
<b>Xcytrin®</b> motexafin gadolinium	Pharmacyclics <i>Sunnyvale, CA</i>	(see also brain, leukemia, lung, lymphoma)	Phase II (408) 774-0330
XL-880	Exelixis <i>South San Francisco, CA</i> GlaxoSmithKline <i>Rsch. Triangle Park, NC</i>	(see also head/neck, stomach)	Phase II (650) 837-7000 (888) 825-5249
<b>Zolinza®</b> vorinostat	Merck <i>Whitehouse Station, NJ</i>	(see also brain, breast, colorectal, leukemia, lung, lymphoma, multiple myeloma)	Phase I/II (800) 672-6372
ZRx101	ZelleRx <i>Chicago, IL</i>	(see also multiple myeloma, skin, cancer-related)	Phase I (312) 243-5200
ZYC300	Eisai <i>Woodcliff Lake, NJ</i>	(see also breast, colorectal, ovarian, prostate)	Phase I (888) 422-4743

## LEUKEMIA

Product Name	Sponsor	Indication	Development Status
ABIO05/01 (TALL-104)	Abiogen Pharma <i>Pisa, Italy</i>	chronic myeloid leukemia (CML) (combination therapy)	Phase II
<b>Ablvax™</b> (VAXICO)	Breakthrough Therapeutics <i>Greenwich, CT</i>	CML	Phase II
ABT-263	Abbott Laboratories <i>Abbott Park, IL</i> Genentech <i>South San Francisco, CA</i>	chronic lymphocytic leukemia (CLL) (see also lung, lymphoma)	Phase I/II (847) 937-6100 (650) 225-1000
AC220	Ambit Biosciences <i>San Diego, CA</i>	acute myeloid leukemia (AML)	Phase I (858) 334-2100

## LEUKEMIA

Product Name	Sponsor	Indication	Development Status
AEG-35156	Aegera Therapeutics <i>Montreal, Canada</i>	AML (combination therapy)	Phase II (514) 288-5532
AEG-41174	Aegera Therapeutics <i>Montreal, Canada</i>	hematological malignancies (combination therapy)	Phase I (514) 288-5532
AEW541	Novartis Pharmaceuticals <i>East Hanover, NJ</i>	hematological malignancies (see also solid tumors)	Phase I (888) 669-6682
<b>Aezea™</b> cenersen	Eleos <i>Omaha, NE</i>	AML, CLL	Phase II (402) 255-5775
AFX-9154	Afecta Pharmaceuticals <i>Irvine, CA</i>		in clinical trials (949) 253-4688
ALD-151	Aldagen <i>Durham, NC</i>	adjunctive treatment (adolescents and children)	Phase I (919) 484-2571
alvocidib	sanofi-aventis <i>Bridgewater, NJ</i>	CLL	Phase III (800) 633-1610
ALXN-6000	Alexion Pharmaceuticals <i>Cheshire, CT</i>	CLL	Phase I/II (203) 272-2596
annamycin liposomal <b>(Orphan Drug)</b>	Callisto Pharmaceuticals <i>New York, NY</i>	acute lymphocytic leukemia (ALL), AML	Phase I/II (212) 297-0010
AP24534	ARIAD Pharmaceuticals <i>Cambridge, MA</i>	hematological malignancies	Phase I (617) 494-0400
ARRY-520	Array BioPharma <i>Boulder, CO</i>	AML (see also solid tumors)	Phase I/II (303) 381-6600
AS-1411	Antisoma <i>Cambridge, MA</i>	AML (combination therapy) (see also kidney)	Phase II (617) 225-0522
AS-1413 <b>(Orphan Drug)</b>	Antisoma <i>Cambridge, MA</i>	AML (combination therapy)	Phase III (617) 225-0522
AT9283	Astex Therapeutics <i>Cambridge, United Kingdom</i>	hematological malignancies (see also solid tumors)	Phase I/II
atacept (TACI-Ig)	EMD Serono <i>Rockland, MA</i> ZymoGenetics <i>Seattle, WA</i>	CLL (see also lymphoma, multiple myeloma)	Phase I (800) 283-8088 (206) 442-6600
AVN-944	Avalon Pharmaceuticals <i>Germantown, MD</i>	hematological malignancies (see also pancreatic)	Phase I (301) 556-9900
AZD1152	AstraZeneca <i>Wilmington, DE</i>	AML	Phase I/II (800) 236-9933
AZD4877	AstraZeneca <i>Wilmington, DE</i>	AML (see also lymphoma)	Phase I/II (800) 236-9933
AZD6244	AstraZeneca <i>Wilmington, DE</i>	AML (see also liver, lung, multiple myeloma, ovarian, pancreatic, skin, other)	Phase II (800) 236-9933
AZM475271	AstraZeneca <i>Wilmington, DE</i>	hematological malignancies (see also solid tumors)	Phase II (800) 236-9933

## LEUKEMIA

Product Name	Sponsor	Indication	Development Status
bafetinib <b>(Orphan Drug)</b>	CytRx <i>Los Angeles, CA</i>	ALL, CML	Phase I (310) 826-5648
belinostat	TopoTarget USA <i>Rockaway, NJ</i>	AML, myelodysplastic syndromes (see also bladder, colorectal, liver, lung, lymphoma, ovarian)	Phase II (973) 895-6900
<b>Bexxar</b> <sup>®</sup> tositumomab	GlaxoSmithKline <i>Rsch. Triangle Park, NC</i>	CLL (see also lymphoma, cancer-related)	Phase I (888) 825-5249
bosutinib	Wyeth Pharmaceuticals <i>Collegeville, PA</i>	CML (see also breast, solid tumors)	Phase III (800) 934-5556
		ALL	Phase I/II (800) 934-5556
CAL-101	Calistoga Pharmaceuticals <i>Seattle, WA</i>	AML, CLL (see also lymphoma)	Phase I (206) 728-4700
<b>Campath</b> <sup>®</sup> alemtuzumab (subcutaneous) <b>(Orphan Drug)</b>	Bayer HealthCare Pharmaceuticals <i>Wayne, NJ</i>	CLL	Phase II (888) 842-2937
carfilzomib	Proteolix <i>South San Francisco, CA</i>	hematological malignancies (see also multiple myeloma, solid tumors)	Phase I (650) 615-7550
CAT-8015	MedImmune <i>Gaithersburg, MD</i>	CLL, hairy cell leukemia (see also lymphoma)	Phase I (301) 398-0000
cediranib	AstraZeneca <i>Wilmington, DE</i>	AML in children (see also breast, kidney)	Phase I (800) 236-9933
<b>Ceflatonin</b> <sup>®</sup> omacetaxine mepesuccinate <b>(Orphan Drug)</b>	ChemGenex Pharmaceuticals <i>Menlo Park, CA</i>	CML (second-line therapy)	application submitted (650) 474-9800
		AML, CML (combination therapy), myelodysplastic syndromes	Phase II (650) 474-9800
cell permeation therapeutic	MaxCyte <i>Gaithersburg, MD</i>	CLL	Phase I/II (301) 944-1700
<b>Ceplene</b> <sup>™</sup> histamine dehydrochloride <b>(Orphan Drug)</b>	EpiCept <i>Tarrytown, NY</i>	AML	Phase III completed (914) 606-3500
<b>Clolar</b> <sup>®</sup> clofarabine	Genzyme <i>Cambridge, MA</i>	AML (see also lymphoma)	application submitted (617) 252-7500
		CLL, myelodysplastic syndromes	Phase II (617) 252-7500
CNF-2024	Biogen Idec <i>Cambridge, MA</i>	CLL (see also breast, solid tumors, stomach)	Phase I (617) 679-2000
CPX-351	Celator Pharmaceuticals <i>Princeton, NJ</i>	AML	Phase II (609) 243-0123

## LEUKEMIA

Product Name	Sponsor	Indication	Development Status
CYT-107	Cytheris <i>Rockville, MD</i>	myeloid leukemia (see also kidney, skin, solid tumors)	Phase I (301) 231-0450
dacetuzumab (anti-CD40) <b>(Orphan Drug)</b>	Genentech <i>South San Francisco, CA</i> Seattle Genetics <i>Bothell, WA</i>	CLL (see also lymphoma, multiple myeloma)	Phase I/II (650) 225-1000 (425) 527-4000
darinaparsin (ZIO-101)	ZIOPHARM Oncology <i>New York, NY</i>	hematological malignancies (see also liver, multiple myeloma, solid tumors)	Phase II (646) 214-0700
DCC-2036	Deciphera Pharmaceuticals <i>Lawrence, KS</i>	ALL, CML	Phase I/II (785) 838-3767
<b>Elacyt™</b> elacytarabine <b>(Orphan Drug)</b>	Clavis Pharma <i>Oslo, Norway</i>	AML (see also ovarian, skin)	Phase II www.clavispharma.com
<b>Fodosine™</b> forodesine	BioCryst Pharmaceuticals <i>Birmingham, AL</i>	CLL, leukemia (see also lymphoma)	Phase II (205) 444-4600
GCS-100	Prospect Therapeutics <i>Woburn, MA</i>	CLL (see also lymphoma, multiple myeloma)	Phase II (781) 939-5750
<b>Genasense®</b> oblimersen <b>(Orphan Drug)</b>	Genta <i>Berkeley Heights, NJ</i>	CLL (see also breast, lung, lymphoma, skin, solid tumors)	application submitted (908) 286-9800
		AML	Phase III (908) 286-9800
gimatecan	Novartis Pharmaceuticals <i>East Hanover, NJ</i>	myelodysplastic syndromes (see also brain)	Phase I (888) 669-6682
<b>Gleevec®</b> imatinib	Novartis Pharmaceuticals <i>East Hanover, NJ</i>	AML (see also prostate)	Phase II (888) 669-6682
GRN-163L	Geron <i>Menlo Park, CA</i>	CLL (see also breast, lung, multiple myeloma)	Phase I/II (650) 473-7700
GRNVAC1	Argos Therapeutics <i>Durham, NC</i> Geron <i>Menlo Park, CA</i>	AML (see also prostate)	Phase II (919) 287-6300 (650) 473-7700
GS-9219	Gilead Sciences <i>Foster City, CA</i>	CLL (see also lymphoma)	Phase I/II (800) 445-3235
HRC-302	Hemosol BioPharma <i>Mississauga, Canada</i>	CML	Phase I (905) 286-6349
<b>Hycamtin®</b> topotecan	GlaxoSmithKline <i>Rsch. Triangle Park, NC</i>	preleukemia (see also breast, colorectal, head/neck, kidney, lung, lymphoma, multiple myeloma, ovarian, pancreatic, prostate, stomach, other)	Phase III (888) 825-5249
		CML	Phase II (888) 825-5249

## LEUKEMIA

Product Name	Sponsor	Indication	Development Status
INNO-305	CytRx <i>Los Angeles, CA</i>	AML, myelodysplastic syndromes (see also solid tumors)	Phase I (310) 826-5648
ISF35	Memgen <i>Dallas, TX</i>	CLL	Phase I (214) 731-3141
ispinesib	CytoKinetics <i>South San Francisco, CA</i>	hematological malignancies (see also breast, colorectal, kidney)	Phase I (650) 624-3000
JNJ-26481585	Johnson & Johnson Pharmaceutical Research & Development <i>Raritan, NJ</i>	refractory metastatic leukemia, refractory metastatic myelodysplastic syndromes	Phase I (800) 817-5286
JVRS-100	Juvaris BioTherapeutics <i>Burlingame, CA</i>		Phase I (650) 259-1800
KW-2449	Kyowa Pharmaceutical <i>Princeton, NJ</i>	ALL, AML, CML, myelodysplastic syndromes	Phase I (609) 919-1100
laromustine (VNP 40101M) <b>(Orphan Drug)</b>	Vion Pharmaceuticals <i>New Haven, CT</i>	AML (first-line therapy in elderly patients) (see also brain)	application submitted (203) 498-4210
		AML (combination second-line therapy)	Phase III (203) 498-4210
		AML (combination therapy in elderly patients), myelodysplastic syndromes (combination therapy in elderly patients)	Phase I/II (203) 498-4210
lestaurtinib	Cephalon <i>Frazer, PA</i>	AML (see also multiple myeloma)	Phase II (610) 344-0200
<b>Leukine</b> <sup>®</sup> sargramostim	Bayer HealthCare Pharmaceuticals <i>Wayne, NJ</i>	CLL (see also lymphoma, ovarian, prostate, skin)	Phase II (888) 842-2937
lintuzumab (SGN-33) <b>(Orphan Drug)</b>	Facet Biotech <i>Redwood City, CA</i> Seattle Genetics <i>Seattle, WA</i>	AML (combination therapy in elderly patients)	Phase II (650) 454-1000 (425) 527-4000
		myelodysplastic syndromes	Phase I (650) 454-1000 (425) 527-4000
lintuzumab Ac-225	Actinium Pharmaceuticals <i>Florham Park, NJ</i>	AML	Phase I (973) 377-0713
LOR-2040 <b>(Orphan Drug)</b>	Lorus Therapeutics <i>Toronto, Canada</i>	AML (see also breast, colorectal, kidney)	Phase II (416) 798-1200
		CML, myelodysplastic syndromes	Phase I (416) 798-1200
lumilixmab (anti-CD23 mAb)	Biogen Idec <i>Cambridge, MA</i>	CLL	Phase II/III (617) 679-2000

## LEUKEMIA

Product Name	Sponsor	Indication	Development Status
LY2181308	Eli Lilly <i>Indianapolis, IN</i> Isis Pharmaceuticals <i>Carlsbad, CA</i>	AML (see also solid tumors)	Phase I/II (800) 545-5979 (760) 931-9200
<b>LymphoCide®</b> epratuzumab <b>(Orphan Drug)</b>	Immunomedics <i>Morris Plains, NJ</i>	ALL in children (see also lymphoma)	Phase II (973) 605-8200
<b>Marqibo™</b> vincristine liposomal <b>(Orphan Drug)</b>	Hana Biosciences <i>South San Francisco, CA</i>	ALL (see also skin)	Phase I/II (650) 588-6404
masitinib	AB Science USA <i>Short Hills, NJ</i>	mastocytosis (see also pancreatic, stomach)	Phase III (973) 218-2437
MDX-1342	Medarex <i>Princeton, NJ</i>	CLL	Phase I (609) 430-2880
MGCD-0103	MethylGene <i>Montreal, Canada</i>	AML, CLL, myelodysplastic syndromes (see also lymphoma, solid tumors)	Phase II (514) 337-3333
midostaurin (PKC412)	Novartis Pharmaceuticals <i>East Hanover, NJ</i>	AML	Phase III (888) 669-6682
milatuzumab (IMMU-115)	Immunomedics <i>Morris Plains, NJ</i>	CLL (see lymphoma, multiple myeloma)	Phase I/II (973) 605-8200
MK-0752	Merck <i>Whitehouse Station, NJ</i>	hematological malignancies (see also breast)	Phase I (800) 672-6372
MKC 1	EntreMed <i>Rockville, MD</i>	hematological malignancies (see also breast, lung, pancreatic)	Phase I completed (240) 864-2600
MLN4924	Millennium Pharmaceuticals <i>Cambridge, MA</i>	hematological malignancies (see also solid tumors)	Phase I (800) 390-5663
MLN8237	Millennium Pharmaceuticals <i>Cambridge, MA</i>	AML, myelodysplastic syndromes (see also brain, lymphoma, solid tumors)	Phase II (800) 390-5663
		----- ALL	Phase I/II (800) 390-5663
MPC-2130	Myriad Pharmaceuticals <i>Salt Lake City, UT</i>	hematological malignancies	Phase I (801) 584-3600
<b>Nipent®</b> pentostatin <b>(Orphan Drug)</b>	Hospira <i>Lake Forest, IL</i>	CLL (see also lymphoma, cancer-related)	Phase III (224) 212-2000
<b>Nplate™</b> romiplostim	Amgen <i>Thousand Oaks, CA</i>	myelodysplastic syndromes (see also cancer-related)	Phase II (805) 447-1000
obatoclax	Gemin X Biotechnologies <i>Montreal, Canada</i>	AML in elderly patients, myelodysplastic syndromes (see also lung, lymphoma)	Phase II (514) 281-8989
		----- CLL	Phase I/II completed (514) 281-8989

## LEUKEMIA

Product Name	Sponsor	Indication	Development Status
ofatumumab	GlaxoSmithKline <i>Rsch. Triangle Park, NC</i>	CLL (second-line therapy) (see also lymphoma)	application submitted (888) 825-5249
		CLL (first-line therapy)	Phase III (888) 825-5249
ON-01910	Onconova Therapeutics <i>Princeton, NJ</i>	AML, myelodysplastic syndromes (see also solid tumors)	Phase I (609) 844-7735
OVI-123 <b>(Orphan Drug)</b>	OncoVista <i>San Antonio, TX</i>	TdT-positive leukemia	Phase I/II (210) 677-6000
panobinostat	Novartis Pharmaceuticals <i>East Hanover, NJ</i>	CML (see also brain, breast, lymphoma, prostate)	Phase II/III completed (888) 669-6682
		AML	Phase II (888) 669-6682
PCI-24781	Pharmacyclics <i>Sunnyvale, CA</i>	hematological malignancies (see also solid tumors)	Phase II (408) 774-0330
<b>PEG-Intron A®</b> peginterferon alfa-2b	Schering-Plough <i>Kenilworth, NJ</i>	CML (see also skin)	Phase II (908) 298-4000
PHA-739358	Nerviano Medical Sciences <i>Nerviano, Italy</i>	CML	Phase II <a href="http://www.nervianoms.com">www.nervianoms.com</a>
polyphenon E <b>(Orphan Drug)</b>	Polyphenon Pharma <i>New York, NY</i>	CLL (see also bladder, prostate)	Phase I/II (212) 661-0578
PR1 cancer vaccine	Vaccine Company <i>South San Francisco, CA</i>	AML	Phase III (650) 244-4100
		CML, myelodysplastic syndromes	Phase II (650) 244-4100
PRO-131921	Genentech <i>South San Francisco, CA</i>	CLL (see also lymphoma)	Phase I/II (650) 224-1000
<b>Proleukin®</b> aldesleukin	Novartis Pharmaceuticals <i>East Hanover, NJ</i>	AML	Phase III (888) 669-6682
PS-095760	Ligand Pharmaceuticals <i>San Diego, CA</i> Schering-Plough <i>Kenilworth, NJ</i>	(see also lung)	Phase II (858) 550-7500 (908) 298-4000
R7112	Roche <i>Nutley, NJ</i>	hematological malignancies (see also solid tumors)	Phase I (973) 235-5000
recombinant Wolinella succinogenes asparaginase (rWS)	Rare Disease Therapeutics <i>Nashville, TN</i>	ALL	Phase I/II (615) 399-0700

## LEUKEMIA

Product Name	Sponsor	Indication	Development Status
<b>Revlimid®</b> lenalidomide	Celgene <i>Summit, NJ</i>	CLL (see also lymphoma, multiple myeloma, prostate, other)	Phase III (908) 673-9000
		AML	Phase II (908) 673-9000
<b>Rituxan®</b> rituxumab	Biogen Idec <i>Cambridge, MA</i> Genentech <i>South San Francisco, CA</i>	relapsed CLL	Phase III (617) 679-2000 (650) 225-1000
RTA-402	Reata Pharmaceuticals <i>Dallas, TX</i>	hematological malignancies (see also pancreatic)	Phase I (972) 865-2200
sapacitabine	Cyclacel Pharmaceuticals <i>Short Hills, NJ</i>	AML in elderly patients, myelodysplastic syndromes in elderly patients (see also lung, lymphoma)	Phase II (973) 847-5955
<b>Sarasar™</b> lonafarnib	Schering-Plough <i>Kenilworth, NJ</i>	myelodysplastic syndromes (see also breast, pancreatic)	Phase III (908) 298-4000
		leukemia	Phase II (908) 298-4000
SB-1518	S*Bio <i>Redwood City, CA</i>	(see also lymphoma)	Phase I (650) 730-2860
SCH-727965	Schering-Plough <i>Kenilworth, NJ</i>	(see also breast, lung)	Phase II (908) 298-4000
SGN-35	Seattle Genetics <i>Bothell, WA</i>	hematological malignancies (see also lymphoma)	Phase I (425) 527-4000
SL-401	Stemline Therapeutics <i>New York, NY</i>	AML	Phase I/II (212) 831-1111
SNS-595	Sunesis Pharmaceuticals <i>South San Francisco, CA</i>	AML in elderly patients (see also ovarian)	Phase II (650) 266-3500
		AML (combination therapy)	Phase I/II (650) 266-3500
		AML (monotherapy)	Phase I (650) 266-3500
SPC-2996	Santaris Pharma <i>Horsholm, Denmark</i>	CLL	Phase I/II completed
<b>Sprycel™</b> dasatinib	Bristol-Myers Squibb <i>Princeton, NJ</i>	first-line CML (see also prostate, solid tumors)	Phase III (212) 546-4000
		other hematological malignancies	in clinical trials (212) 546-4000
STA-9090	Synta Pharmaceuticals <i>Lexington, MA</i>	hematological malignancies (see also solid tumors)	Phase I/II (781) 274-8200

## LEUKEMIA

Product Name	Sponsor	Indication	Development Status
<b>StemEx<sup>®</sup></b> hematopoietic stem cell therapy <b>(Orphan Drug)</b>	Gamida Cell <i>Jerusalem, Israel</i> Teva Pharmaceuticals USA <i>North Wales, PA</i>	hematological malignancies	Phase II/III (215) 591-3000
TAK901	Millennium Pharmaceuticals <i>Cambridge, MA</i>	hematological malignancies	Phase I (800) 390-5663
tamibarotene <b>(Orphan Drug)</b>	CytRx <i>Los Angeles, CA</i>	APL	Phase II (310) 826-5648
<b>Tasigna<sup>®</sup></b> nilotinib <b>(Orphan Drug)</b>	Novartis Pharmaceuticals <i>East Hanover, NJ</i>	CML (first-line therapy) (see also stomach)	Phase II (888) 669-6682
tasisulam (ASAP)	Eli Lilly <i>Indianapolis, IN</i>	AML (see also ovarian, sarcoma, skin)	Phase I (800) 545-5979
<b>Telintra<sup>®</sup></b> ezatiostat	Telik <i>Palo Alto, CA</i>	myelodysplastic syndromes (see also cancer-related)	Phase II (650) 845-7700
<b>Temodar<sup>®</sup></b> temozolomide	Schering-Plough <i>Kenilworth, NJ</i>	AML (see also lung)	Phase II (908) 298-4000
<b>Triapine<sup>®</sup></b>	Vion Pharmaceuticals <i>New Haven, CT</i>	leukemia (see also lung, pancreatic, prostate)	Phase II (203) 498-4210
		hematological malignancies	Phase I (203) 498-4210
tricitriline (VQD-002)	VioQuest Pharmaceuticals <i>Basking Ridge, NJ</i>	hematological malignancies (see also solid tumors)	Phase I/II (908) 766-4400
<b>Trisenox<sup>®</sup></b> arsenic trioxide	Cephalon <i>Frazer, PA</i>	AML in elderly patients (combination therapy) (see also brain, multiple myeloma)	Phase III (610) 344-0200
TRU-016	Trubion Pharmaceuticals <i>Seattle, WA</i>	CLL	Phase I/II (206) 838-0500
<b>Vidaza<sup>®</sup></b> azacitidine <b>(Orphan Drug)</b>	Celgene <i>Summit, NJ</i>	AML, myelodysplastic syndromes (see also lymphoma, prostate)	Phase I (908) 673-9000
VP101	Access Pharmaceuticals <i>Dallas, TX</i>	hematological malignancies (see also brain, colorectal, prostate)	Phase II (214) 905-5100
VP701	Virium Pharmaceuticals <i>Princeton, NJ</i>		Phase I (609) 951-2270
<b>Xcytrin<sup>®</sup></b> motexafin gadolinium	Pharmacyclics <i>Sunnyvale, CA</i>	CLL (see also brain, kidney, lung, lymphoma)	Phase II (408) 774-0330
XL-228	Exelixis <i>South San Francisco, CA</i>	ALL, CML	Phase I (650) 837-7000
<b>Zarnestra<sup>™</sup></b> tipifarnib	Johnson & Johnson Pharmaceutical Research & Development <i>Raritan, NJ</i>	AML (see also pancreatic)	Phase III (800) 817-5286

## LEUKEMIA

Product Name	Sponsor	Indication	Development Status
<b>Zolinza®</b> vorinostat	Merck <i>Whitehouse Station, NJ</i>	AML, myelodysplastic syndromes (see also brain, breast, colorectal, kidney, lung, lymphoma, multiple myeloma)	Phase II (800) 672-6372
zosuquidar	Kanisa Pharmaceuticals <i>San Diego, CA</i>	AML in elderly patients	Phase I/II (858) 436-1800

## LIVER CANCER

Product Name	Sponsor	Indication	Development Status
ABT-869	Abbott Laboratories <i>Abbott Park, IL</i> Genentech <i>South San Francisco, CA</i>	(see also breast, kidney, lung)	Phase II (847) 937-6100 (650) 225-1000
amsilarotene	Taiho Pharma USA <i>Princeton, NJ</i>		Phase I/II (609) 750-5300
<b>Armala™</b> pazopanib	GlaxoSmithKline <i>Rsch. Triangle Park, NC</i>	(see also brain, breast, cervical, kidney, lung, ovarian, sarcoma, other)	Phase I (888) 825-5249
ARQ-197	ArQule <i>Woburn, MA</i> Daiichi Sankyo <i>Parsippany, NJ</i>	hepatocellular carcinoma (see also lung, pancreatic, solid tumors)	Phase I (781) 994-0300 (973) 359-2600
<b>Avastin®</b> bevacizumab	Genentech <i>South San Francisco, CA</i>	(see also brain, colorectal, head/neck, kidney, lung, lymphoma, multiple myeloma, ovarian, pancreatic, prostate, stomach, other)	Phase II (650) 225-1000
AZD6244	AstraZeneca <i>Wilmington, DE</i>	biliary cancer, liver cancer (see also leukemia, lung, multiple myeloma, ovarian, pancreatic, skin, other)	Phase II (800) 236-9933
batabulin	Amgen <i>Thousand Oaks, CA</i>		Phase III (805) 447-1000
belinostat	TopoTarget USA <i>Rockaway, NJ</i>	inoperable/unresectable liver cancer (see also bladder, colorectal, leukemia, lung, lymphoma, ovarian)	Phase I/II (973) 895-6900
brivanib (VEGFR/FGFR kinase inhibitor)	Bristol-Myers Squibb <i>Princeton, NJ</i>	hepatocellular carcinoma (see also colorectal)	Phase III (212) 546-4000
CRS-100	Cerus <i>Concord, CA</i>		Phase I (925) 288-6000
darinaparsin (ZIO-101)	ZIOPHARM Oncology <i>New York, NY</i>	(see also leukemia, multiple myeloma, solid tumors)	Phase II completed (646) 214-0700
DENSPM <b>(Orphan Drug)</b>	Genzyme <i>Cambridge, MA</i>		Phase I/II (617) 252-7500

# LIVER CANCER

Product Name	Sponsor	Indication	Development Status
doxorubicin (percutaneous hepatic perfusion)	Delcath Systems New York, NY		Phase II (212) 489-2100
EHC-18	Enzo BioChem New York, NY		Phase I (212) 583-0100
eniluracil	Adherex Technologies Durham, NC	(see also solid tumors)	Phase I/II (919) 484-8484
ferucarbotran	Bayer HealthCare Pharmaceuticals Wayne, NJ	liver cancer imaging	application submitted (888) 842-2937
GC-33	Chugai Pharma USA Berkeley Heights, NJ		Phase I (908) 516-1350
IMC-1121B	Eli Lilly Indianapolis, IN ImClone Systems New York, NY	(see also breast, colorectal, kidney, lung, ovarian, prostate, skin)	Phase II (800) 545-5979 (212) 645-1405
IMC-A12	Eli Lilly Indianapolis, IN ImClone Systems New York, NY	(see also breast, colorectal, head/neck, lung, pancreatic, prostate, sarcoma, solid tumors)	Phase II (800) 545-5979 (212) 645-1405
irinotecan eluting beads	Biocompatibles International Surrey, United Kingdom	metastatic liver cancer from colorectal cancer	Phase II www.biocompatibles.com
JX-594	Jennerex Biotherapeutics San Francisco, CA	(see also solid tumors)	Phase II (415) 281-8886
mapatumumab	Human Genome Sciences Rockville, MD	(see also lung, multiple myeloma)	Phase I/II (301) 309-8504
MB-7133 <b>(Orphan Drug)</b>	Metabasis Therapeutics La Jolla, CA	inoperable, unresectable liver cancer	Phase I/II (858) 587-2770
melphalan drug delivery system	Delcath Systems New York, NY		Phase III (212) 489-2100
NV1020	MediGene San Diego, CA		Phase I/II (858) 586-2240
patupilone (EPO906)	Novartis Pharmaceuticals East Hanover, NJ	(see also brain, breast, colorectal, lung, ovarian)	Phase II (888) 669-6682
<b>Photofrin® PDT</b> porfimer sodium	Axcan Pharma Birmingham, AL	cholangiocarcinoma	Phase II (205) 991-8085
PR-104	Proacta Therapeutics San Diego, CA	(see also lung)	Phase I (858) 642-0386
SCH-58500 (p53 gene therapy)	Schering-Plough Kenilworth, NJ	(see also bladder, head/neck, lung, cancer-related)	Phase I (908) 298-4000
<b>Sutent®</b> sunitinib	Pfizer New York, NY	(see also breast, colorectal, lung, pancreatic, prostate, sarcoma, stomach)	Phase III (860) 732-5156

## LIVER CANCER

Product Name	Sponsor	Indication	Development Status
tacatuzumab-Y-90 (IMMU-105)	Immunomedics <i>Morris Plains, NJ</i>		Phase I (973) 605-8200
<b>Tarceva</b> <sup>®</sup> erlotinib	Genentech <i>South San Francisco, CA</i> OSI Pharmaceuticals <i>Melville, NY</i>	(see also bladder, brain, breast, colorectal, head/neck, lung, other)	Phase II (650) 224-1000 (800) 572-1932
<b>Thermodox</b> <sup>™</sup> LTSDEL	Celsion <i>Columbia, MD</i>	inoperable, unresectable liver cancer (see also breast)	Phase III (410) 290-5390
<b>Thymitaq</b> <sup>®</sup> nolatrexed <b>(Orphan Drug)</b>	YM BioSciences <i>Wayne, PA</i>	(see also colorectal, head/neck, lung, pancreatic, prostate)	Phase III (610) 560-0600
TJ9	Tsumura <i>Tokyo, Japan</i>		Phase II www.tsumura.co.jp

## LUNG CANCER

Product Name	Sponsor	Indication	Development Status
1572932A	GlaxoSmithKline <i>Rsch. Triangle Park, NC</i>	non-small-cell lung cancer (NSCLC)	Phase III (888) 825-5249
<b>Abraxane</b> <sup>™</sup> albumin-bound paclitaxel	Abraxis BioScience <i>Los Angeles, CA</i>	NSCLC (see also head/neck, ovarian, pancreatic, prostate, skin)	Phase III (310) 883-1300
ABT-263	Abbott Laboratories <i>Abbott Park, IL</i> Genentech <i>South San Francisco, CA</i>	small-cell-lung cancer (SCLC) (see also leukemia, lymphoma)	Phase I/II (847) 937-6100 (650) 225-1000
ABT-751	Abbott Laboratories <i>Abbott Park, IL</i>	NSCLC (see also breast, colorectal, kidney)	Phase II (847) 937-6100
ABT-869	Abbott Laboratories <i>Abbott Park, IL</i> Genentech <i>South San Francisco, CA</i>	NSCLC (see also breast, kidney, liver)	Phase II (847) 937-6100 (650) 225-1000
<b>Actimid</b> <sup>™</sup> pomalidomide	Celgene <i>Summit, NJ</i>	SCLC (combination therapy) (see also multiple myeloma, pancreatic, prostate, sarcoma)	Phase I/II (908) 673-9000
<b>Advexin</b> <sup>®</sup> contusugene ladenovec	Introgen Therapeutics <i>Austin, TX</i>	NSCLC (combination therapy) (see also bladder, brain, breast, head/neck, ovarian, prostate, stomach)	Phase II (512) 708-9310
		----- bronchioloalveolar adenocarcinoma	Phase I (512) 708-9310
aflibercept (VEGF-trap)	sanofi-aventis <i>Bridgewater, NJ</i> Regeneron Pharmaceuticals <i>Tarrytown, NY</i>	second-line NSCLC (combination therapy) (see also colorectal, pancreatic, prostate, other)	Phase III (800) 633-1610 (914) 345-7400

# LUNG CANCER

Product Name	Sponsor	Indication	Development Status
<b>Alimta</b> <sup>®</sup> pemetrexed	Eli Lilly <i>Indianapolis, IN</i>	NSCLC (maintenance therapy) (see also breast, head/neck, ovarian)	Phase III (800) 545-5979
AMG 102	Amgen <i>Thousand Oaks, CA</i>	SCLC (see also brain, colorectal, kidney, stomach)	Phase I/II (805) 447-1000
AMG 479	Amgen <i>Thousand Oaks, CA</i>	(see also breast, colorectal, pancreatic, sarcoma)	Phase II (805) 447-1000
<b>Amplimexon</b> <sup>®</sup> imexon	AmpliMed <i>Tucson, AZ</i>	(see also breast, multiple myeloma, pancreatic, prostate, skin)	Phase I (520) 529-1000
amrubicin <b>(Orphan Drug)</b>	Celgene <i>Summit, NJ</i>	SCLC (second-line therapy)	Phase III (908) 673-9000
ANZ-207	Anza Therapeutics <i>Concord, CA</i>	mesothelioma, NSCLC (see also ovarian, pancreatic)	Phase I (925) 288-6000
apomab	Genentech <i>South San Francisco, CA</i>	NSCLC (combination therapy) (see also colorectal, lymphoma)	Phase II (650) 225-1000
<b>Armala</b> <sup>™</sup> pazopanib	GlaxoSmithKline <i>Rsch. Triangle Park, NC</i>	NSCLC (see also brain, breast, cervical, kidney, liver, ovarian, sarcoma, other)	Phase II (888) 825-5249
ARQ-197	ArQule <i>Woburn, MA</i> Daiichi Sankyo <i>Parsippany, NJ</i>	NSCLC (see also liver, pancreatic, solid tumors)	Phase I/II (781) 994-0300 (973) 359-2600
AT-101	Ascenta Therapeutics <i>San Diego, CA</i>	NSCLC, SCLC (see also lymphoma, prostate)	Phase II (858) 436-1200
AV-951	AVEO Pharmaceuticals <i>Cambridge, MA</i>	NSCLC (see also kidney, stomach)	Phase I/II (617) 299-5000
<b>Avastin</b> <sup>®</sup> bevacizumab	Genentech <i>South San Francisco, CA</i>	SCLC (see also brain, colorectal, head/neck, kidney, liver, lymphoma, multiple myeloma, ovarian, pancreatic, prostate, stomach, other)	Phase II (650) 225-1000
axitinib	Pfizer <i>New York, NY</i>	NSCLC (first-line therapy) (see also colorectal, kidney, solid tumors, other)	Phase II (860) 732-5156
AZD6244	AstraZeneca <i>Wilmington, DE</i>	NSCLC (see also leukemia, liver, multiple myeloma, ovarian, pancreatic, skin, other)	Phase II (800) 236-9933
belinostat	TopoTarget USA <i>Rockaway, NJ</i>	mesothelioma (see also bladder, colorectal, leukemia, liver, lymphoma, ovarian, stomach)	Phase II (973) 895-6900
BIBF 1120	Boehringer Ingelheim Pharmaceuticals <i>Ridgefield, CT</i>	NSCLC (see also solid tumors)	Phase III (800) 243-0127

# LUNG CANCER

Product Name	Sponsor	Indication	Development Status
BIBW 2992	Boehringer Ingelheim Pharmaceuticals <i>Ridgefield, CT</i>	NSCLC (second-line therapy) (see also brain, breast, head/neck)	Phase II/III (800) 243-0127
BMS-690514 (ErbB/VEGF receptor inhibitor)	Bristol-Myers Squibb <i>Princeton, NJ</i>	(see also solid tumors)	in clinical trials (212) 546-4000
<b>Camptosar</b> <sup>®</sup> irinotecan	Pfizer <i>New York, NY</i>	(see also cervical, pancreatic, prostate)	application submitted (860) 732-5156
canertinib	Pfizer <i>New York, NY</i>	NSCLC	Phase II (860) 732-5156
<b>Capoxigem</b> <sup>®</sup> apricoxib	Tragara Pharmaceuticals <i>San Diego, CA</i>	NSCLC (combination therapy) (see also breast, pancreatic)	Phase II (858) 350-6900
CBP501	Millennium Pharmaceuticals <i>Cambridge, MA</i>	mesothelioma (combination therapy) (see also solid tumors)	Phase II (800) 390-5663
cisplatin liposomal	Transave <i>Monmouth Junction, NJ</i>		Phase II (732) 438-9434
conatumumab	Amgen <i>Thousand Oaks, CA</i>	NSCLC (see also colorectal, pancreatic, sarcoma)	Phase I/II (805) 447-1000
CP-751871	Pfizer <i>New York, NY</i>	NSCLC (combination therapy), metastatic disease (see also breast, colorectal, multiple myeloma, prostate, sarcoma)	Phase III (860) 732-5156
		NSCLC (combination first-line therapy)	Phase I/II (860) 732-5156
CS-1017	Daiichi Sankyo <i>Parsippany, NJ</i>	NSCLC (see also other)	Phase II (973) 359-2600
deforolimus (MK-8669)	ARIAD Pharmaceuticals <i>Cambridge, MA</i> Merck <i>Whitehouse Station, NJ</i>	NSCLC (see also breast, prostate, sarcoma, other)	Phase II (617) 494-0400 (800) 672-6372
diflomotecan	Biomeasure (Ipsen) <i>Milford, MA</i>	SCLC	Phase II (508) 478-0144
DMXAA	Antisoma <i>Cambridge, MA</i> Novartis Pharmaceuticals <i>East Hanover, NJ</i>	NSCLC (first-line therapy) (see also prostate)	Phase III (617) 225-0522 (888) 669-6682
doxorubicin inhaled	Zivena <i>Columbus, OH</i>		Phase II (614) 340-2370
EC-145	Endocyte <i>West Lafayette, IN</i>	late-stage NSCLC (see also ovarian, other)	Phase II (765) 463-7175

# LUNG CANCER

Product Name	Sponsor	Indication	Development Status
<b>Erbix<sup>®</sup></b> cetuximab	Bristol-Myers Squibb <i>Princeton, NJ</i> Eli Lilly <i>Indianapolis, IN</i> ImClone Systems <i>New York, NY</i>	advanced NSCLC, locally advanced NSCLC, first-line, second-line (see also bladder, colorectal, head/neck, prostate, stomach)	Phase III (212) 546-4000 (800) 545-5979 (212) 645-1405
eribulin mesylate (E7389)	Eisai <i>Woodcliff Lake, NJ</i>	NSCLC (see also breast, head/neck, ovarian, prostate, sarcoma, solid tumors)	Phase II (888) 422-4743
<b>Gemzar<sup>®</sup></b> gemcitabine	Eli Lilly <i>Indianapolis, IN</i>	metastatic SCLC (see also head/neck, lymphoma, sarcoma)	Phase II (800) 545-5979
<b>Genasense<sup>®</sup></b> oblimersen	Genta <i>Berkeley Heights, NJ</i>	NSCLC (see also breast, leukemia, lymphoma, skin, solid tumors)	Phase II/III (908) 286-9800
GI-4000	GlobelImmune <i>Louisville, CO</i>	NSCLC (see also pancreatic)	Phase II (303) 625-2700
glufosfamide	Threshold Pharmaceuticals <i>Redwood City, CA</i>	SCLC (see also breast, pancreatic, sarcoma)	Phase II (650) 474-8200
GRN-163L	Geron <i>Menlo Park, CA</i>	NSCLC (combination therapy) (see also breast, leukemia, multiple myeloma)	Phase I (650) 473-7700
<b>Hycamtin<sup>®</sup></b> topotecan	GlaxoSmithKline <i>Rsch. Triangle Park, NC</i>	NSCLC (see also breast, colorectal, head/neck, kidney, leukemia, lymphoma, multiple myeloma, ovarian, pancreatic, prostate, stomach, other)	Phase III (888) 825-5249
<b>HyperAcute<sup>®</sup> Lung</b> lung cancer vaccine	NewLink Genetics <i>Ames, IA</i>	NSCLC	Phase I/II (515) 296-5555
IMC-1121B	Eli Lilly <i>Indianapolis, IN</i> ImClone Systems <i>New York, NY</i>	NSCLC (see also breast, colorectal, kidney, liver, ovarian, prostate, skin)	Phase II (800) 545-5979 (212) 645-1405
IMC-A12	Eli Lilly <i>Indianapolis, IN</i> ImClone Systems <i>New York, NY</i>	NSCLC (combination therapy) (see also breast, colorectal, head/neck, liver, pancreatic, prostate, sarcoma, solid tumors)	Phase II (800) 545-5979 (212) 645-1405
IMGN-901	ImmunoGen <i>Cambridge, MA</i>	SCLC (see also multiple myeloma)	Phase II (617) 995-2500
IMO-2055	Idera Pharmaceuticals <i>Cambridge, MA</i>	NSCLC (second-line therapy) (see also colorectal, kidney)	Phase I (617) 679-5500
INGN 225 (p53 vaccine)	Introgen Therapeutics <i>Austin, TX</i>	SCLC (see also breast)	Phase II (512) 708-9310
INGN 401 (nano-FUS-1)	Introgen Therapeutics <i>Austin, TX</i>	NSCLC	Phase I (512) 708-9310

# LUNG CANCER

Product Name	Sponsor	Indication	Development Status
<b>Ixemptra™</b> ixabepilone	Bristol-Myers Squibb <i>Princeton, NJ</i>	NSCLC (see also breast, pancreatic, prostate)	in clinical trials (212) 546-4000
JNJ-26854165	Johnson & Johnson Pharmaceutical Research & Development <i>Raritan, NJ</i>	NSCLC (see also prostate)	Phase I (800) 817-5286
<b>Karenitecin®</b> cositecan	BioNumerik Pharmaceuticals <i>San Antonio, TX</i>	NSCLC (intravenous) (see also brain, ovarian, skin)	Phase II (210) 614-1701
		NSCLC (oral)	Phase I/II (210) 614-1701
<b>Levulan® PD</b> aminolevulinic acid	DUSA Pharmaceuticals <i>Wilmington, MA</i>	(see also bladder, cervical, colorectal, stomach)	in clinical trials (978) 657-7500
<b>Lucanix®</b> belagenpumatucel-L	NovaRx <i>San Diego, CA</i>	NSCLC (see also brain)	Phase III (858) 552-8600
lung cancer vaccine	AVAX Technologies <i>Philadelphia, PA</i>	NSCLC	Phase I/II (215) 241-9760
lung cancer vaccine (NY-ESO-1)	Pfizer <i>New York, NY</i>	NSCLC	Phase I (860) 732-5156
mapatumumab	Human Genome Sciences <i>Rockville, MD</i>	NSCLC (see also liver, multiple myeloma)	Phase II (301) 309-8504
milataxel	Taxolog <i>Fairfield, NJ</i>	NSCLC (see also breast, colorectal)	Phase II (877) 829-6564
MK-0646	Merck <i>Whitehouse Station, NJ</i>	NSCLC (see also breast, pancreatic, other)	Phase I/II (800) 672-6372
MKC 1	EntreMed <i>Rockville, MD</i>	NSCLC (see also breast, leukemia, pancreatic)	Phase II (240) 864-2600
MORAb-009	Eisai <i>Woodcliff Lake, NJ</i>	mesothelioma (see also ovarian, pancreatic)	Phase II (888) 422-4743
		NSCLC	Phase I (888) 422-4743
motesanib	Amgen <i>Thousand Oaks, CA</i> Millennium Pharmaceuticals <i>Cambridge, MA</i>	NSCLC (combination therapy) (see also breast, colorectal, other)	Phase III (805) 447-1000 (800) 390-5663
naptumomab estafenatox	Active Biotech <i>Lund, Sweden</i>	NSCLC (see also kidney, pancreatic)	Phase I completed www.activebiotech.com
neratinib (HKI272)	Wyeth Pharmaceuticals <i>Collegeville, PA</i>	NSCLC (see also breast)	Phase II (800) 934-5556

# LUNG CANCER

Product Name	Sponsor	Indication	Development Status
<b>Nexavar®</b> sorafenib	Bayer HealthCare Pharmaceuticals Wayne, NJ	NSCLC (combination therapy) (see also breast, skin)	Phase III (888) 842-2837 (510) 597-6500
	Onyx Pharmaceuticals Emeryville, CA	SCLC	Phase II (888) 842-2837 (510) 597-6500
NOV-002	Novelos Therapeutics Newton, MA	NSCLC (combination first-line therapy) (see also breast, ovarian)	Phase III (617) 244-1616
NPI-2358	Nereus Pharmaceuticals San Diego, CA	NSCLC (see also lymphoma)	Phase I (858) 587-4090
obatoclax	Gemin X Biotechnologies Montreal, Canada	NSCLC, SCLC (combination therapy) (see also leukemia, lymphoma)	Phase I/II (514) 281-8989
OBP-301	Oncolys Biopharma Tokyo, Japan	mesothelioma (see also breast, head/neck)	Phase I www.oncolys.com
OGX-011 (ISIS-112989)	Isis Pharmaceuticals Carlsbad, CA Oncogenex Pharmaceuticals Bothell, WA	NSCLC	Phase I/II (760) 931-9200 (425) 686-1500
OGX-427	Oncogenex Pharmaceuticals Bothell, WA	NSCLC (see also bladder, breast, ovarian, prostate)	Phase I (425) 686-1500
<b>Onconase®</b> ranpirnase (Orphan Drug)	Alfacell Bloomfield, NJ	mesothelioma (combination therapy)	Phase III (973) 748-8082
	Strativa Pharmaceuticals Woodcliff Lake, NJ	NSCLC	Phase I/II (973) 748-8082
<b>Opaxio™</b> paclitaxel poliglumex	Cell Therapeutics Seattle, WA Novartis Pharmaceuticals East Hanover, NJ	NSCLC (see also ovarian, stomach, other)	Phase III (800) 215-2355 (888) 669-6682
P-2045	Antisoma Cambridge, MA	NSCLC, SCLC	Phase I (617) 225-0522
patupilone (EPO906)	Novartis Pharmaceuticals East Hanover, NJ	NSCLC (see also brain, breast, colorectal, liver, ovarian)	Phase II (888) 669-6682
pelitinib (EKB569)	Wyeth Pharmaceuticals Collegeville, PA	NSCLC (second-line therapy) (see also colorectal)	Phase II (800) 934-5556
PF-299804	Pfizer New York, NY	NSCLC	Phase II (860) 732-5156
picoplatin (Orphan Drug)	Poniard Pharmaceuticals Seattle, WA	SCLC (see also colorectal)	Phase II (206) 281-7001
plitidepsin	PharmaMar USA Cambridge, MA	SCLC (see also multiple myeloma, prostate)	Phase II (617) 868-3797

# LUNG CANCER

Product Name	Sponsor	Indication	Development Status
PR-104	Proacta Therapeutics <i>San Diego, CA</i>	NSCLC, SCLC (see also liver)	Phase II (858) 642-0386
pralatrexate (PDX)	Allos Therapeutics <i>Westminster, CO</i>	NSCLC (see also bladder, lymphoma)	Phase II (303) 426-6262
<b>ProMune</b> <sup>®</sup> agatolimod	Pfizer <i>New York, NY</i>	NSCLC	Phase II (860) 732-5156
PS-095760	Ligand Pharmaceuticals <i>San Diego, CA</i> Schering-Plough <i>Kenilworth, NJ</i>	NSCLC (see also leukemia)	Phase II (858) 550-7500 (908) 298-4000
R1454	Roche <i>Nutley, NJ</i>	NSCLC	Phase I (973) 235-5000
R1507	Roche <i>Nutley, NJ</i>	NSCLC (combination therapy) (see also breast, lymphoma, sarcoma)	Phase II (973) 235-5000
<b>Reolysin</b> <sup>®</sup> reovirus	Oncolytics Biotech <i>Calgary, Canada</i>	NSCLC (combination therapy) (see also brain, head/neck, sarcoma, skin)	Phase II (403) 670-7377
retaspimycin (IPI 504)	Infinity Pharmaceuticals <i>Cambridge, MA</i>	NSCLC (see also breast, stomach)	Phase II (617) 453-1000
S-1	Taiho Pharma USA <i>Princeton, NJ</i>	NSCLC	Phase II (609) 750-5300
salirasib	Concordia Pharmaceuticals <i>Ft. Lauderdale, FL</i>	NSCLC (see also pancreatic)	Phase II <a href="http://www.concordiapharma.com">www.concordiapharma.com</a>
sapacitabine	Cyclacel Pharmaceuticals <i>Short Hills, NJ</i>	NSCLC (see also leukemia, lymphoma)	Phase II (973) 847-5955
satraplatin	Spectrum Pharmaceuticals <i>Irvine, CA</i>	NSCLC (combination therapy) (see also breast, prostate)	Phase II (949) 788-6700
SCH-58500 (p53 gene therapy)	Schering-Plough <i>Kenilworth, NJ</i>	NSCLC (see also bladder, head/neck, liver, cancer-related)	Phase II (908) 298-4000
SCH-727965	Schering-Plough <i>Kenilworth, NJ</i>	NSCLC (see also breast, leukemia)	Phase II (908) 298-4000
seliciclib	Cyclacel Pharmaceuticals <i>Short Hills, NJ</i>	NSCLC (see also other)	Phase II (973) 847-5955
sibrotuzumab	Life Science Pharmaceuticals <i>Greenwich, CT</i>	NSCLC (see also colorectal, head/neck)	Phase II (203) 422-6500
SNDX-275	Syndax Pharmaceuticals <i>Waltham, MA</i>	NSCLC (see also breast)	Phase I/II (781) 839-7301
<b>Stimuvax</b> <sup>®</sup> BLP25 liposomal cancer vaccine	EMD Serono <i>Rockland, MA</i> Oncothyreon <i>Bellevue, WA</i>	NSCLC	Phase III (800) 283-8088 (425) 450-0370

# LUNG CANCER

Product Name	Sponsor	Indication	Development Status
<b>Sutent</b> <sup>®</sup> sunitinib	Pfizer New York, NY	NSCLC (combination therapy, second-line therapy) (see also breast, colorectal, liver, pancreatic, prostate, sarcoma, stomach)	Phase III (860) 732-5156
talactoferrin <b>(Orphan Drug)</b>	Agennix Houston, TX	NSCLC (see also kidney)	Phase III (713) 552-1091
<b>Tarceva</b> <sup>®</sup> erlotinib	Genentech South San Francisco, CA OSI Pharmaceuticals Melville, NY	NSCLC (combination therapy) (see also bladder, brain, breast, colorectal, head/neck, liver, other)	Phase III (650) 225-1000 (800) 572-1932
<b>Telcyta</b> <sup>™</sup> canfosfimide	Telik Palo Alto, CA	NSCLC (third-line therapy) (see also breast, colorectal, ovarian)	Phase III (650) 845-7700
<b>Temodar</b> <sup>®</sup> temozolomide	Schering-Plough Kenilworth, NJ	SCLC (see also leukemia)	Phase II (908) 298-4000
TG-4010	Transgene Kensington, MD		Phase I (301) 816-5404
<b>Thymitaq</b> <sup>®</sup> nolatrexed	YM BioSciences Wayne, PA	(see also colorectal, head/neck, liver, pancreatic, prostate)	Phase II (610) 560-0600
topotecan liposomal	Hana Biosciences South San Francisco, CA	SCLC (see also ovarian)	Phase I (650) 588-6404
<b>Torisel</b> <sup>™</sup> temsirolimus	Wyeth Pharmaceuticals Collegeville, PA	NSCLC (see also colorectal, kidney, lymphoma, multiple myeloma, prostate)	Phase II (800) 934-5556
tremelimumab	Pfizer New York, NY	NSCLC (see also breast, colorectal, kidney, prostate, skin)	Phase II (860) 732-5156
<b>Triapine</b> <sup>®</sup>	Vion Pharmaceuticals New Haven, CT	NSCLC (see also leukemia, pancreatic, prostate)	Phase II (203) 498-4210
tucotuzumab celmoleukin	EMD Serono Rockland, MA	NSCLC, SCLC (see also colorectal, ovarian, prostate)	Phase II (800) 283-8088
<b>Vectibix</b> <sup>™</sup> panitumumab	Amgen Thousand Oaks, CA	NSCLC (see also head/neck)	Phase II (805) 447-1000
<b>Velcade</b> <sup>®</sup> bortezomib	Millennium Pharmaceuticals Cambridge, MA	NSCLC (combination therapy, metastatic disease, monotherapy, second-line therapy) (see also lymphoma, multiple myeloma, solid tumors)	Phase II (800) 390-5663
volociximab	Biogen Idec Cambridge, MA Facet Biotech Redwood City, CA	NSCLC (see also ovarian, pancreatic, skin)	Phase II (617) 679-2000 (650) 454-1000

## LUNG CANCER

Product Name	Sponsor	Indication	Development Status
<b>Xcytrin</b> <sup>®</sup> motexafin gadolinium	Pharmacyclics <i>Sunnyvale, CA</i>	NSCLC (see also brain, kidney, leukemia, lymphoma)	Phase II (408) 774-0330
XL-647	Exelixis <i>South San Francisco, CA</i>	NSCLC (first-line therapy, second-line therapy)	Phase II (650) 837-7000
<b>Zactima</b> <sup>™</sup> vandetanib	AstraZeneca <i>Wilmington, DE</i>	NSCLC (see also brain, breast, other)	Phase III (800) 236-9933
		SCLC	Phase II (800) 236-9933
<b>Zolinza</b> <sup>®</sup> vorinostat	Merck <i>Whitehouse Station, NJ</i>	mesothelioma (see also brain, breast, colorectal, kidney, leukemia, lymphoma, multiple myeloma)	Phase III (800) 672-6372
<b>Zybrestat</b> <sup>™</sup> fosbretabulin	OXIGENE <i>Waltham, MA</i>	NSCLC (first-line therapy) (see also head/neck, ovarian, other)	Phase II (781) 547-5900

## LYMPHOMA

Product Name	Sponsor	Indication	Development Status
461364	GlaxoSmithKline <i>Rsch. Triangle Park, NC</i>	non-Hodgkin's lymphoma (see also solid tumors)	Phase I (888) 825-5249
690693	GlaxoSmithKline <i>Rsch. Triangle Park, NC</i>	(see also solid tumors)	Phase I (888) 825-5249
743921	Cytokinetics <i>South San Francisco, CA</i>	non-Hodgkin's lymphoma	Phase I/II (650) 624-3000
		Hodgkin's disease	Phase I (650) 624-3000
1018 ISS	Dynavax Technologies <i>Berkeley, CA</i>	non-Hodgkin's lymphoma (see also colorectal)	Phase II (510) 848-5100
ABT-263	Abbott Laboratories <i>Abbott Park, IL</i> Genentech <i>South San Francisco, CA</i>	(see also leukemia, lung)	Phase I/II (847) 937-6100 (650) 225-1000
AME-133	Applied Molecular Evolution <i>San Diego, CA</i>	non-Hodgkin's lymphoma	Phase I/II (858) 597-4990
AMG 951 (rhApo2L/TRAIL)	Amgen <i>Thousand Oaks, CA</i> Genentech <i>South San Francisco, CA</i>	non-Hodgkin's lymphoma (see also colorectal)	Phase II (805) 447-1000 (650) 225-1000
apomab	Genentech <i>South San Francisco, CA</i>	non-Hodgkin's lymphoma (combination therapy) (see also colorectal, lung)	Phase II (650) 225-1000

## LYMPHOMA

Product Name	Sponsor	Indication	Development Status
AR-726	Antigenics <i>New York, NY</i>	non-Hodgkin's lymphoma (see also colorectal)	Phase I (212) 994-8200
AT-101	Ascenta Therapeutics <i>San Diego, CA</i>	non-Hodgkin's lymphoma (see also lung, prostate)	Phase II (858) 436-1200
atacept (TACI-Ig)	EMD Serono <i>Rockland, MA</i> ZymoGenetics <i>Seattle, WA</i>	non-Hodgkin's lymphoma (see also leukemia, multiple myeloma)	Phase I (800) 283-8088 (206) 442-6600
AV-299 (SCH-90015)	AVEO Pharmaceuticals <i>Cambridge, MA</i> Schering-Plough <i>Kenilworth, NJ</i>	(see also solid tumors)	Phase I (617) 299-5000
<b>Avastin®</b> bevacizumab	Genentech <i>South San Francisco, CA</i>	diffuse large B-cell lymphoma (first-line therapy) (see also brain, colorectal, head/neck, kidney, liver, lung, multiple myeloma, ovarian, pancreatic, prostate, stomach, other)	Phase III (650) 225-1000
		non-Hodgkin's lymphoma	Phase II (650) 225-1000
AZD4877	AstraZeneca <i>Wilmington, DE</i>	(see also leukemia)	Phase I (800) 236-9933
bectumomab	Immunomedics <i>Morris Plains, NJ</i>	non-Hodgkin's lymphoma imaging agent	Phase II (973) 605-8200
belinostat	TopoTarget USA <i>Rockaway, NJ</i>	peripheral T-cell lymphoma (see also bladder, colorectal, leukemia, liver, lung, ovarian)	Phase III (973) 895-6900
		cutaneous T-cell lymphoma, non-Hodgkin's lymphoma, thymoma	Phase II (973) 895-6900
<b>Bexxar®</b> tositumomab	GlaxoSmithKline <i>Rsch. Triangle Park, NC</i>	(see also leukemia, cancer-related)	Phase II (888) 825-5249
BI 2536	Boehringer Ingelheim Pharmaceuticals <i>Ridgefield, CT</i>	non-Hodgkin's lymphoma	Phase I (800) 243-0127
<b>BiovaxID™</b> B-cell lymphoma vaccine	Accentia BioPharmaceuticals <i>Tampa, FL</i>	non-Hodgkin's lymphoma	Phase III (813) 864-2554
CAL-101	Calistoga Pharmaceuticals <i>Seattle, WA</i>	non-Hodgkin's lymphoma (see also leukemia)	Phase I (206) 728-4700
CAT-8015	MedImmune <i>Gaithersburg, MD</i>	non-Hodgkin's lymphoma (see also leukemia)	Phase I (301) 398-0000
cilengitide	EMD Serono <i>Rockland, MA</i>	late-stage lymphoma (see also brain, prostate, solid tumors)	Phase I (800) 283-8088

## LYMPHOMA

Product Name	Sponsor	Indication	Development Status
<b>Clearazide™</b>	Yaupon Therapeutics <i>Radnor, PA</i>	cutaneous T-cell lymphoma	Phase III (610) 975-9290
<b>Clolar®</b> clofarabine	Genzyme <i>Cambridge, MA</i>	B-cell lymphoma, non-Hodgkin's lymphoma (see also leukemia)	Phase I/II (617) 252-7500
crinobulin	EpiCept <i>Tarrytown, NY</i>	(see also solid tumors)	Phase I (914) 606-3500
CT-011	CureTech <i>Yavne, Israel</i>	B-cell lymphoma	Phase II www.curetechbio.com
dacetuzumab (anti-CD40)	Genentech <i>South San Francisco, CA</i> Seattle Genetics <i>Bothell, WA</i>	diffuse large B-cell lymphoma (see also leukemia, multiple myeloma)	Phase II (650) 225-1000 (425) 527-4000
		non-Hodgkin's lymphoma	Phase I (650) 225-1000 (425) 527-4000
denenicokin (IL-21)	ZymoGenetics <i>Seattle, WA</i>	non-Hodgkin's lymphoma (combination therapy) (see also colorectal, kidney, ovarian, skin)	Phase I (206) 442-6600
DI-Leu16-IL2	EMD Serono <i>Rockland, MA</i> Provenance Biopharmaceuticals <i>Waltham, MA</i>	non-Hodgkin's lymphoma	Phase I (800) 283-8088 (781) 491-9888
elsamitrucin	Spectrum Pharmaceuticals <i>Irvine, CA</i>	non-Hodgkin's lymphoma	Phase II completed (949) 788-6700
enzastaurin (LY317615)	Eli Lilly <i>Indianapolis, IN</i>	non-Hodgkin's lymphoma (see also brain, breast, colorectal, multiple myeloma, ovarian, prostate)	Phase III (800) 545-5979
EZN-2968	Enzon Pharmaceuticals <i>Bridgewater, NJ</i>	(see also solid tumors)	Phase I (866) 792-5172
<b>Fodosine™</b> forodesine	BioCryst Pharmaceuticals <i>Birmingham, AL</i>	cutaneous T-cell lymphoma (see also leukemia)	Phase III (205) 444-4600
		T-cell lymphoma	Phase II (205) 444-4600
fostamatinib	Rigel Pharmaceuticals <i>South San Francisco, CA</i>	B-cell lymphoma, T-cell lymphoma	Phase II (650) 624-1100
GA101	Biogen Idec <i>Cambridge, MA</i> Genentech <i>South San Francisco, CA</i>	B-cell lymphoma, non-Hodgkin's lymphoma	Phase II (617) 679-2000 (650) 225-1000
galiximab (anti-CD80 mAb)	Biogen Idec <i>Cambridge, MA</i>	non-Hodgkin's lymphoma	Phase III (617) 679-2000

## LYMPHOMA

Product Name	Sponsor	Indication	Development Status
GCS-100	Prospect Therapeutics <i>Woburn, MA</i>	diffuse large B-cell lymphoma (combination therapy) (see also leukemia, multiple myeloma)	Phase I/II (781) 939-5750
<b>Gemzar®</b> gemcitabine	Eli Lilly <i>Indianapolis, IN</i>	(see also head/neck, lung, sarcoma)	Phase II (800) 545-5979
<b>Genasense®</b> oblimersen	Genta <i>Berkeley Heights, NJ</i>	non-Hodgkin's lymphoma (see also breast, leukemia, lung, skin, solid tumors)	Phase II (908) 286-9800
GMX-1777	Gemin X Biotechnologies <i>Montreal, Canada</i>	(see also skin, solid tumors)	Phase I (514) 281-8989
GS-9219	Gilead Sciences <i>Foster City, CA</i>	non-Hodgkin's lymphoma (see also leukemia)	Phase I/II (800) 445-3235
<b>Hycamtin®</b> topotecan	GlaxoSmithKline <i>Rsch. Triangle Park, NC</i>	non-Hodgkin's lymphoma (see also breast, colorectal, head/neck, kidney, leukemia, lung, multiple myeloma, ovarian, pancreatic, prostate, stomach, other)	Phase II (888) 825-5249
iboctadekin	GlaxoSmithKline <i>Rsch. Triangle Park, NC</i>	non-Hodgkin's lymphoma (combination therapy) (see also ovarian)	Phase I (888) 825-5249
<b>Idamycin®</b> idarubicin	Pfizer <i>New York, NY</i>	non-Hodgkin's lymphoma (see also multiple myeloma)	Phase III (860) 732-5156
inotuzumab ozogamicin	UCB <i>Smyrna, GA</i> Wyeth Pharmaceuticals <i>Collegeville, PA</i>	non-Hodgkin's lymphoma, (combination therapy)	Phase III (770) 970-7500 (800) 934-5556
iratumumab (MDX-060) <b>(Orphan Drug)</b>	Medarex <i>Princeton, NJ</i>	Hodgkin's disease, lymphoma, non-Hodgkin's lymphoma	Phase II (609) 430-2880
IT-101	Calando Pharmaceuticals <i>Pasadena, CA</i>	(see also ovarian)	Phase II (626) 683-7200
<b>Leukine®</b> sargramostim	Bayer HealthCare Pharmaceuticals <i>Wayne, NJ</i>	non-Hodgkin's lymphoma (see also leukemia, ovarian, prostate, skin)	Phase II (888) 842-2937
lucatumumab	Novartis Pharmaceuticals <i>East Hanover, NJ</i> XOMA <i>Berkeley, CA</i>	(see also multiple myeloma)	Phase I/II (888) 669-6682 (510) 204-7200
LY2469298	Eli Lilly <i>Indianapolis, IN</i>		Phase I (800) 545-5979
<b>LymphoCide®</b> epratuzumab <b>(Orphan Drug)</b>	Immunomedics <i>Morris Plains, NJ</i>	non-Hodgkin's lymphoma (see also leukemia)	Phase II (973) 605-8200
MDX-1401	Medarex <i>Princeton, NJ</i>	Hodgkin's disease	Phase I (609) 430-2880

## LYMPHOMA

Product Name	Sponsor	Indication	Development Status
MGCD-0103	MethylGene <i>Montreal, Canada</i>	B-cell lymphoma, Hodgkin's disease, non-Hodgkin's lymphoma (see also leukemia, solid tumors)	Phase II (514) 337-3333
milatuzumab (IMMU-115)	Immunomedics <i>Morris Plains, NJ</i>	non-Hodgkin's lymphoma (see also leukemia, multiple myeloma)	Phase I/II (973) 605-8200
MLN8237	Millennium Pharmaceuticals <i>Cambridge, MA</i>	non-Hodgkin's lymphoma (see also brain, leukemia, solid tumors)	Phase II (800) 390-5663
<b>Nipent®</b> pentostatin <b>(Orphan Drug)</b>	Hospira <i>Lake Forest, IL</i>	cutaneous T-cell lymphoma (see also leukemia, cancer-related)	application submitted (224) 212-2000
		non-Hodgkin's lymphoma	Phase II (224) 212-2000
NPI-0052	Nereus Pharmaceuticals <i>San Diego, CA</i>	(see also multiple myeloma, solid tumors)	Phase I (858) 587-4090
NPI-2358	Nereus Pharmaceuticals <i>San Diego, CA</i>	(see also lung)	Phase I (858) 587-4090
obatoclax	Gemin X Biotechnologies <i>Montreal, Canada</i>	follicular lymphoma, Hodgkin's disease (see also leukemia, lung)	Phase II (514) 281-8989
		mantle-cell lymphoma (combination therapy)	Phase I (514) 281-8989
ofatumumab	GlaxoSmithKline <i>Rsch. Triangle Park, NC</i>	non-Hodgkin's lymphoma (second-line therapy) (see also leukemia)	Phase III (888) 825-5249
		non-Hodgkin's lymphoma (first-line therapy), Waldenström's macroglobulinemia	Phase II (888) 825-5249
<b>Oncaspar®</b> pegaspargase	Enzon Pharmaceuticals <i>Bridgewater, NJ</i>	combination therapy (see also solid tumors)	Phase I (866) 792-5172
ortatexal	Spectrum Pharmaceuticals <i>Irvine, CA</i>	non-Hodgkin's lymphoma (see also kidney)	Phase II (949) 788-6700
P276	Piramal Life Sciences <i>Mumbai, India</i>	mantle-cell lymphoma (see also multiple myeloma)	Phase II
panobinostat	Novartis Pharmaceuticals <i>East Hanover, NJ</i>	cutaneous T-cell lymphoma (see also brain, breast, leukemia, prostate)	Phase II/III (888) 669-6682
		Hodgkin's disease	Phase II (888) 669-6682
PCI-32765	Pharmacyclics <i>Sunnyvale, CA</i>	B-cell lymphoma	Phase I (408) 774-0330

## LYMPHOMA

Product Name	Sponsor	Indication	Development Status
PD-332991	Pfizer <i>New York, NY</i>	mantle-cell lymphoma (see also breast, multiple myeloma)	Phase I (860) 732-5156
perifosine	AEterna Zentaris <i>Montreal, Canada</i> Keryx Biopharmaceuticals <i>New York, NY</i>	Waldenström's macroglobulinemia (see also brain, head/neck, kidney, multiple myeloma, ovarian, sarcoma)	Phase II (212) 531-5965
pixantrone	Cell Therapeutics <i>Seattle, WA</i>	non-Hodgkin's lymphoma	Phase III (800) 215-2355
PM-00104	PharmaMar USA <i>Cambridge, MA</i>	(see also solid tumors)	Phase I (617) 868-3797
pralatrexate (PDX) <b>(Orphan Drug)</b>	Allos Therapeutics <i>Westminster, CO</i>	B-cell lymphoma, peripheral T-cell lymphoma (see also bladder, lung)	Phase II (303) 426-6262
		Hodgkin's disease, non-Hodgkin's lymphoma	Phase I/II (303) 426-6262
		cutaneous T-cell lymphoma	Phase I (303) 426-6262
PRO-131921	Genentech <i>South San Francisco, CA</i>	non-Hodgkin's lymphoma (see also leukemia)	Phase I/II (650) 224-1000
PX-478	Oncothyreon <i>Seattle, WA</i>	(see also solid tumors)	Phase I (206) 801-2100
R1507	Roche <i>Nutley, NJ</i>	Hodgkin's disease, non-Hodgkin's lymphoma (see also breast, lung, sarcoma)	Phase I (973) 235-5000
<b>Revlimid®</b> lenalidomide	Celgene <i>Summit, NJ</i>	mantle-cell lymphoma, non-Hodgkin's lymphoma (see also leukemia, multiple myeloma, prostate, other)	Phase II (908) 673-9000
RH-1	Allos Therapeutics <i>Westminster, CO</i>	non-Hodgkin's lymphoma (see also solid tumors)	Phase I (303) 426-6262
romidepsin <b>(Orphan Drug)</b>	Gloucester Pharmaceuticals <i>Cambridge, MA</i>	cutaneous T-cell lymphoma, peripheral T-cell lymphoma (see also kidney, multiple myeloma, pancreatic, prostate)	Phase II (617) 583-1300
sapacitabine	Cyclacel Pharmaceuticals <i>Short Hills, NJ</i>	cutaneous T-cell lymphoma (see also leukemia, lung)	Phase II (973) 847-5955
SAR3419	sanofi-aventis <i>Bridgewater, NJ</i>	non-Hodgkin's lymphoma	Phase I (800) 633-1610
sardomozide	Novartis Pharmaceuticals <i>East Hanover, NJ</i>	non-Hodgkin's lymphoma (see also solid tumors)	Phase II (888) 669-6682
SB-1518	S*Bio <i>Redwood City, CA</i>	(see also leukemia)	Phase I (650) 730-2860
SCH-900776	Schering-Plough <i>Kenilworth, NJ</i>	(see also solid tumors)	Phase I (908) 298-4000

## LYMPHOMA

Product Name	Sponsor	Indication	Development Status
SGN-30 <b>(Orphan Drug)</b>	Seattle Genetics <i>Bothell, WA</i>	cutaneous T-cell lymphoma, Hodgkin's disease	Phase II (425) 527-4000
SGN-35 <b>(Orphan Drug)</b>	Seattle Genetics <i>Bothell, WA</i>	Hodgkin's disease (see also leukemia)	Phase II (425) 527-4000
SNS-032	Sunesis Pharmaceuticals <i>South San Francisco, CA</i>	B-cell lymphoma (see also solid tumors)	Phase I (650) 266-3500
stem cell therapy	Benitec <i>Melbourne, Australia</i> City of Hope Medical Center <i>Duarte, CA</i>	AIDS-related lymphoma	Phase I
TG-1042	Transgene <i>Kensington, MD</i>	cutaneous B-cell lymphoma	Phase II (301) 816-5404
TNX-650	Genentech <i>South San Francisco, CA</i>	refractory metastatic Hodgkin's disease	Phase I/II (650) 225-1000
<b>Torisel™</b> temsirolimus	Wyeth Pharmaceuticals <i>Collegeville, PA</i>	mantle-cell lymphoma (see also colorectal, kidney, lung, multiple myeloma, prostate)	Phase III (800) 934-5556
UNBS-5162	Drais Pharmaceuticals <i>Bridgewater, NJ</i>	(see also solid tumors)	Phase I (908) 895-1200
<b>Velcade®</b> bortezomib	Millennium Pharmaceuticals <i>Cambridge, MA</i>	non-Hodgkin's lymphoma (see also lung, multiple myeloma, solid tumors)	Phase III (800) 390-5663
veltuzumab (IMMU-106)	Immunomedics <i>Morris Plains, NJ</i>	non-Hodgkin's lymphoma (see also cancer-related)	Phase I/II (973) 605-8200
<b>Vidaza®</b> azacitidine	Celgene <i>Summit, NJ</i>	(see also leukemia, prostate)	Phase I (908) 673-9000
vinorelbine liposomal	Hana Biosciences <i>South San Francisco, CA</i>	non-Hodgkin's lymphoma (see also solid tumors)	Phase I (650) 588-6404
<b>Xcytrin®</b> motexafin gadolinium	Pharmacyclics <i>Sunnyvale, CA</i>	lymphoma, non-Hodgkin's lymphoma (see also brain, kidney, leukemia, lung)	Phase II (408) 774-0330
XmAb 2513	Xencor <i>Monrovia, CA</i>	Hodgkin's disease, T-cell lymphoma	Phase I (626) 305-5900
YM-155	Astellas Pharma US <i>Deerfield, IL</i>	refractory, metastatic diffuse large B-cell lymphoma (see also prostate)	Phase II (800) 727-7003
ZEN-012	AEterna Zentaris <i>Warren, NJ</i>	(see also solid tumors)	Phase I (908) 626-5428
<b>Zevalin®</b> ibritumomab tiuxetan	Spectrum Pharmaceuticals <i>Irvine, CA</i>	non-Hodgkin's lymphoma (first-line therapy)	application submitted (949) 788-6700
<b>Zolinza®</b> vorinostat	Merck <i>Whitehouse Station, NJ</i>	B-cell lymphoma, lymphoma (see also brain, breast, colorectal, kidney, leukemia, lung, multiple myeloma)	Phase II (800) 672-6372

## MULTIPLE MYELOMA

Product Name	Sponsor	Indication	Development Status
<b>Actimid™</b> pomalidomide	Celgene <i>Summit, NJ</i>	(see also lung, pancreatic, prostate, sarcoma)	Phase I/II (908) 673-9000
<b>Amplimexon®</b> imexon	AmpliMed <i>Tucson, AZ</i>	(see also breast, lung, pancreatic, prostate, skin)	Phase I/II completed (520) 529-1000
anti-MUC1 mAb	Paladin Labs <i>St. Laurent, Canada</i>	(see also breast, pancreatic)	Phase I completed (888) 376-7830
<b>Aredia®</b> pamidronic acid	Novartis Pharmaceuticals <i>East Hanover, NJ</i>	(see also cancer-related)	Phase II (888) 669-6682
atacept (TACI-Ig)	EMD Serono <i>Rockland, MA</i> ZymoGenetics <i>Seattle, WA</i>	(see also leukemia, lymphoma)	Phase II (800) 283-8088 (206) 442-6600
ATN-224	Attenuon <i>San Diego, CA</i>	(see also prostate, skin)	Phase I/II (858) 558-4111
AUY922	Novartis Pharmaceuticals <i>East Hanover, NJ</i>	(see also solid tumors)	Phase I/II (888) 669-6682
<b>Avastin®</b> bevacizumab	Genentech <i>South San Francisco, CA</i>	combination therapy (see also brain, colorectal, head/neck, kidney, liver, lung, lymphoma, ovarian, pancreatic, prostate, stomach, other)	Phase II (650) 225-1000
AZD6244	AstraZeneca <i>Wilmington, DE</i>	(see also leukemia, liver, lung, ovarian, pancreatic, skin, other)	Phase II (800) 236-9933
BIW 8962	BioWa <i>Princeton, NJ</i>		Phase I/II (609) 734-3420
carfilzomib <b>(Orphan Drug)</b>	Proteolix <i>South San Francisco, CA</i>	monotherapy (see also leukemia, solid tumors)	Phase II (650) 615-7550
		combination therapy	Phase I (650) 615-7550
CEP-18770	Cephalon <i>Frazer, PA</i>		Phase I (610) 344-0200
CP-751871	Pfizer <i>New York, NY</i>	(see also breast, colorectal, lung, prostate, sarcoma)	Phase I completed (860) 732-5156
CX-4945	Cylene Pharmaceuticals <i>San Diego, CA</i>	(see also solid tumors, other)	Phase I (858) 875-5100
dacetuzumab (anti-CD40) <b>(Orphan Drug)</b>	Genentech <i>South San Francisco, CA</i> Seattle Genetics <i>Bothell, WA</i>	(see also leukemia, lymphoma)	Phase I (650) 225-1000 (425) 527-4000
darinaparsin (ZIO-101)	Ziopharm Oncology <i>New York, NY</i>	(see also leukemia, liver, solid tumors)	Phase II (646) 214-0700
denosumab (AMG 162)	Amgen <i>Thousand Oaks, CA</i>	(see also cancer-related, other)	Phase III (805) 447-1000

## MULTIPLE MYELOMA

Product Name	Sponsor	Indication	Development Status
elotuzumab	Bristol-Myers Squibb <i>Princeton, NJ</i> Facet Biotech <i>Redwood City, CA</i>		Phase I (212) 546-4000 (650) 454-1000
ENMD-2076	EntreMed <i>Rockville, MD</i>	(see also solid tumors)	Phase I (240) 864-2600
enzastaurin (LY317615)	Eli Lilly <i>Indianapolis, IN</i>	(see also brain, breast, colorectal, lymphoma, ovarian, prostate)	Phase II (800) 545-5979
GCS-100	Prospect Therapeutics <i>Woburn, MA</i>	(see also leukemia, lymphoma)	Phase I (781) 939-5750
GRN-163L	Geron <i>Menlo Park, CA</i>	(see also breast, leukemia, lung)	Phase I (650) 473-7700
<b>Hycamtin</b> <sup>®</sup> topotecan	GlaxoSmithKline <i>Rsch. Triangle Park, NC</i>	(see also breast, colorectal, head/neck, kidney, leukemia, lung, lymphoma, ovarian, pancreatic, prostate, stomach, other)	in clinical trials (888) 825-5249
<b>Idamycin</b> <sup>®</sup> idarubicin	Pfizer <i>New York, NY</i>	(see also lymphoma)	Phase III (860) 732-5156
IMGN-901	ImmunoGen <i>Cambridge, MA</i>	(see also lung)	Phase I (617) 995-2500
INCB-18424	Incyte <i>Wilmington, DE</i>	(see also prostate)	Phase II (302) 498-6700
IPH-2101	Innate Pharma <i>Marseille, France</i>		Phase I <a href="http://www.innate-pharma.com">www.innate-pharma.com</a>
KRX-0402	Keryx Biopharmaceuticals <i>New York, NY</i>	(see also brain, colorectal, kidney, sarcoma)	Phase II (212) 531-5965
lestaurtinib	Cephalon <i>Frazer, PA</i>	(see also leukemia)	Phase II (610) 344-0200
lucatumumab	Novartis Pharmaceuticals <i>East Hanover, NJ</i> XOMA <i>Berkeley, CA</i>	(see also lymphoma)	Phase I (888) 669-6682 (510) 204-7200
LY2127399	Eli Lilly <i>Indianapolis, IN</i>		Phase II (800) 545-5979
mapatumumab	Human Genome Sciences <i>Rockville, MD</i>	(see also liver, lung)	Phase II (301) 309-8504
milatuzumab (IMMU-115)	Immunomedics <i>Morris Plains, NJ</i>	(see also leukemia, lymphoma)	Phase I/II (973) 605-8200
natalizumab	Biogen Idec <i>Cambridge, MA</i>		Phase I/II (617) 679-2000
noscipine	Cougar Biotechnology <i>Los Angeles, CA</i>		Phase I/II (310) 943-8040
NPI-0052	Nereus Pharmaceuticals <i>San Diego, CA</i>	(see also lymphoma, solid tumors)	Phase I (858) 587-4090

## MULTIPLE MYELOMA

Product Name	Sponsor	Indication	Development Status
P276	Piramal Life Sciences <i>Mumbai, India</i>	(see also lymphoma)	Phase I
PD-332991	Pfizer <i>New York, NY</i>	combination therapy (see also breast, lymphoma)	Phase I/II (860) 732-5156
perifosine	AEterna Zentaris <i>Montreal, Canada</i> Keryx Biopharmaceuticals <i>New York, NY</i>	(see also brain, head/neck, kidney, lymphoma, ovarian, sarcoma)	Phase II (212) 531-5965
plitidepsin (Orphan Drug)	PharmaMar USA <i>Cambridge, MA</i>	(see also lung, prostate)	Phase II (617) 868-3797
Quadramet® samarium sm-153 lexidronam injection	Cytogen <i>Princeton, NJ</i>	(see also prostate, sarcoma, other)	Phase I/II (800) 833-3533
Revlimid® lenalidomide	Celgene <i>Summit, NJ</i>	newly-diagnosed multiple myeloma (see also leukemia, lymphoma, prostate, other)	Phase III (908) 673-9000
romidepsin	Gloucester Pharmaceuticals <i>Cambridge, MA</i>	(see also kidney, lymphoma, pancreatic, prostate)	Phase II (617) 583-1300
SF1126	Semafore Pharmaceuticals <i>Indianapolis, IN</i>	(see also solid tumors)	Phase I (317) 876-3075
tanespimycin (Hsp90 inhibitor)	Bristol-Myers Squibb <i>Princeton, NJ</i>	(see also solid tumors)	Phase III (212) 546-4000
Torisel™ temsirolimus	Wyeth Pharmaceuticals <i>Collegeville, PA</i>	(see also colorectal, kidney, lung, lymphoma, prostate)	Phase I/II (800) 934-5556
Treanda® bendamustine	Cephalon <i>Frazer, PA</i>		Phase II (610) 344-0200
Trisenox® arsenic trioxide	Cephalon <i>Frazer, PA</i>	combination therapy (see also brain, leukemia)	Phase II (610) 344-0200
VEL-0230	Velcura Therapeutics <i>Ann Arbor, MI</i>		Phase I completed (734) 973-1000
Velcade® bortezomib (subcutaneous)	Millennium Pharmaceuticals <i>Cambridge, MA</i>	previously untreated multiple myeloma (see also lung, lymphoma, solid tumors)	Phase III (800) 390-5663
Zolinza® vorinostat	Merck <i>Whitehouse Station, NJ</i>	(see also brain, breast, colorectal, kidney, leukemia, lung, lymphoma)	Phase III (800) 672-6372
ZRx101	ZelleRx <i>Chicago, IL</i>	(see also kidney, skin, cancer-related)	Phase I (312) 243-5200

## OVARIAN CANCER

Product Name	Sponsor	Indication	Development Status
Å6	Angstrom Pharmaceuticals <i>Solana Beach, CA</i>	(see also other)	Phase II (858) 314-2356

## OVARIAN CANCER

Product Name	Sponsor	Indication	Development Status
abagovomab (anti-idiotypic ovarian cancer vaccine)	Menarini <i>Florence, Italy</i>		Phase II/III www.menarini.com
<b>Abraxane™</b> albumin-bound paclitaxel	Abraxis BioScience <i>Los Angeles, CA</i>	(see also head/neck, lung, pancreatic, prostate, skin)	Phase II (310) 883-1300
<b>Advexin®</b> contusugene ladenovec	Introgen Therapeutics <i>Austin, TX</i>	(see also bladder, brain, breast, head/neck, lung, prostate, stomach)	Phase I (512) 708-9310
AE-37	Antigen Express <i>Worcester, MA</i>	combination therapy (see also breast)	Phase I (508) 852-8783
AG-14699	Pfizer <i>New York, NY</i>	(see also breast)	Phase II (860) 732-5156
AGS-8M4	Agensys <i>Santa Monica, CA</i> Astellas Pharma US <i>Deerfield, IL</i>		Phase I (310) 820-8029 (800) 477-6472
<b>Alimta®</b> pemetrexed	Eli Lilly <i>Indianapolis, IN</i>	(see also breast, head/neck, lung)	Phase II (800) 545-5979
AMG 386	Amgen <i>Thousand Oaks, CA</i>	(see also breast, kidney, stomach, other)	Phase II (805) 447-1000
ANZ-207	Anza Therapeutics <i>Concord, CA</i>	(see also lung, pancreatic)	Phase I (925) 288-6000
<b>Armala™</b> pazopanib	GlaxoSmithKline <i>Rsch. Triangle Park, NC</i>	(see also brain, breast, cervical, kidney, liver, lung, sarcoma, other)	Phase II (888) 825-5249
<b>Avastin®</b> bevacizumab	Genentech <i>South San Francisco, CA</i>	(see also brain, colorectal, head/neck, kidney, liver, lung, lymphoma, multiple myeloma, pancreatic, prostate, stomach, other)	Phase III (650) 225-1000
AZD2281	AstraZeneca <i>Wilmington, DE</i>	(see also breast)	Phase II (800) 236-9933
AZD6244	AstraZeneca <i>Wilmington, DE</i>	(see also leukemia, liver, lung, multiple myeloma, pancreatic, skin, other)	Phase II (800) 236-9933
belinostat	TopoTarget USA <i>Rockaway, NJ</i>	(see also bladder, colorectal, leukemia, liver, lung, lymphoma)	Phase II (973) 895-6900
BMS-753493 (epothilone-folate)	Bristol-Myers Squibb <i>Princeton, NJ</i>		in clinical trials (212) 546-4000
BSI-201	BiPar Sciences <i>Brisbane, CA</i>	combination and monotherapy (see also brain, breast, other)	Phase II (650) 635-6050
catumaxomab	Fresenius Biotech North America <i>Waltham, MA</i>	(see also other)	Phase II www.fresenius-biotech.com
CDX-1307	Celldex Therapeutics <i>Needham, MA</i>	(see also bladder, breast, colorectal, pancreatic)	Phase I (781) 433-0771

## OVARIAN CANCER

Product Name	Sponsor	Indication	Development Status
D4064A	Genentech <i>South San Francisco, CA</i>	(see also other)	Phase I (650) 224-1000
<b>DCVax®-L</b> ovarian cancer vaccine	Northwest Biotherapeutics <i>Bothell, WA</i>		Phase I/II (425) 608-3000
denenicokin (IL-21)	ZymoGenetics <i>Seattle, WA</i>	(see also colorectal, kidney, lymphoma, skin)	Phase I/II (206) 442-6600
EC-145	Endocyte <i>West Lafayette, IN</i>	(see also lung, other)	Phase II (765) 463-7175
EGEN 001 <b>(Orphan Drug)</b>	Expression Genetics <i>Huntsville, AL</i>	recurrent ovarian cancer (combination therapy)	Phase I (256) 512-0077
<b>Elacyt™</b> elacytarabine	Clavis Pharma <i>Oslo, Norway</i>	(see also leukemia, skin)	Phase II www.clavispharma.com
enzastaurin (LY317615)	Eli Lilly <i>Indianapolis, IN</i>	combination therapy (see also brain, breast, colorectal, lymphoma, multiple myeloma, prostate)	Phase II (800) 545-5979
eribulin mesylate (E7389)	Eisai <i>Woodcliff Lake, NJ</i>	(see also breast, head/neck, lung, prostate, sarcoma, solid tumors)	Phase II (888) 422-4743
farletuzumab (MORAb-003)	Eisai <i>Woodcliff Lake, NJ</i>		Phase II/III (888) 422-4743
<b>Herceptin®</b> trastuzumab	Genentech <i>South San Francisco, CA</i>	(see also colorectal, pancreatic, prostate, stomach, other)	Phase II (650) 225-1000
<b>Hycamtin®</b> topotecan (oral)	GlaxoSmithKline <i>Rsch. Triangle Park, NC</i>	(see also breast, colorectal, head/neck, kidney, leukemia, lung, lymphoma, multiple myeloma, pancreatic, prostate, stomach, other)	Phase III (888) 825-5249
iboctadekin	GlaxoSmithKline <i>Rsch. Triangle Park, NC</i>	combination therapy (see also lymphoma)	Phase I (888) 825-5249
idronoxil	Marshall Edwards <i>North Ryde, Australia</i>	combination therapy (see also prostate, other)	Phase III
IMC-1121B	Eli Lilly <i>Indianapolis, IN</i> ImClone Systems <i>New York, NY</i>	(see also breast, colorectal, kidney, liver, lung, prostate, skin)	Phase II (800) 545-5979 (212) 645-1405
IMT-1012	ImmunoVaccine Technologies <i>Halifax, Canada</i>	(see also breast)	Phase I (902) 492-1819
IT-101	Calando Pharmaceuticals <i>Pasadena, CA</i>	(see also lymphoma)	Phase II (626) 683-7200
<b>Karenitecin®</b> cositecan	BioNumerik Pharmaceuticals <i>San Antonio, TX</i>	(see also brain, lung, skin)	Phase III (210) 614-1701
lapuleucel-T	Dendreon <i>Seattle, WA</i>	(see also breast, colorectal)	Phase I completed (206) 256-4545

## OVARIAN CANCER

Product Name	Sponsor	Indication	Development Status
<b>Leukine®</b> sargramostim	Bayer HealthCare Pharmaceuticals Wayne, NJ	(see also leukemia, lymphoma, prostate, skin)	Phase II (888) 842-2937
MK-4827	Merck Whitehouse Station, NJ		Phase I (800) 672-6372
MORAb-009	Eisai Woodcliff Lake, NJ	(see also lung, pancreatic)	Phase I (888) 422-4743
NKTR-102	Nektar Therapeutics San Carlos, CA	metastatic ovarian cancer (second-line therapy) (see also colorectal)	Phase II (650) 631-3100
NOV-002	Novelos Therapeutics Newton, MA	combination therapy (see also breast, lung)	Phase II completed (617) 244-1616
oglufanide	Implicit Bioscience Woodside, CA		Phase II (650) 851-3133
OGX-427	Oncogenex Pharmaceuticals Bothell, WA	(see also bladder, breast, lung, prostate)	Phase I (425) 686-1500
<b>Opaxio™</b> paclitaxel poliglumex	Cell Therapeutics Seattle, WA Novartis Pharmaceuticals East Hanover, NJ	(see also lung, stomach, other)	Phase III (800) 215-2355 (888) 669-6682
<b>OvaRex®</b> oregovomab	Paladin Labs St. Laurent, Canada		Phase III (514) 340-1112
<b>OVax®</b> ovarian cancer vaccine <b>(Orphan Drug)</b>	AVAX Technologies Philadelphia, PA		Phase I/II (215) 241-9760
patupilone (EPO906)	Novartis Pharmaceuticals East Hanover, NJ	(see also brain, breast, colorectal, liver, lung)	Phase III (888) 669-6682
perifosine	AEterna Zentaris Montreal, Canada Keryx Biopharmaceuticals New York, NY	(see also brain, head/neck, kidney, lymphoma, multiple myeloma, sarcoma)	Phase I (212) 531-5965
pertuzumab	Genentech South San Francisco, CA	(see also breast)	Phase II completed (650) 225-1000
plevitrexed (BGC 9331) <b>(Orphan Drug)</b>	BTG International West Conshohocken, PA		Phase II (610) 278-1660
<b>Quinamed®</b> amonafide	ChemGenex Pharmaceuticals Menlo Park, CA	(see also breast, prostate)	Phase II (650) 474-9800
sagopilone	Bayer HealthCare Pharmaceuticals Wayne, NJ	combination therapy (see also brain, breast, prostate)	Phase I/II (888) 842-2937
SNS-595	Sunesis Pharmaceuticals South San Francisco, CA	(see also leukemia)	Phase II (650) 266-3500

## OVARIAN CANCER

Product Name	Sponsor	Indication	Development Status
systemic hedgehog antagonist	Genentech <i>South San Francisco, CA</i>	(see also brain, colorectal, skin)	Phase II (650) 224-1000
tasisulam (ASAP)	Eli Lilly <i>Indianapolis, IN</i>	(see also leukemia, sarcoma, skin)	Phase II (800) 545-5979
<b>Telcyta™</b> canfosfimide	Telik <i>Palo Alto, CA</i>	(see also breast, colorectal, lung)	Phase III (650) 845-7700
topotecan liposomal	Hana Biosciences <i>South San Francisco, CA</i>	(see also lung)	Phase I (650) 588-6404
tucotuzumab celmoleukin	EMD Serono <i>Rockland, MA</i>	(see also colorectal, lung, prostate)	Phase II (800) 283-8088
volociximab	Biogen Idec <i>Cambridge, MA</i> Facet Biotech <i>Redwood City, CA</i>	(see also lung, pancreatic, skin)	Phase II (617) 679-2000 (650) 454-1000
<b>Yondelis®</b> trabectedin <b>(Orphan Drug)</b>	Johnson & Johnson Pharmaceutical Research & Development <i>Raritan, NJ</i>	combination therapy, second-line therapy (see also breast, prostate, sarcoma, other)	application submitted (800) 817-5286
<b>Zybrexat™</b> fosbretabulin <b>(Orphan Drug)</b>	OxIGENE <i>Waltham, MA</i>	(see also head/neck, lung, other)	Phase II (781) 547-5900
ZYC300	Eisai <i>Woodcliff Lake, NJ</i>	(see also breast, colorectal, kidney, prostate)	Phase I (888) 422-4743

## PANCREATIC CANCER

Product Name	Sponsor	Indication	Development Status
<b>Abraxane™</b> albumin-bound paclitaxel	Abraxis BioScience <i>Los Angeles, CA</i>	(see also head/neck, lung, ovarian, prostate, skin)	Phase I/II (310) 883-1300
<b>Actimid™</b> pomalidomide	Celgene <i>Summit, NJ</i>	combination therapy (see also lung, multiple myeloma, prostate, sarcoma)	Phase I/II (908) 673-9000
aflibercept (VEGF-trap)	sanofi-aventis <i>Bridgewater, NJ</i> Regeneron Pharmaceuticals <i>Tarrytown, NY</i>	first-line metastatic pancreatic cancer (combination therapy) (see also colorectal, lung, prostate, other)	Phase III (800) 633-1810 (914) 345-7400
AMG 479	Amgen <i>Thousand Oaks, CA</i>	(see also breast, colorectal, lung, sarcoma)	Phase I/II (805) 447-1000
<b>Amplimexon®</b> imexon	AmpliMed <i>Tucson, AZ</i>	(see also breast, lung, multiple myeloma, prostate, skin)	Phase II (520) 529-1000
anti-MUC1 mAb	Paladin Labs <i>St. Laurent, Canada</i>	(see also breast, multiple myeloma)	Phase I completed (888) 376-7830

## PANCREATIC CANCER

Product Name	Sponsor	Indication	Development Status
ANZ-207	Anza Therapeutics <i>Concord, CA</i>	(see also lung, ovarian)	Phase I (925) 288-6000
ARQ-197	ArQule <i>Woburn, MA</i> Daiichi Sankyo <i>Parsippany, NJ</i>	(see also liver, lung, solid tumors)	Phase I/II (781) 994-0300 (973) 359-2600
ARQ-501 (beta lapachone)	ArQule <i>Woburn, MA</i>	combination therapy, inoperable/ unresectable pancreatic cancer (see also head/neck, solid tumors, other)	Phase II (781) 994-0300
<b>Avastin</b> <sup>®</sup> bevacizumab	Genentech <i>South San Francisco, CA</i>	combination first-line therapy (see also brain, colorectal, head/neck, kidney, liver, lung, lymphoma, multiple myeloma, ovarian, prostate, stomach, other)	Phase III (650) 225-1000
		pancreatic cancer	Phase II (650) 225-1000
AVN-944	Avalon Pharmaceuticals <i>Germantown, MD</i>	combination therapy (see also leukemia)	Phase II (301) 556-9900
AZD6244	AstraZeneca <i>Wilmington, DE</i>	(see also leukemia, liver, lung, multiple myeloma, ovarian, skin, other)	Phase II (800) 236-9933
<b>Camptosar</b> <sup>®</sup> irinotecan	Pfizer <i>New York, NY</i>	(see also cervical, lung, prostate)	Phase III (860) 732-5156
<b>Capoxigem</b> <sup>®</sup> apricoxib	Tragara Pharmaceuticals <i>San Diego, CA</i>	combination therapy (see also breast, lung)	Phase II (858) 350-6900
CDX-1307	Celldex Therapeutics <i>Needham, MA</i>	(see also bladder, breast, colorectal, ovarian)	Phase I (781) 433-0771
conatumumab	Amgen <i>Thousand Oaks, CA</i>	(see also colorectal, lung, sarcoma)	Phase I/II (805) 447-1000
everolimus	Novartis Pharmaceuticals <i>East Hanover, NJ</i>	(see also kidney, other)	Phase II (888) 669-6682
FG-3019	Fibrogen <i>San Francisco, CA</i>	combination therapy	Phase I (415) 978-1200
GI-4000	Globelmmune <i>Louisville, CO</i>	combination therapy (see also lung)	Phase II (303) 625-2700
glufosfamide <b>(Orphan Drug)</b>	Threshold Pharmaceuticals <i>Redwood City, CA</i>	(see also breast, lung, sarcoma)	Phase III (650) 474-8200
<b>Herceptin</b> <sup>®</sup> trastuzumab	Genentech <i>South San Francisco, CA</i>	(see also colorectal, ovarian, prostate, stomach, other)	Phase II (650) 225-1000
<b>Hycamtin</b> <sup>®</sup> topotecan	GlaxoSmithKline <i>Rsch. Triangle Park, NC</i>	(see also breast, colorectal, head/neck, kidney, leukemia, lung, lymphoma, multiple myeloma, ovarian, prostate, stomach, other)	Phase II (888) 825-5249

## PANCREATIC CANCER

Product Name	Sponsor	Indication	Development Status
<b>HyperAcute® Pancreas</b> pancreatic cancer vaccine	NewLink Genetics <i>Ames, IA</i>		Phase II (515) 296-5555
IMC-A12	Eli Lilly <i>Indianapolis, IN</i> ImClone Systems <i>New York, NY</i>	first-line combination therapy (see also breast, colorectal, head/neck, liver, lung, prostate, sarcoma, solid tumors)	Phase I/II (800) 545-5979 (212) 645-1405
<b>Ixempra™</b> ixabepilone	Bristol-Myers Squibb <i>Princeton, NJ</i>	(see also breast, lung, prostate)	in clinical trials (212) 546-4000
larotaxel (XRP9881)	sanofi-aventis <i>Bridgewater, NJ</i>	(see also bladder)	Phase III (800) 633-1610
masitinib	AB Science USA <i>Short Hills, NJ</i>	(see also leukemia, stomach)	Phase III (973) 218-2437
MK-0646	Merck <i>Whitehouse Station, NJ</i>	(see also breast, lung, other)	Phase I/II (888) 669-6682
MKC 1	EntreMed <i>Rockville, MD</i>	(see also breast, leukemia, lung)	Phase II (240) 864-2600
MORAb-009	Eisai <i>Woodcliff Lake, NJ</i>	(see also lung, ovarian)	Phase II (888) 422-4743
naptumomab estafenatox	Active Biotech <i>Lund, Sweden</i>	(see also kidney, lung)	Phase I completed <a href="http://www.activebiotech.com">www.activebiotech.com</a>
<b>OncoGel™</b>	Protherics <i>Brentwood, TN</i>	(see also brain, stomach)	Phase II (615) 327-1027
<b>Oncophage®</b> vitespen	Antigenics <i>New York, NY</i>	(see also brain, colorectal, kidney, skin, stomach)	Phase I/II (866) 805-8994
OncoVEX GM-CSF	BioVex <i>Woburn, MA</i>	(see also skin)	Phase I (781) 376-4900
<b>PancAtak™</b> gene therapy	Advantagene <i>Boston, MA</i> <i>San Diego, CA</i>		Phase I (617) 916-5445 (760) 943-8981
PN401	Wellstat Therapeutics <i>Gaithersburg, MD</i>	(see also colorectal, stomach)	Phase III (240) 631-2500
PX-12	Oncothyreon <i>Seattle, WA</i>	(see also stomach, other)	Phase II (206) 801-2100
RAV-12	Raven Biotechnologies <i>South San Francisco, CA</i>	combination therapy (see also other)	Phase II (650) 624-2600
<b>Rexin-G™</b> tumor-targeted gene therapy <b>(Orphan Drug)</b>	Epeius Biotechnologies <i>San Marino, CA</i>	recurrent, refractory metastatic pancreatic cancer (see also breast, sarcoma)	Phase I/II (626) 441-6695
romidepsin	Gloucester Pharmaceuticals <i>Cambridge, MA</i>	(see also kidney, lymphoma, multiple myeloma, prostate)	Phase I/II (617) 583-1300
RP-101 <b>(Orphan Drug)</b>	SciClone Pharmaceuticals <i>Foster City, CA</i>		Phase II (650) 358-3456

## PANCREATIC CANCER

Product Name	Sponsor	Indication	Development Status
RTA-402	Reata Pharmaceuticals <i>Dallas, TX</i>	combination therapy (see also leukemia)	Phase I/II (972) 865-2200
salirasib (Orphan Drug)	Concordia Pharmaceuticals <i>Ft. Lauderdale, FL</i>	(see also lung)	Phase I/II www.concordiapharma.com
Sarasar™ lonafarnib	Schering-Plough <i>Kenilworth, NJ</i>	(see also breast, leukemia)	Phase II (908) 298-4000
Sutent® sunitinib	Pfizer <i>New York, NY</i>	(see also breast, colorectal, liver, lung, prostate, sarcoma, stomach)	Phase III (860) 732-5156
Thymitaq® nolatrexed	YM BioSciences <i>Wayne, PA</i>	(see also colorectal, head/neck, liver, lung, prostate)	Phase II (610) 560-0600
tigatuzumab	Daiichi Sankyo <i>Parsippany, NJ</i>		Phase II (973) 359-2600
TNFerade™	GenVec <i>Gaithersburg, MD</i>	(see also colorectal, head/neck, skin, stomach)	Phase III (240) 632-0740
TPI-287	Tapestry Pharmaceuticals <i>Boulder, CO</i>	(see also prostate)	Phase II (303) 516-8500
Triapine®	Vion Pharmaceuticals <i>New Haven, CT</i>	(see also leukemia, lung, prostate)	Phase II (203) 498-4210
Virulizin®	Lorus Therapeutics <i>Toronto, Canada</i>		Phase III (416) 798-1200
volociximab	Biogen Idec <i>Cambridge, MA</i> Facet Biotech <i>Redwood City, CA</i>	(see also lung, ovarian, skin)	Phase II (617) 679-2000 (650) 454-1000
Y-90 hPAM4 (IMMU-107) (Orphan Drug)	Immunomedics <i>Morris Plains, NJ</i>	metastatic pancreatic cancer	Phase I/II (973) 605-8200
Zarnestra™ tipifarnib	Johnson & Johnson Pharmaceutical Research & Development <i>Raritan, NJ</i>	(see also leukemia)	Phase III (800) 817-5286

## PROSTATE CANCER

Product Name	Sponsor	Indication	Development Status
ABI-008	Abraxis BioScience <i>Los Angeles, CA</i>	hormone-refractory prostate cancer (see also breast)	Phase I/II (310) 883-1300
abiraterone acetate (CB7630)	Cougar Biotechnology <i>Los Angeles, CA</i>	combination therapy, second-line therapy	Phase III (310) 943-8040
ABR-215050	Active Biotech <i>Lund, Sweden</i>		Phase II www.activebiotech.com
Abraxane™ albumin-bound paclitaxel	Abraxis BioScience <i>Los Angeles, CA</i>	(see also head/neck, lung, ovarian, pancreatic, skin)	Phase II (310) 883-1300

## PROSTATE CANCER

Product Name	Sponsor	Indication	Development Status
<b>Acapodene</b> <sup>®</sup> toremifene	GTx <i>Memphis, TN</i>	prostatic intraepithelial neoplasia (prevention) (see also cancer-related)	Phase III (901) 523-9700
<b>Actimid</b> <sup>™</sup> pomalidomide	Celgene <i>Summit, NJ</i>	(see also lung, multiple myeloma, pancreatic, sarcoma)	Phase II (908) 673-9000
<b>Advexin</b> <sup>®</sup> contusugene ladenovec	Introgen Therapeutics <i>Austin, TX</i>	(see also bladder, brain, breast, head/neck, lung, ovarian, stomach)	Phase I (512) 708-9310
aflibercept (VEGF-trap)	sanofi-aventis <i>Bridgewater, NJ</i> Regeneron Pharmaceuticals <i>Tarrytown, NY</i>	first-line metastatic prostate cancer (combination therapy) (see also colorectal, lung, pancreatic, other)	Phase III (800) 633-1610 (714) 345-7400
AGS-1C4D4	Agensys <i>Santa Monica, CA</i> Astellas Pharma US <i>Deerfield, IL</i>		Phase I completed (310) 820-8029 (800) 477-6472
<b>Amplimexon</b> <sup>®</sup> imexon	AmpliMed <i>Tucson, AZ</i>	(see also breast, lung, multiple myeloma, pancreatic, skin)	Phase I (520) 529-1000
anti-idiotype cancer vaccine 105AD7	Onyvax <i>London, England</i>		Phase II www.onyvax.com
AT-101	Ascenta Therapeutics <i>San Diego, CA</i>	(see also lung, lymphoma)	Phase II (858) 436-1200
ATN-224	Attenuon <i>San Diego, CA</i>	(see also multiple myeloma, skin)	Phase II (858) 558-4111
<b>Avastin</b> <sup>®</sup> bevacizumab	Genentech <i>South San Francisco, CA</i>	(see also brain, colorectal, head/neck, kidney, liver, lung, lymphoma, multiple myeloma, ovarian, pancreatic, stomach, other)	Phase III (650) 225-1000
<b>Avodart</b> <sup>®</sup> dutasteride	GlaxoSmithKline <i>Rsch. Triangle Park, NC</i>	prostate cancer prevention, prostatic intraepithelial neoplasia	Phase III (888) 825-5249
AZD4054	AstraZeneca <i>Wilmington, DE</i>	hormone-refractory, metastatic prostate cancer	Phase III (800) 236-9933
BMS-641988 (androgen receptor antagonist)	Bristol-Myers Squibb <i>Princeton, NJ</i>		Phase I (212) 546-4000
cabazitaxel (XRP6258)	sanofi-aventis <i>Bridgewater, NJ</i>		Phase III (800) 633-1610
<b>Camptosar</b> <sup>®</sup> irinotecan	Pfizer <i>New York, NY</i>	(see also cervical, lung, pancreatic)	Phase II (860) 732-5156
<b>Celebrex</b> <sup>®</sup> celecoxib	Pfizer <i>New York, NY</i>	(see also bladder)	Phase II (860) 732-5156
cilengitide	EMD Serono <i>Rockland, MA</i>	(see also brain, lymphoma, solid tumors)	Phase II (800) 283-8088
CNTO 95	Centocor <i>Horsham, PA</i>	(see also skin, solid tumors)	Phase II completed (610) 651-6000

## PROSTATE CANCER

Product Name	Sponsor	Indication	Development Status
CNTO 328	Centocor <i>Horsham, PA</i>	hormone-refractory prostate cancer (see also kidney)	Phase II (610) 651-6000
CP-751871	Pfizer <i>New York, NY</i>	combination therapy (see also breast, colorectal, lung, multiple myeloma, sarcoma)	Phase II (860) 732-5156
CYT-500	Cytogen <i>Princeton, NJ</i>		Phase I (800) 833-3533
deforolimus (MK-8669)	ARIAD Pharmaceuticals <i>Cambridge, MA</i> Merck <i>Whitehouse Station, NJ</i>	(see also breast, lung, sarcoma, other)	Phase II (617) 494-0400 (800) 672-6372
DMXAA	Antisoma <i>Cambridge, MA</i> Novartis Pharmaceuticals <i>East Hanover, NJ</i>	(see also lung)	Phase II completed (617) 225-0522 (888) 669-6682
enzastaurin (LY317615)	Eli Lilly <i>Indianapolis, IN</i>	(see also brain, breast, colorectal, lymphoma, multiple myeloma, ovarian)	Phase II (800) 545-5979
<b>Erbix<sup>®</sup></b> cetuximab	Bristol-Myers Squibb <i>Princeton, NJ</i> Eli Lilly <i>Indianapolis, IN</i> ImClone Systems <i>New York, NY</i>	(see also bladder, colorectal, head/neck, lung, stomach)	Phase III (212) 546-4000 (800) 545-5979 (212) 645-1405
eribulin mesylate (E7389)	Eisai <i>Woodcliff Lake, NJ</i>	hormone-refractory prostate cancer, prostate cancer (see also breast, head/neck, lung, ovarian, sarcoma, solid tumors)	Phase II (888) 422-4743
<b>Gleevec<sup>®</sup></b> imatinib	Novartis Pharmaceuticals <i>East Hanover, NJ</i>	(see also leukemia)	Phase II/III (888) 669-6682
GRNVAC1	Argos Therapeutics <i>Durham, NC</i> Geron <i>Menlo Park, CA</i>	(see also leukemia)	Phase I/II (919) 287-6300 (650) 473-7700
GTx-758	GTx <i>Memphis, TN</i>		Phase I (901) 523-9700
HE-3235	Hollis-Eden Pharmaceuticals <i>San Diego, CA</i>	late-stage prostate cancer	Phase I/II (858) 587-9333
<b>Herceptin<sup>®</sup></b> trastuzumab	Genentech <i>South San Francisco, CA</i>	(see also colorectal, ovarian, pancreatic, stomach, other)	Phase II (650) 225-1000
<b>Hycamtin<sup>®</sup></b> topotecan (oral)	GlaxoSmithKline <i>Rsch. Triangle Park, NC</i>	(see also breast, colorectal, head/neck, kidney, leukemia, lung, lymphoma, multiple myeloma, ovarian, pancreatic, stomach, other)	Phase II (888) 825-5249

## PROSTATE CANCER

Product Name	Sponsor	Indication	Development Status
<b>HyperAcute® Prostate</b> prostate cancer vaccine	NewLink Genetics Ames, IA		Phase I/II (515) 296-5555
idronoxil	Marshall Edwards North Ryde, Australia	(see also ovarian, other)	Phase II
IMC-1121B	Eli Lilly Indianapolis, IN ImClone Systems New York, NY	(see also breast, colorectal, kidney, liver, lung, ovarian, skin)	Phase II (800) 545-5979 (212) 645-1405
IMC-A12	Eli Lilly Indianapolis, IN ImClone Systems New York, NY	(see also breast, colorectal, head/neck, liver, lung, pancreatic, sarcoma, solid tumors)	Phase II (800) 545-5979 (212) 645-1045
INCB-18424	Incyte Wilmington, DE	(see also multiple myeloma)	Phase II (302) 498-6700
INSM-18	Insmad Glen Allen, VA		Phase I/II completed (804) 565-3000
<b>Ixempra™</b> ixabepilone	Bristol-Myers Squibb Princeton, NJ	(see also breast, lung, pancreatic)	in clinical trials (212) 546-4000
JNJ-26854165	Johnson & Johnson Pharmaceutical Research & Development Raritan, NJ	(see also lung)	Phase I (800) 817-5286
<b>Leukine®</b> sargramostim	Bayer HealthCare Pharmaceuticals Wayne, NJ	(see also leukemia, lymphoma, ovarian, skin)	Phase II (888) 842-2937
<b>Leupron Depot®</b> leuprorelin depot (6-month formulation)	Abbott Pharmaceuticals Abbott Park, IL		Phase III (847) 937-6100
leuprorelin inhalation	Enzon Pharmaceuticals Bridgewater, NJ Nektar Therapeutics San Carlos, CA		Phase I (908) 541-8600 (650) 631-3100
MCS110	Novartis Pharmaceuticals East Hanover, NJ	(see also other)	Phase I/II (888) 669-6682
MDV-3100	Medivation San Francisco, CA	hormone-refractory prostate cancer	Phase I/II (415) 543-3470
mepacrine	Cleveland BioLabs Buffalo, NY		Phase II (716) 849-6810
MER-104	Merrion Pharmaceuticals Wilmington, NC		Phase I/II (910) 799-1847
MIP1072	Molecular Insight Pharmaceuticals Cambridge, MA	diagnosis of prostate cancer	Phase I (617) 492-5554

## PROSTATE CANCER

Product Name	Sponsor	Indication	Development Status
MIP1095	Molecular Insight Pharmaceuticals Cambridge, MA	diagnosis of prostate cancer	Phase I (617) 492-5554
MK-0429	Merck Whitehouse Station, NJ		Phase I (800) 672-6372
<b>MVA-BN®-PRO</b>	BN ImmunoTherapeutics Mountain View, CA		Phase I/II (650) 681-4660
NBI-42902	Neurocrine Biosciences San Diego, CA	(see also breast, other)	Phase I (858) 617-7600
<b>NeuVax™</b> E75 cancer vaccine	Aphera Scottsdale, AZ	(see also breast)	Phase I/II (480) 882-8841
OGX-427	Oncogenex Pharmaceuticals Bothell, WA	(see also bladder, breast, lung, ovarian)	Phase I (425) 686-1500
<b>Oncolar®</b> octreotide	Novartis Pharmaceuticals East Hanover, NJ		Phase II (888) 669-6682
ONY-105 (cancer vaccine)	Onyvox London, England		Phase II www.onyvox.com
ONY-P (prostate cancer vaccine)	Onyvox London, England		Phase II www.onyvox.com
ozarelix	Spectrum Pharmaceuticals Irvine, CA		Phase I/II (949) 788-6700
panobinostat	Novartis Pharmaceuticals East Hanover, NJ	(see also brain, breast, leukemia, lymphoma)	Phase II (888) 669-6682
plitidepsin	PharmaMar USA Cambridge, MA	(see also lung, multiple myeloma)	Phase II (617) 868-3797
polyphenon E	Polyphenon Pharma New York, NY	prostatic intraepithelial neoplasia (see also bladder, leukemia)	Phase II (212) 661-0578
<b>Proscar®</b> finasteride	Merck Whitehouse Station, NJ	prostate cancer prevention	Phase III (800) 672-6372
<b>ProstAtak™</b> gene therapy	Advantagene Boston, MA San Diego, CA		Phase II (617) 916-5445 (760) 943-8981
prostate cancer vaccine	Novartis Pharmaceuticals East Hanover, NJ		Phase I/II (888) 669-6682
<b>Prostvac®-VF</b> prostate cancer vaccine	BN ImmunoTherapeutics Mountain View, CA		Phase II (650) 681-4660
<b>Provenge®</b> sipuleucel-T	Dendreon Seattle, WA	hormone-refractory, metastatic prostate cancer	application submitted (206) 256-4545
		non-metastatic androgen-dependent prostate cancer	Phase III (206) 256-4545

## PROSTATE CANCER

Product Name	Sponsor	Indication	Development Status
PRX-302	Protox Therapeutics <i>Vancouver, Canada</i>		Phase II (604) 688-0199
PSMA-ADC	Progenics Pharmaceuticals <i>Tarrytown, NY</i>		Phase I (914) 789-2800
PSMA cancer vaccine	Progenics Pharmaceuticals <i>Tarrytown, NY</i>		Phase I (914) 789-2800
<b>Quadramet</b> <sup>®</sup> samarium SM-153 lexidronam injection	Cytogen <i>Princeton, NJ</i>	(see also multiple myeloma, sarcoma, other)	Phase II (800) 833-3533
<b>Quinamed</b> <sup>®</sup> amonafide	ChemGenex Pharmaceuticals <i>Menlo Park, CA</i>	(see also breast, ovarian)	Phase II (650) 474-9800
<b>Revlimid</b> <sup>®</sup> lenalidomide	Celgene <i>Summit, NJ</i>	(see also leukemia, lymphoma, multiple myeloma, other)	Phase II (908) 673-4900
romidepsin	Gloucester Pharmaceuticals <i>Cambridge, MA</i>	(see also kidney, lymphoma, multiple myeloma, pancreatic)	Phase II completed (617) 583-1300
sagopilone	Bayer HealthCare Pharmaceuticals <i>Wayne, NJ</i>	combination therapy (see also brain, breast, ovarian)	Phase II (888) 842-2937
satraplatin	Spectrum Pharmaceuticals <i>Irvine, CA</i>	hormone-refractory prostate cancer (combination therapy, second-line therapy) (see also breast, lung)	Phase III (949) 788-6700
seocalcitol (CB1089)	Cougar Biotechnology <i>Los Angeles, CA</i>		Phase I (310) 943-8040
<b>Sprycel</b> <sup>™</sup> dasatinib	Bristol-Myers Squibb <i>Princeton, NJ</i>	(see also leukemia, solid tumors)	in clinical trials (212) 546-4000
<b>Sutent</b> <sup>®</sup> sunitinib	Pfizer <i>New York, NY</i>	hormone-refractory metastatic prostate cancer (see also breast, colorectal, liver, lung, pancreatic, sarcoma, stomach)	Phase III (860) 732-5156
		----- adjunctive treatment	Phase II (860) 732-5156
TAK683	Millennium Pharmaceuticals <i>Cambridge, MA</i>		Phase I (800) 390-5663
TAK700	Millennium Pharmaceuticals <i>Cambridge, MA</i>		Phase I/II (800) 390-5663
tandutinib (MLN0518)	Millennium Pharmaceuticals <i>Cambridge, MA</i>	(see also brain)	Phase II (800) 390-5663
tesmilifene	YM BioSciences <i>Wayne, PA</i>	(see also breast)	Phase II (610) 560-0600

## PROSTATE CANCER

Product Name	Sponsor	Indication	Development Status
<b>TheraCIM™</b> nimotuzumab	YM Biosciences Wayne, PA	hormone-refractory prostate cancer (see also brain, breast, stomach)	Phase II (610) 560-0600
<b>Thymitaq®</b> nolatrexed	YM BioSciences Wayne, PA	(see also colorectal, head/neck, liver, lung, pancreatic)	Phase II (610) 560-0600
tigapotide	Ambrilia Biopharma Verdun, Canada		Phase II (514) 751-2003
<b>Torisel™</b> temsirolimus	Wyeth Pharmaceuticals Collegetown, PA	(see also colorectal, kidney, lung, lymphoma, multiple myeloma)	Phase II (800) 934-5556
TPI-287	Tapestry Pharmaceuticals Boulder, CO	hormone-refractory prostate cancer (see also pancreatic)	Phase II (303) 516-8500
transgenic B lymphocyte immunotherapy/ cancer vaccine	Cosmo Bioscience San Diego, CA		Phase II (858) 823-0413
tremelimumab	Pfizer New York, NY	high-risk prostate cancer (see also breast, colorectal, kidney, lung, skin)	Phase II completed (860) 732-5156
		combination therapy	Phase I (860) 732-5156
<b>Triapine®</b>	Vion Pharmaceuticals New Haven, CT	(see also leukemia, lung, pancreatic)	Phase II (203) 498-4210
trilostane	Genzyme Cambridge, MA	(see also breast)	Phase II (617) 252-7500
tucotuzumab celmoleukin	EMD Serono Rockland, MA	(see also colorectal, lung, ovarian)	Phase II (800) 283-8088
VDC2008	Bostwick Laboratories Glen Allen, VA		Phase I/II (804) 967-9225
<b>Vidaza®</b> azacitidine	Celgene Summit, NJ	(see also leukemia, lymphoma)	Phase II (908) 673-9000
VP101	Access Pharmaceuticals Dallas, TX	(see also brain, colorectal, leukemia)	Phase II (214) 905-5100
YM-155	Astellas Pharma US Deerfield, IL	hormone-refractory prostate cancer (see also lymphoma)	Phase II (800) 727-7003
YMB2002 (prostate cancer vaccine)	YM BioSciences Wayne, PA		Phase II (610) 560-0600
<b>Yondelis®</b> trabectedin	Johnson & Johnson Pharmaceutical Research & Development Raritan, NJ	(see also breast, ovarian, sarcoma, other)	Phase II (800) 817-5286
ZYC300	Eisai Woodcliff Lake, NJ	(see also breast, colorectal, kidney, ovarian)	Phase I (888) 422-4743

# SARCOMA

Product Name	Sponsor	Indication	Development Status
<b>Actimid™</b> pomalidomide	Celgene <i>Summit, NJ</i>	(see also lung, multiple myeloma, pancreatic, prostate)	Phase II (908) 673-9000
AMG 479	Amgen <i>Thousand Oaks, CA</i>	(see also breast, colorectal, lung, pancreatic)	Phase II (805) 447-1000
<b>Armala™</b> pazopanib	GlaxoSmithKline <i>Rsch. Triangle Park, NC</i>	(see also brain, breast, cervical, kidney, liver, lung, ovarian, other)	Phase III (888) 669-6682
AVE8062	sanofi-aventis <i>Bridgewater, NJ</i>		Phase III (800) 633-1610
brostallicin	Cell Therapeutics <i>Seattle, WA</i>	soft tissue sarcoma (see also solid tumors)	Phase II (800) 215-2355
cancer vaccine	MabVax Therapeutics <i>San Diego, CA</i>	(see also breast)	Phase I (858) 259-9405
conatumumab	Amgen <i>Thousand Oaks, CA</i>	(see also colorectal, lung, pancreatic)	Phase I/II (805) 447-1000
CP-751871	Pfizer <i>New York, NY</i>	(see also breast, colorectal, lung, multiple myeloma, prostate)	Phase I/II (860) 732-5156
deforolimus (MK-8669) <b>(Orphan Drug)</b>	ARIAD Pharmaceuticals <i>Cambridge, MA</i> Merck <i>Whitehouse Station, NJ</i>	oral formulation (see also breast, lung, prostate, other)	Phase III (617) 494-0400 (800) 672-6372
		----- intravenous formulation	Phase I/II (617) 494-0400 (800) 672-6372
eribulin mesylate (E7389)	Eisai <i>Woodcliff Lake, NJ</i>	(see also breast, head/neck, lung, ovarian, prostate, solid tumors)	Phase II (877) 873-4724
<b>Fusilev™</b> levoleucovorin for injection	Spectrum Pharmaceuticals <i>Irvine, CA</i>	(see also colorectal)	application submitted (949) 788-6700
<b>Gemzar®</b> gemcitabine	Eli Lilly <i>Indianapolis, IN</i>	(see also head/neck, lung, lymphoma)	Phase II (800) 545-5979
glufosfamide	Threshold Pharmaceuticals <i>Redwood City, CA</i>	(see also breast, lung, pancreatic)	Phase II (650) 474-8200
IMC-A12	Eli Lilly <i>Indianapolis, IN</i> ImClone Systems <i>New York, NY</i>	soft tissue sarcoma (see also breast, colorectal, head/neck, liver, lung, pancreatic, prostate, solid tumors)	Phase II (800) 545-5979 (212) 645-1405
<b>Junovan™</b> mifamurtide	IDM Pharma <i>Irvine, CA</i>	osteosarcoma	application submitted (949) 470-4751
KRX-0402	Keryx Biopharmaceuticals <i>New York, NY</i>	(see also brain, colorectal, kidney, multiple myeloma)	Phase II (212) 531-5965
palifosfamide (ZIO-201) <b>(Orphan Drug)</b>	ZIOPHARM Oncology <i>New York, NY</i>	combination therapy (see also solid tumors)	Phase II (212) 214-0700
		----- monotherapy	Phase I/II (212) 214-0700

## SARCOMA

Product Name	Sponsor	Indication	Development Status
perifosine	AEterna Zentaris <i>Montreal, Canada</i> Keryx Biopharmaceuticals <i>New York, NY</i>	(see also brain, head/neck, kidney, lymphoma, multiple myeloma, ovarian)	Phase II (212) 531-5965
<b>Quadramet®</b> samarium sm-153 lexidronam injection	Cytogen <i>Princeton, NJ</i>	osteosarcoma (see also multiple myeloma, prostate, other)	Phase I/II (800) 833-3533
R1507	Roche <i>Nutley, NJ</i>	(see also breast, lung, lymphoma)	Phase II (973) 235-5000
<b>Reolysin®</b> reovirus	Oncolytics Biotech <i>Calgary, Canada</i>	(see also brain, head/neck, lung, skin)	Phase II (403) 670-7377
<b>Rexin-G™</b> tumor-targeted gene therapy	Epeius Biotechnologies <i>San Marino, CA</i>	osteosarcoma (see also breast, pancreatic)	Phase II (626) 441-6695
		soft tissue sarcoma	Phase I/II (626) 441-6695
robatumumab	Schering-Plough <i>Kenilworth, NJ</i>	osteosarcoma, sarcoma (see also colorectal)	Phase II (908) 298-4000
<b>Sutent®</b> sunitinib	Pfizer <i>New York, NY</i>	soft tissue sarcoma (see also breast, colorectal, liver, lung, pancreatic, prostate, stomach)	Phase II (860) 732-5156
tasisulam (ASAP)	Eli Lilly <i>Indianapolis, IN</i>	soft tissue sarcoma (see also leukemia, ovarian, skin)	Phase II (800) 545-5979
TH-302	Threshold Pharmaceuticals <i>Redwood City, CA</i>	soft tissue sarcoma (see also solid tumors)	Phase I/II (650) 474-8200
<b>Yondelis®</b> trabectedin <b>(Orphan Drug)</b>	Johnson & Johnson Pharmaceutical Research & Development <i>Raritan, NJ</i>	first-line therapy (see also breast, ovarian, prostate, other)	Phase III (800) 817-5286
		in adolescents and children	Phase II (800) 817-5286

## SKIN CANCER

Product Name	Sponsor	Indication	Development Status
1203486A	GlaxoSmithKline <i>Rsch. Triangle Park, NC</i>	malignant melanoma	Phase II (888) 825-5249
2132231A	GlaxoSmithKline <i>Rsch. Triangle Park, NC</i>	malignant melanoma	Phase III (888) 825-5249
<b>Abraxane™</b> albumin-bound paclitaxel	Abraxis BioScience <i>Los Angeles, CA</i>	malignant melanoma (see also head/neck, lung, ovarian, pancreatic, prostate)	Phase II (310) 883-1300
ABT-888	Abbott Laboratories <i>Abbott Park, IL</i>	malignant melanoma (see also solid tumors)	Phase II (847) 937-6100

## SKIN CANCER

Product Name	Sponsor	Indication	Development Status
<b>Allovectin-7®</b> velimogene aliplasmid (immunotherapeutic vaccine) <b>(Orphan Drug)</b>	Vical <i>San Diego, CA</i>	metastatic melanoma	Phase III (858) 646-1100
ALS-357 (betulinic topical)	Advanced Life Sciences <i>Woodridge, IL</i>	malignant melanoma	Phase I (630) 739-6744
<b>Amplimexon®</b> imexon	AmpliMed <i>Tucson, AZ</i>	malignant melanoma (see also breast, lung, multiple myeloma, pancreatic, prostate)	Phase I/II completed (520) 529-1000
ATN-224	Attenuon <i>San Diego, CA</i>	malignant melanoma (see also multiple myeloma, prostate)	Phase II (858) 720-8797
AZD6244	AstraZeneca <i>Wilmington, DE</i>	malignant melanoma (see also leukemia, liver, lung, multiple myeloma, ovarian, pancreatic, other)	Phase II (800) 236-9933
<b>Azixa™</b> (MPC-6827)	Myriad Pharmaceuticals <i>Salt Lake City, UT</i>	malignant melanoma (see also brain)	Phase I/II (801) 584-3600
BMS-663513 (anti-CD137 antibody)	Bristol-Myers Squibb <i>Princeton, NJ</i>	second-line melanoma	in clinical trials (212) 546-4000
Cadi 05	Cadila Pharmaceuticals <i>Bhat, India</i>	malignant melanoma (see also solid tumors)	Phase I/II <a href="http://www.cadilapharma.com">www.cadilapharma.com</a>
CNTO 95	Centocor <i>Horsham, PA</i>	malignant melanoma (see also prostate, solid tumors)	Phase I/II (610) 651-6000
CR011-vcMMAE	CuraGen <i>Branford, CT</i>	malignant melanoma (see also breast)	Phase II (888) 436-6642
CYT-107	Cytheris <i>Rockville, MD</i>	malignant melanoma (see also kidney, leukemia, solid tumors)	Phase I/II (301) 231-0450
denenicokin (IL-21)	ZymoGenetics <i>Seattle, WA</i>	malignant melanoma (see also colorectal, kidney, lymphoma, ovarian)	Phase I/II (206) 442-6600
<b>Dimericine®</b> T4N5 liposome lotion	AGI Dermatics <i>Freeport, NY</i>		Phase II (516) 868-9026
dovitinib	Novartis Pharmaceuticals <i>East Hanover, NJ</i>	malignant melanoma (see also kidney)	Phase I/II (888) 669-6682
ecromeximab	Life Sciences Pharmaceuticals <i>Greenwich, CT</i>	malignant melanoma (combination therapy)	Phase II (203) 422-6500
<b>Elacyt™</b> elacytarabine	Clavis Pharma <i>Oslo, Norway</i>	malignant melanoma (combination therapy), malignant melanoma (first-line therapy) (see also leukemia, ovarian)	Phase II <a href="http://www.clavispharma.com">www.clavispharma.com</a>

## SKIN CANCER

Product Name	Sponsor	Indication	Development Status
EMD 273063	EMD Serono <i>Rockland, MA</i>	malignant melanoma (see also brain)	Phase II (800) 283-8088
<b>Exherin™</b> (ADH-1)	Adherex Technologies <i>Durham, NC</i>	malignant melanoma (see also solid tumors)	Phase I/II (919) 484-8484
GC-1008	Genzyme <i>Cambridge, MA</i>	malignant melanoma (see also kidney)	Phase I (617) 252-7000
<b>Genasense®</b> oblimersen <b>(Orphan Drug)</b>	Genta <i>Berkeley Heights, NJ</i>	malignant melanoma (see also breast, leukemia, lung, lymphoma, solid tumors)	Phase III (908) 286-9800
GMX-1777	Gemin X Biotechnologies <i>Montreal, Canada</i>	malignant melanoma (combination therapy) (see also lymphoma, solid tumors)	Phase I/II (514) 281-8989
<b>HyperAcute®</b> <b>Melanoma</b> melanoma vaccine	NewLink Genetics <i>Ames, IA</i>	malignant melanoma	Phase I/II (515) 296-5555
IMC-1121B	Eli Lilly <i>Indianapolis, IN</i> ImClone Systems <i>New York, NY</i>	metastatic malignant melanoma (see also breast, colorectal, kidney, liver, lung, ovarian, prostate)	Phase II (800) 545-5979 (212) 645-1405
INGN 241 (mda-7)	Introgen Therapeutics <i>Austin, TX</i>	malignant melanoma (see also head/neck)	Phase II (512) 708-9310
interleukin-12 gene therapy	Inovio <i>San Diego, CA</i>	malignant melanoma	Phase I (877) 446-6846
<b>Karenitecin®</b> cositecan	BioNumerik Pharmaceuticals <i>San Antonio, TX</i>	malignant melanoma (see also brain, lung, ovarian)	Phase II completed (201) 614-1710
<b>Leukine®</b> sargramostim	Bayer HealthCare Pharmaceuticals <i>Wayne, NJ</i>	malignant melanoma (see also leukemia, lymphoma, ovarian, prostate)	Phase II (888) 842-2937
<b>Lymphoseek™</b>	Neoprobe <i>Dublin, OH</i>	diagnosis of malignant melanoma (see also breast)	Phase III (800) 793-0079
<b>Marqibo™</b> vincristine liposomal <b>(Orphan Drug)</b>	Hana Biosciences <i>South San Francisco, CA</i>	malignant melanoma (see also leukemia)	Phase II (650) 588-6404
MDX-010 (ipilimumab)	Bristol-Myers Squibb <i>Princeton, NJ</i> Medarex <i>Princeton, NJ</i>	adjuvant melanoma, metastatic melanoma (see also solid tumors)	Phase III (212) 546-4000
melanoma vaccine	Ichor Medical Systems <i>San Diego, CA</i>	malignant melanoma	Phase I (858) 550-2022
melanoma vaccine	Novavax <i>Malvern, PA</i>	malignant melanoma	Phase I (484) 913-1200
melanoma vaccine	sanofi-aventis <i>Bridgewater, NJ</i>	treatment of stage III and stage IV melanoma	Phase II (800) 633-1610

## SKIN CANCER

Product Name	Sponsor	Indication	Development Status
<b>Melaxin®</b> autologous dendritoma vaccine	Oncolix <i>Greenville, SC</i>	malignant melanoma	Phase II
<b>Metvixia®</b> methyl aminolevulinate	PhotoCure <i>Oslo, Norway</i>	basal cell cancer	Phase III www.photocure.com
MKC 1106-MT	MannKind <i>Valencia, CA</i>	malignant melanoma	Phase I (661) 775-5300
<b>M-Vax®</b> melanoma vaccine	AVAX Technologies <i>Philadelphia, PA</i>	malignant melanoma	Phase III (215) 241-9760
<b>Nexavar®</b> sorafenib	Bayer HealthCare Pharmaceuticals <i>Wayne, NJ</i> Onyx Pharmaceuticals <i>Emeryville, CA</i>	malignant melanoma (combination therapy) (see also breast, lung)	Phase III (888) 842-2837 (510) 597-6500
ODC-0501	ODC Therapy <i>Dallas, TX</i>	malignant melanoma	Phase I/II (214) 826-7019
<b>Oncophage®</b> vitespen	Antigenics <i>New York, NY</i>	malignant melanoma (see also brain, colorectal, kidney, pancreatic, stomach)	Phase III (866) 805-8994
<b>OncoVAX®</b> cancer vaccine	Vaccinogen <i>Frederick, MD</i>	malignant melanoma (see also colorectal, kidney)	Phase I/II (301) 668-8400
OncoVEX GM-CSF	BioVex <i>Woburn, MA</i>	malignant melanoma (see also pancreatic)	Phase II (781) 376-4900
PARP inhibitor	Genentech <i>South San Francisco, CA</i>	malignant melanoma	Phase I (650) 225-1000
<b>PEG-Intron A®</b> peginterferon alfa-2b	Schering-Plough <i>Kenilworth, NJ</i>	adjunctive treatment of stage III malignant melanoma (see also leukemia)	application submitted (908) 298-4000
PEP-005	Peplin <i>Emeryville, CA</i>	basal cell cancer	Phase II (510) 653-9700
PHP	Curacyte <i>Chapel Hill, NC</i>	malignant melanoma	Phase II www.curacyte.com
PI-88	Progen Pharmaceuticals <i>Redwood City, CA</i>	malignant melanoma	Phase II (650) 610-7080
PLX-4032	Plexxikon <i>Berkeley, CA</i> Roche <i>Nutley, NJ</i>	malignant melanoma	Phase I (510) 647-4000 (973) 235-5000
PTC-299	PTC Therapeutics <i>South Plainfield, CT</i>	Kaposi's sarcoma (see also breast)	Phase I/II (908) 222-7000
PV-10	Provectus Pharmaceuticals <i>Knoxville, TN</i>	malignant melanoma	Phase II (866) 594-5999

## SKIN CANCER

Product Name	Sponsor	Indication	Development Status
RAF265	Novartis Pharmaceuticals <i>East Hanover, NJ</i>	malignant melanoma	Phase I (888) 669-6682
<b>Reolysin</b> <sup>®</sup> reovirus	Oncolytics Biotech <i>Calgary, Canada</i>	malignant melanoma (see also brain, head/neck, lung, sarcoma)	Phase II (403) 670-7377
systemic hedgehog antagonist	Genentech <i>South San Francisco, CA</i>	basal cell cancer (see also brain, colorectal, ovarian)	Phase II (650) 224-1000
tasisulam (ASAP)	Eli Lilly <i>Indianapolis, IN</i>	malignant melanoma (see also leukemia, ovarian, sarcoma)	Phase II (800) 545-5979
TM-601-I-131	TransMolecular <i>Cambridge, MA</i>	metastatic malignant melanoma (see also brain)	Phase I/II (617) 995-3050
<b>TNFerade</b> <sup>™</sup>	GenVec <i>Gaithersburg, MD</i>	malignant melanoma (see also colorectal, head/neck, pancreatic, stomach)	Phase II (240) 632-0740
tremelimumab	Pfizer <i>New York, NY</i>	malignant melanoma (see also breast, colorectal, kidney, lung, prostate)	Phase II (860) 732-5156
VCL-IM01	Vical <i>San Diego, CA</i>	metastatic malignant melanoma	Phase I (858) 646-1100
vegin	VasGene Therapeutics <i>Los Angeles, CA</i>	Kaposi's sarcoma	Phase I (323) 221-7818
<b>Visudyne</b> <sup>®</sup> verteporfin	QLT USA <i>Fort Collins, CO</i>	malignant melanoma	Phase I/II (800) 663-5486
volociximab	Biogen Idec <i>Cambridge, MA</i> Facet Biotech <i>Redwood City, CA</i>	malignant melanoma (see also lung, ovarian, pancreatic)	Phase II (617) 679-2000 (650) 454-1000
<b>Zadaxin</b> <sup>®</sup> thymalfasin	SciClone Pharmaceuticals <i>Foster City, CA</i>	malignant melanoma	Phase II (650) 358-3456
ZRx101	ZelleRx <i>Chicago, IL</i>	malignant melanoma (see also kidney, multiple myeloma, cancer-related)	Phase I (312) 243-5200

## SOLID TUMORS

Product Name	Sponsor	Indication	Development Status
461364	GlaxoSmithKline <i>Rsch. Triangle Park, NC</i>	(see also lymphoma)	Phase I (888) 825-5249
690693	GlaxoSmithKline <i>Rsch. Triangle Park, NC</i>	(see also lymphoma)	Phase I (888) 825-5249
923295	GlaxoSmithKline <i>Rsch. Triangle Park, NC</i>	refractory metastatic disease	Phase I (888) 825-5249
1MT	NewLink Genetics <i>Ames, IA</i>		Phase I (515) 296-5555

## SOLID TUMORS

Product Name	Sponsor	Indication	Development Status
2DG (2-deoxy-d-glucose)	Threshold Pharmaceuticals <i>Redwood City, CA</i>		Phase I (605) 474-8200
ABI-009	Abraxis BioScience <i>Los Angeles, CA</i>		Phase I (310) 883-1300
ABT-828	Abbott Laboratories <i>Abbott Park, IL</i>		Phase I (847) 937-6100
ABT-888	Abbott Laboratories <i>Abbott Park, IL</i>	(see also skin)	Phase I (847) 937-6100
AEE788	Novartis Pharmaceuticals <i>East Hanover, NJ</i>	(see also brain)	Phase I (888) 669-6682
AEW541	Novartis Pharmaceuticals <i>East Hanover, NJ</i>	(see also leukemia)	Phase I (888) 669-6682
AFP-464	Tigris Pharmaceuticals <i>Bonita Springs, FL</i>		Phase I (239) 444-5400
AI-850	Acusphere <i>Watertown, MA</i> Cephalon <i>Frazer, PA</i>		Phase I (617) 648-8800 (610) 344-0200
ALB 109564(a)	AMRI <i>Albany, NY</i>		Phase I (518) 512-2000
AMG 208	Amgen <i>Thousand Oaks, CA</i>		Phase I (805) 447-1000
AMG 888 (U3-1287)	Amgen <i>Thousand Oaks, CA</i> Daiichi Sankyo <i>Parsippany, NJ</i>		Phase I (805) 447-1000 (973) 359-2600
ANA-773	Anadys Pharmaceuticals <i>San Diego, CA</i>		Phase I (858) 530-3600
angiostatic cocktail	Angiogen <i>Evanston, IL</i>		Phase I (847) 866-6700
anti-EGFR mAb-806	Abbott Laboratories <i>Abbott Park, IL</i>		Phase I (847) 937-6100
anti-IGF-1R mAb	Genentech <i>South San Francisco, CA</i>		Phase I (650) 225-1000
AR-67	Arno Therapeutics <i>Fairfield, NJ</i>		Phase I (862) 703-7170
ARQ-197	ArQule <i>Woburn, MA</i> Daiichi Sankyo <i>Parsippany, NJ</i>	microphthalmia transcription factor tumors (see also liver, lung, pancreatic)	Phase I/II (781) 994-0300 (973) 359-2600
ARQ-501 (beta lapachone)	ArQule <i>Woburn, MA</i>	refractory metastatic solid tumors (combination therapy) (see also head/neck, pancreatic, other)	Phase I/II (781) 994-0300
ARRY-520	Array BioPharma <i>Boulder, CO</i>	(see also leukemia)	Phase I (303) 381-6600

## SOLID TUMORS

Product Name	Sponsor	Indication	Development Status
AT7519	Astex Therapeutics <i>Cambridge, United Kingdom</i>		Phase I
AT9283	Astex Therapeutics <i>Cambridge, United Kingdom</i>	(see also leukemia)	Phase I
AT13387	Astex Therapeutics <i>Cambridge, United Kingdom</i>		Phase I
ATN-161	Attenuon <i>San Diego, CA</i>		Phase I (858) 720-8797
AUY922	Novartis Pharmaceuticals <i>East Hanover, NJ</i>	(see also multiple myeloma)	Phase I/II (888) 669-6682
AV-299 (SCH-90015)	AVEO Pharmaceuticals <i>Cambridge, MA</i> Schering-Plough <i>Kenilworth, NJ</i>	advanced solid tumors (see also lymphoma)	Phase I (617) 299-5000
AV-412	AVEO Pharmaceuticals <i>Cambridge, MA</i>		Phase I (617) 299-5000
axitinib	Pfizer <i>New York, NY</i>	combination therapy, late-stage disease (see also colorectal, kidney, lung, other)	Phase I (860) 732-5156
AZD4769	AstraZeneca <i>Wilmington, DE</i>		Phase I (800) 236-9933
AZD6918	AstraZeneca <i>Wilmington, DE</i>		Phase I (800) 236-9933
AZD7762	AstraZeneca <i>Wilmington, DE</i>		Phase I (800) 236-9933
AZD8055	AstraZeneca <i>Wilmington, DE</i>		Phase I/II (800) 236-9933
AZD8330	AstraZeneca <i>Wilmington, DE</i>		Phase I (800) 236-9933
AZD8931	AstraZeneca <i>Wilmington, DE</i>		Phase I (800) 236-9933
AZM475271	AstraZeneca <i>Wilmington, DE</i>	(see also leukemia)	Phase I (800) 236-9933
BEZ235	Novartis Pharmaceuticals <i>East Hanover, NJ</i>		Phase I (888) 669-6682
BGT226	Novartis Pharmaceuticals <i>East Hanover, NJ</i>		Phase I/II (888) 669-6682
BHQ880	Novartis Pharmaceuticals <i>East Hanover, NJ</i>		Phase I (888) 669-6682
BI 6727	Boehringer Ingelheim Pharmaceuticals <i>Ridgefield, CT</i>		Phase I (800) 243-0127
BI 831266	Boehringer Ingelheim Pharmaceuticals <i>Ridgefield, CT</i>		Phase I (800) 243-0127

## SOLID TUMORS

Product Name	Sponsor	Indication	Development Status
BIBF 1120	Boehringer Ingelheim Pharmaceuticals <i>Ridgefield, CT</i>	combination therapy (see also lung)	Phase I (800) 243-0127
BIIB 015	Biogen Idec <i>Cambridge, MA</i>		Phase I (617) 679-2000
BIIB 022	Biogen Idec <i>Cambridge, MA</i>		Phase I (617) 679-2000
BMS-690514 (ErbB/VEGF receptor inhibitor)	Bristol-Myers Squibb <i>Princeton, NJ</i>	(see also lung)	in clinical trials (212) 546-4000
BMS-754807 (IGF-1R antagonist)	Bristol-Myers Squibb <i>Princeton, NJ</i>		in clinical trials (212) 546-4000
BMS-833923 (SMO inhibitor)	Bristol-Myers Squibb <i>Princeton, NJ</i> Exelixis <i>South San Francisco, CA</i>		Phase I (212) 546-4000
BMS-844203 (VEGF inhibitor- adnectin)	Bristol-Myers Squibb <i>Princeton, NJ</i>	(see also brain)	in clinical trials (212) 546-4000
bosutinib	Wyeth Pharmaceuticals <i>Collegeville, PA</i>	(see also breast, leukemia)	Phase I (800) 934-5556
BQS481	Novartis Pharmaceuticals <i>East Hanover, NJ</i>		Phase I (888) 669-6682
brostallicin	Cell Therapeutics <i>Seattle, WA</i>	advanced solid tumors (see also sarcoma)	Phase II (800) 215-2355
		combination therapy	Phase I/II (800) 215-2355
Cadi 05	Cadila Pharmaceuticals <i>Bhat, India</i>	(see also skin)	Phase I <a href="http://www.cadilapharma.com">www.cadilapharma.com</a>
CALAA 01	Calando Pharmaceuticals <i>Pasadena, CA</i>		Phase I (626) 683-7200
carfilzomib	Proteolix <i>South San Francisco, CA</i>	relapsed solid tumors (see also leukemia, multiple myeloma)	Phase I/II (650) 615-7550
CBP501	Millennium Pharmaceuticals <i>Cambridge, MA</i>	(see also lung)	Phase I (800) 390-5663
CDX-110	Celldex Therapeutics <i>Needham, MA</i> Pfizer <i>New York, NY</i>	(see also brain)	Phase I (781) 433-0771 (860) 732-5156
CEP-11981	Cephalon <i>Frazer, PA</i>		Phase I (610) 344-0200
cevipabulin	Wyeth Pharmaceuticals <i>Collegeville, PA</i>		Phase I (800) 934-5556

## SOLID TUMORS

Product Name	Sponsor	Indication	Development Status
CG-201	CG Therapeutics <i>Seattle, WA</i>		Phase I (206) 336-5604
cilengitide	EMD Serono <i>Rockland, MA</i>	late-stage solid tumors (see also brain, lymphoma, prostate)	Phase I (800) 283-8088
CNF-2024	Biogen Idec <i>Cambridge, MA</i>	(see also breast, leukemia, stomach)	Phase I (617) 679-2000
CNTO 95	Centocor <i>Horsham, PA</i>	(see also prostate, skin)	Phase I completed (610) 651-6000
CNTO 888	Centocor <i>Horsham, PA</i>		Phase I (610) 651-6000
CP-870893	Pfizer <i>New York, NY</i>		Phase I (860) 732-5156
crinobulin	EpiCept <i>Tarrytown, NY</i>	(see also lymphoma)	Phase I (914) 606-3500
CRx-026	CombinatoRx <i>Cambridge, MA</i>	late-stage, metastatic solid tumors	Phase I/II (617) 301-7000
CUDC-101	Curis <i>Cambridge, MA</i>		Phase I (617) 503-6500
CX-4945	Cylene Pharmaceuticals <i>San Diego, CA</i>	(see also multiple myeloma, other)	Phase I (858) 875-5100
CYC-116	Cyclacel Pharmaceuticals <i>Berkeley Heights, NJ</i>		Phase I (908) 517-7330
CYT-107	Cytheris <i>Rockville, MD</i>	(see also kidney, leukemia, skin)	Phase I (301) 231-0450
CYT 6091	CytImmune Sciences <i>Rockville, MD</i>		Phase I (240) 864-2796
darinaparsin (ZIO-101)	ZIOPHARM Oncology <i>New York, NY</i>	(see also leukemia, liver, multiple myeloma)	Phase I (646) 214-0700
<b>Davanat</b> <sup>TM</sup> galactomannan C	Pro-Pharmaceuticals <i>Newton, MA</i>	(see also colorectal)	Phase I (617) 559-0033
denibulin (MN-029)	MediciNova <i>San Diego, CA</i>		Phase I (858) 373-1500
DMPEN	Antisoma <i>Cambridge, MA</i>		Phase I (617) 225-0522
E6201	Eisai <i>Woodcliff Lake, NJ</i>	advanced solid tumors	Phase I (888) 422-4743
E7050	Eisai <i>Woodcliff Lake, NJ</i>		Phase I (888) 422-4743
E7080	Eisai <i>Woodcliff Lake, NJ</i>	(see also other)	Phase I/II (888) 422-4743
ENMD-2076	EntreMed <i>Rockville, MD</i>	refractory metastatic disease (see also multiple myeloma)	Phase I (240) 864-2600
eniluracil	Adherex Technologies <i>Durham, NC</i>	(see also liver)	Phase I (919) 484-8484

## SOLID TUMORS

Product Name	Sponsor	Indication	Development Status
eribulin mesylate (E7389)	Eisai <i>Woodcliff Lake, NJ</i>	advanced solid tumors, solid tumors (see also breast, head/neck, lung, ovarian, prostate, sarcoma)	Phase I (888) 422-4743
<b>Exherin™</b> (ADH-1)	Adherex Technologies <i>Durham, NC</i>	(see also skin)	Phase II (919) 484-8484
EZN-2968	Enzon Pharmaceuticals <i>Bridgewater, NJ</i>	(see also lymphoma)	Phase I (866) 792-5172
FP-1039	Five Prime Therapeutics <i>San Francisco, CA</i>		Phase I (415) 365-5600
<b>Genasense®</b> oblimersen	Genta <i>Berkeley Heights, NJ</i>	brief, high-dose IV-infusion (see also breast, leukemia, lung, lymphoma, skin)	Phase I/II (908) 286-9800
		intermittent therapy	Phase I (908) 286-9800
GMX-1777	Gemin X Biotechnologies <i>Montreal, Canada</i>	(see also lymphoma, skin)	Phase I (514) 281-8989
HGS-1029	Human Genome Sciences <i>Rockville, MD</i>		Phase I (301) 309-8504
HMN-214	NS Pharma <i>Parsippany, NJ</i>		Phase I (973) 285-7010
IMC-3G3	Eli Lilly <i>Indianapolis, IN</i> ImClone Systems <i>New York, NY</i>		Phase I (800) 545-5979 (212) 645-1405
IMC-18F1	Eli Lilly <i>Indianapolis, IN</i> ImClone Systems <i>New York, NY</i>		Phase I (800) 545-5979 (212) 645-1405
IMC-A12	Eli Lilly <i>Indianapolis, IN</i> ImClone Systems <i>New York, NY</i>	solid tumors in adolescents and children (see also breast, colorectal, head/neck, liver, lung, pancreatic, prostate, sarcoma)	Phase I/II (800) 545-5979 (212) 645-1405
		solid tumor combination therapy, other solid tumors	Phase I (800) 545-5979 (212) 645-1405
IMGN-242	ImmunoGen <i>Cambridge, MA</i>	(see also stomach)	Phase I (617) 995-2500
IMGN-388	ImmunoGen <i>Cambridge, MA</i>		Phase I (617) 679-5500
INNO-206	CytRx <i>Los Angeles, CA</i>		Phase I (310) 826-5648
INNO-305	CytRx <i>Los Angeles, CA</i>	(see also leukemia)	Phase I (310) 826-5648

## SOLID TUMORS

Product Name	Sponsor	Indication	Development Status
IPI-493	Infinity Pharmaceuticals <i>Cambridge, MA</i>		Phase I (617) 453-1000
IPI-926	Infinity Pharmaceuticals <i>Cambridge, MA</i>		Phase I (617) 453-100
Jl-101	Jubilant Innovation <i>Bedminster, NJ</i>		Phase I (215) 369-0965
JNJ-38877605	Johnson & Johnson Pharmaceutical Research & Development <i>Raritan, NJ</i>		Phase I (800) 817-5286
JX-594	Jennerex Biotherapeutics <i>San Francisco, CA</i>	(see also liver)	Phase I (415) 281-8886
LE-DT	NeoPharm <i>Lake Bluff, IL</i>		Phase I (847) 887-0800
lexatumumab	Human Genome Sciences <i>Rockville, MD</i>		Phase I (301) 309-8504
L-MDAM	BioNumerik Pharmaceuticals <i>San Antonio, TX</i>		Phase I (210) 614-1701
LP-261	Locus Pharmaceuticals <i>Blue Bell, PA</i>		Phase I (215) 358-2000
LY2157299	Eli Lilly <i>Indianapolis, IN</i>		Phase I (800) 545-5979
LY2181308	Eli Lilly <i>Indianapolis, IN</i> Isis Pharmaceuticals <i>Carlsbad, CA</i>	(see also leukemia)	Phase II (800) 545-5979 (760) 931-9200
LY2275796	Eli Lilly <i>Indianapolis, IN</i> Isis Pharmaceuticals <i>Carlsbad, CA</i>		Phase I (800) 545-5979 (760) 931-9200
LY2334737	Eli Lilly <i>Indianapolis, IN</i>		Phase I (800) 545-5979
LY2603618	Eli Lilly <i>Indianapolis, IN</i>		Phase I (800) 545-5979
M1685A	Genentech <i>South San Francisco, CA</i>		Phase I (650) 224-1000
MDX-010 (ipilimumab)	Bristol-Myers Squibb <i>Princeton, NJ</i> Medarex <i>Princeton, NJ</i>	(see also skin)	in clinical trials (212) 546-4000
MDX-1105	Medarex <i>Princeton, NJ</i>		Phase I (609) 430-2880
MDX-1106	Medarex <i>Princeton, NJ</i>		Phase I (609) 430-2880

## SOLID TUMORS

Product Name	Sponsor	Indication	Development Status
MDX-1307	Medarex <i>Princeton, NJ</i>		Phase I (609) 430-2880
MEDI-575	MedImmune <i>Gaithersburg, MD</i>		Phase I (301) 398-0000
MetmAb	Genentech <i>South San Francisco, CA</i>		Phase I (650) 225-1000
MGCD-265	MethylGene <i>Montreal, Canada</i>		Phase I (514) 337-3333
MGCD-0103	MethylGene <i>Montreal, Canada</i>	combination therapy (see also leukemia, lymphoma)	Phase I/II (514) 337-3333
		----- monotherapy	Phase I (514) 337-3333
MK-0731	Merck <i>Whitehouse Station, NJ</i>		Phase I completed (800) 672-6372
MK-1775	Merck <i>Whitehouse Station, NJ</i>		Phase I (800) 672-6372
MK-2206	Merck <i>Whitehouse Station, NJ</i>		Phase I (800) 672-6372
MK-5108	Merck <i>Whitehouse Station, NJ</i> Vertex Pharmaceuticals <i>Cambridge, MA</i>	refractory metastatic disease	Phase I (800) 672-6372
MKC1106-PP	MannKind <i>Valencia, CA</i>		Phase I (661) 775-5300
MLN4924	Millennium Pharmaceuticals <i>Cambridge, MA</i>	(see also leukemia)	Phase I (800) 390-5663
MLN8237	Millennium Pharmaceuticals <i>Cambridge, MA</i>	(see also brain, leukemia, lymphoma)	Phase I (800) 390-5663
MM-121	Merrimack Pharmaceuticals <i>Cambridge, MA</i>		Phase I (617) 441-1000
MN-201	Marillion Pharmaceuticals <i>Malvern, PA</i>	advanced solid tumors	Phase I (610) 644-5732
MORAb-004	Eisai <i>Woodcliff Lake, NJ</i>		Phase I (888) 422-4743
MP-470	SuperGen <i>Dublin, CA</i>		Phase I (925) 560-0100
MSX-122	Metastatix <i>Tucker, GA</i>	late-stage solid tumors	Phase I (678) 367-0720
NB-1011	Kiadis Pharma <i>Amsterdam, The Netherlands</i>		Phase I/II

## SOLID TUMORS

Product Name	Sponsor	Indication	Development Status
NKTR-105	Nektar Therapeutics <i>San Carlos, CA</i>		Phase I (650) 631-3100
NPI-0052	Nereus Pharmaceuticals <i>San Diego, CA</i>	(see also lymphoma, multiple myeloma)	Phase I (858) 587-4090
oleandrin (nerium oleander extract)	Ozelle Pharmaceuticals <i>San Antonio, TX</i>		Phase I (309) 949-3745
OMP-21M18	GlaxoSmithKline <i>Rsch. Triangle Park, NC</i> OncoMed Pharmaceuticals <i>Redwood City, CA</i>		Phase I (888) 825-5249 (650) 995-8200
omtriptolide	Pharmagenesis <i>Palo Alto, CA</i> Pierre Fabre Pharmaceuticals <i>Parsippany, NJ</i>		Phase I (650) 813-1818 (973) 898-1042
ON-01910	Onconova Therapeutics <i>Princeton, NJ</i>	(see also leukemia)	Phase I (609) 844-7735
<b>Oncaspar</b> <sup>®</sup> pegaspargase	Enzon Pharmaceuticals <i>Bridgewater, NJ</i>	combination therapy (see also lymphoma)	Phase I (866) 792-5172
OSI-906	OSI Pharmaceuticals <i>Melville, NY</i>		Phase I (631) 962-2000
OSI-930	OSI Pharmaceuticals <i>Melville, NY</i>		Phase I (631) 962-2000
PI3 kinase inhibitor	Genentech <i>South San Francisco, CA</i>		Phase I (650) 224-1000
palifosfamide (ZIO-201)	ZIOPHARM Oncology <i>New York, NY</i>	combination therapy (see also sarcoma)	Phase I (212) 214-0700
PCI-24781	Pharmacyclics <i>Sunnyvale, CA</i>	(see also leukemia)	Phase I (408) 774-0330
PDL-192	Facet Biotech <i>Redwood City, CA</i>		Phase I (650) 454-1000
PF-477736	Pfizer <i>New York, NY</i>		Phase I (860) 732-5156
PF-3814735	Pfizer <i>New York, NY</i>		Phase I (860) 732-5156
PF-4856882 (CovX045)	Pfizer <i>New York, NY</i>		Phase I (860) 732-5156
PG-11047	Progen Pharmaceuticals <i>Redwood City, CA</i>		Phase I (650) 610-7800
PM-00104	PharmaMar USA <i>Cambridge, MA</i>	(see also lymphoma)	Phase I (617) 868-3797
PM-02734	PharmaMar USA <i>Cambridge, MA</i>		Phase I (617) 868-3797
PRLX-93936	Prolexys Pharmaceuticals <i>Salt Lake City, UT</i>		Phase I (801) 303-1700

## SOLID TUMORS

Product Name	Sponsor	Indication	Development Status
PRX-321	Protox Therapeutics <i>Vancouver, Canada</i>	(see also brain)	Phase I completed (604) 688-0199
PX-478	Oncothyreon <i>Seattle, WA</i>	(see also lymphoma)	Phase I (206) 801-2100
PX-866	Oncothyreon <i>Seattle, WA</i>		Phase I (206) 801-2100
R547	Roche <i>Nutley, NJ</i>		Phase I (973) 235-5000
R763	EMD Serono <i>Rockland, MA</i> Rigel Pharmaceuticals <i>South San Francisco, CA</i>		Phase I (800) 283-8088 (650) 624-1100
R1530	Roche <i>Nutley, NJ</i>		Phase I (973) 235-5000
R4733	Roche <i>Nutley, NJ</i>		Phase I (973) 235-5000
R7112	Roche <i>Nutley, NJ</i>	(see also leukemia)	Phase I (973) 235-5000
R7167	Roche <i>Nutley, NJ</i>		Phase I (973) 235-5000
R7304	Roche <i>Nutley, NJ</i>		Phase I (973) 235-5000
R7347	Roche <i>Nutley, NJ</i>		Phase I (973) 235-5000
RH-1	Allos Therapeutics <i>Westminster, CO</i>	(see also lymphoma)	Phase I (303) 426-6262
rinfabate (rhIGFBP-3)	Insmed <i>Glen Allen, VA</i>		Phase I completed (804) 565-3000
RO-4987655	Roche <i>Nutley, NJ</i>		Phase I (973) 235-5000
RO-5083945	Roche <i>Nutley, NJ</i>		Phase I (973) 235-5000
sardomozide	Novartis Pharmaceuticals <i>East Hanover, NJ</i>	(see also lymphoma)	Phase I (888) 669-6682
SCH-900776	Schering-Plough <i>Kenilworth, NJ</i>	(see also lymphoma)	Phase I (908) 298-4000
SF1126	Semafore Pharmaceuticals <i>Indianapolis, IN</i>	(see also multiple myeloma)	Phase I (317) 876-3075
simotaxel	Taxolog <i>Fairfield, NJ</i> Wyeth Pharmaceuticals <i>Collegeville, PA</i>		Phase I (877) 829-6564 (800) 934-5556
SN2310	OncoGenex Pharmaceuticals <i>Bothell, WA</i>		Phase I (425) 686-1500

## SOLID TUMORS

Product Name	Sponsor	Indication	Development Status
SNS-032	Sunesis Pharmaceuticals <i>South San Francisco, CA</i>	(see also lymphoma)	Phase I/II (650) 266-3500
SNS-314	Sunesis Pharmaceuticals <i>South San Francisco, CA</i>		Phase I (650) 266-3500
sonpcizumab	Lpath <i>San Diego, CA</i>		Phase I (858) 678-0800
SPI-1620	Spectrum Pharmaceuticals <i>Irvine, CA</i>	adjunctive treatment	Phase I (949) 788-6700
<b>Sprycel™</b> dasatinib	Bristol-Myers Squibb <i>Princeton, NJ</i>	(see also leukemia, prostate)	in clinical trials (212) 546-4000
SSR97225	sanofi-aventis <i>Bridgewater, NJ</i>		Phase I (800) 633-1610
STA-9090	Synta Pharmaceuticals <i>Lexington, MA</i>	(see also leukemia)	Phase I (781) 274-8200
TAK593	Millennium Pharmaceuticals <i>Cambridge, MA</i>		Phase I (800) 390-5663
tanespimycin (Hsp90 inhibitor)	Bristol-Myers Squibb <i>Princeton, NJ</i>	(see also multiple myeloma)	Phase II (212) 546-4000
<b>Tarvacin™</b> bavituximab	Peregrine Pharmaceuticals <i>Tustin, CA</i>		Phase I (714) 508-6000
TGF beta inhibitor	Eli Lilly <i>Indianapolis, IN</i>		Phase I (800) 545-5979
TH-302	Threshold Pharmaceuticals <i>Redwood City, CA</i>	combination therapy (see also sarcoma)	Phase I/II (650) 474-8200
		----- monotherapy	Phase I (650) 474-8200
TLC388	Taiwan Liposome <i>Taipei, Taiwan</i>		Phase I
TRC-093	TRACON Pharmaceuticals <i>San Diego, CA</i>		Phase I (858) 550-0780
tricirbine (VQD-002)	VioQuest Pharmaceuticals <i>Basking Ridge, NJ</i>	(see also leukemia)	Phase I/II (908) 766-4400
TST-10088	Twinstrand Therapeutics <i>North Vancouver, Canada</i>		Phase I (604) 960-0857
UNBS-5162	Drais Pharmaceuticals <i>Bridgewater, NJ</i>	(see also lymphoma)	Phase I (908) 895-1200
V935	Merck <i>Whitehouse Station, NJ</i>		Phase III (800) 672-6372
<b>Velcade®</b> bortezomib	Millennium Pharmaceuticals <i>Cambridge, MA</i>	(see also lung, lymphoma, multiple myeloma)	Phase I/II (800) 390-5663
vinorelbine liposomal	Hana Biosciences <i>South San Francisco, CA</i>	(see also lymphoma)	Phase I (650) 588-6404

## SOLID TUMORS

Product Name	Sponsor	Indication	Development Status
VQD-001	VioQuest Pharmaceuticals <i>Basking Ridge, NJ</i>		Phase I/II (908) 766-4400
WX UK1	Wilex <i>Munich, Germany</i>	combination therapy	Phase I www.wilex.com
XL-147	Exelixis <i>South San Francisco, CA</i>		Phase I (650) 837-7000
XL-281 (RAF kinase inhibitor)	Bristol-Myers Squibb <i>Princeton, NJ</i> Exelixis <i>South San Francisco, CA</i>		Phase I (212) 546-4000
XL-518 (MEK inhibitor)	Exelixis <i>South San Francisco, CA</i> Genentech <i>South San Francisco, CA</i>		Phase I (650) 837-7000
XL-765	Exelixis <i>South San Francisco, CA</i>	(see also brain)	Phase I (650) 837-7000
XL-888	Exelixis <i>South San Francisco, CA</i>		Phase I (650) 837-7000
XMT-1001	Mersana Therapeutics <i>Cambridge, MA</i>	refractory metastatic disease	Phase I (617) 498-0020
ZEN-012	AEterna Zentaris <i>Warren, NJ</i>	(see also lymphoma)	Phase I (908) 626-5428
ZIO-301 (indibulin)	ZIOPHARM Oncology <i>New York, NY</i>	combination therapy	Phase I/II (646) 214-0700
		monotherapy	Phase I (646) 214-0700

## STOMACH CANCER

Product Name	Sponsor	Indication	Development Status
<b>Advexin</b> <sup>®</sup> contusugene ladenovec	Introgen Therapeutics <i>Austin, TX</i>	esophageal cancer (see also bladder, brain, breast, head/neck, lung, ovarian, prostate)	Phase I/II (512) 708-9310
AMG 102	Amgen <i>Thousand Oaks, CA</i>	gastric cancer (see also brain, colorectal, kidney, lung)	Phase I/II (805) 447-1000
AMG 386	Amgen <i>Thousand Oaks, CA</i>	gastrointestinal cancer (see also breast, kidney, ovarian, other)	Phase II (805) 447-1000
AV-951	AVEO Pharmaceuticals <i>Cambridge, MA</i>	gastrointestinal cancer (combination therapy) (see also kidney, lung)	Phase I/II (617) 299-5000

## STOMACH CANCER

Product Name	Sponsor	Indication	Development Status
<b>Avastin®</b> bevacizumab	Genentech <i>South San Francisco, CA</i>	gastric cancer (combination therapy), gastrointestinal stromal tumor (GIST) (see also brain, colorectal, head/neck, kidney, liver, lung, lymphoma, multiple myeloma, ovarian, pancreatic, prostate, other)	Phase III (650) 225-1000
CNF-2024	Biogen Idec <i>Cambridge, MA</i>	GIST (see also breast, leukemia, solid tumors)	Phase II (617) 679-2000
<b>Erbix®</b> cetuximab	Bristol-Myers Squibb <i>Princeton, NJ</i> Eli Lilly <i>Indianapolis, IN</i> ImClone Systems <i>New York, NY</i>	esophageal cancer, gastric cancer (see also bladder, colorectal, head/neck, lung, prostate)	Phase III (212) 546-4000 (800) 545-5979 (212) 645-1405
<b>Herceptin®</b> trastuzumab	Genentech <i>South San Francisco, CA</i>	esophageal cancer, gastric cancer (see also colorectal, ovarian, pancreatic, prostate, other)	Phase III (650) 225-1000
<b>Hycamtin®</b> topotecan	GlaxoSmithKline <i>Rsch. Triangle Park, NC</i>	esophageal cancer, gastric cancer (see also breast, colorectal, head/neck, kidney, leukemia, lung, lymphoma, multiple myeloma, ovarian, pancreatic, prostate, other)	Phase II (888) 825-5249
IMGN-242	ImmunoGen <i>Cambridge, MA</i>	gastric cancer (see also solid tumors)	Phase II (617) 995-2500
<b>Levulan® PD</b> aminolevulinic acid	DUSA Pharmaceuticals <i>Wilmington, MA</i>	gastrointestinal cancer (see also bladder, cervical, colorectal, lung)	in clinical trials (978) 657-7500
masitinib	AB Science USA <i>Short Hills, NJ</i>	GIST (see also leukemia, pancreatic)	Phase III (973) 218-2437
<b>OncoGel™</b>	Protherics <i>Brentwood, TN</i>	esophageal cancer (see also brain, pancreatic)	Phase II (615) 327-1027
<b>Oncophage®</b> vitespen	Antigenics <i>New York, NY</i>	(see also brain, colorectal, kidney, pancreatic, skin)	Phase I/II (866) 805-8994
<b>Opaxio™</b> paclitaxel poliglumex	Cell Therapeutics <i>Seattle, WA</i> Novartis Pharmaceuticals <i>East Hanover, NJ</i>	esophageal cancer, gastric cancer (see also lung, ovarian, other)	Phase I (800) 215-2355 (888) 669-6682
PN401	Wellstat Therapeutics <i>Gaithersburg, MD</i>	(see also colorectal, pancreatic)	Phase II (240) 631-2500
PX-12	Oncothyreon <i>Seattle, WA</i>	gastrointestinal cancer (see also pancreatic, other)	Phase I (206) 801-2100
retaspimycin (IPI 504) <b>(Orphan Drug)</b>	Infinity Pharmaceuticals <i>Cambridge, MA</i>	GIST (see also breast, lung)	Phase III (617) 453-1000

## STOMACH CANCER

Product Name	Sponsor	Indication	Development Status
<b>Sutent</b> <sup>®</sup> sunitinib	Pfizer New York, NY	gastric cancer (combination therapy) (see also breast, colorectal, liver, lung, pancreatic, prostate, sarcoma)	Phase II (860) 732-5156
TAS-102	Taiho Pharma USA Princeton, NJ	gastric cancer	Phase II (609) 750-5300
<b>Tasigna</b> <sup>®</sup> nilotinib (Orphan Drug)	Novartis Pharmaceuticals East Hanover, NJ	GIST (see also leukemia)	Phase III (888) 669-6682
tesetaxel (Orphan Drug)	Genta Berkeley Heights, NJ	second-line therapy (see also colorectal)	Phase II (908) 286-9800
<b>TheraCIM</b> <sup>™</sup> nimotuzumab	YM Biosciences Wayne, PA	esophageal cancer (neoadjuvant therapy) (see also brain, breast, prostate)	Phase II (610) 560-0600
<b>TNFerade</b> <sup>™</sup>	GenVec Gaithersburg, MD	esophageal cancer (see also colorectal, head/neck, pancreatic, skin)	Phase II completed (240) 632-0740
<b>Tykerb</b> <sup>®</sup> lapatinib	GlaxoSmithKline Rsch. Triangle Park, NC	gastric cancer (combination therapy) (see also brain, head/neck)	Phase III (888) 825-5249
<b>Xeloda</b> <sup>®</sup> capecitabine	Roche Nutley, NJ	esophageal cancer (see also colorectal)	Phase II (973) 235-5000
XL-880	Exelixis South San Francisco, CA GlaxoSmithKline Rsch. Triangle Park, NC	gastric cancer (see also head/neck, kidney)	Phase II (650) 837-7000 (888) 825-5249

## CANCER/CHEMOTHERAPY-RELATED CONDITIONS

Product Name	Sponsor	Indication	Development Status
802-2	Adeona Pharmaceuticals Ann Arbor, MI	graft-versus-host disease	Phase I/II (734) 332-7800
<b>Acapodene</b> <sup>®</sup> toremifene	GTx Memphis, TN	complications from androgen deprivation therapy (see also prostate)	application submitted (901) 523-9700
acetylcysteine	Adherex Technologies Durham, NC	chemoprotection	Phase I/II (919) 484-8484
AKR-501	Eisai Woodcliff Lake, NJ	idiopathic thrombocytopenic purpura	Phase II (888) 422-4743
<b>Aredia</b> <sup>®</sup> pamidronic acid	Novartis Pharmaceuticals East Hanover, NJ	cancer pain (see also multiple myeloma)	Phase III (888) 669-6682
<b>Bexxar</b> <sup>®</sup> tositumomab	GlaxoSmithKline Rsch. Triangle Park, NC	myeloablation (see also leukemia, lymphoma)	Phase II (888) 825-5249
CB-1400	Canopus BioPharma Studio City, CA	mucositis (prevention)	Phase II (818) 980-5008
CJ-15161	Pfizer New York, NY	cancer pain	Phase II (860) 732-5156

## CANCER/CHEMOTHERAPY-RELATED CONDITIONS

Product Name	Sponsor	Indication	Development Status
denosumab (AMG 162)	Amgen <i>Thousand Oaks, CA</i>	bone loss induced by hormone-ablation therapy in breast or prostate cancers, prevention of cancer-related bone damage in breast, prostate, or solid tumors (see also multiple myeloma, other)	Phase III (805) 447-1000
<b>Elitek</b> <sup>®</sup> rasburicase	sanofi-aventis <i>Bridgewater, NJ</i>	chemotherapy-induced hyperuricemia in adults	application submitted (800) 633-1610
<b>Enbrel</b> <sup>®</sup> etanercept	Amgen <i>Thousand Oaks, CA</i> Wyeth Pharmaceuticals <i>Collegeville, PA</i>	graft-versus-host disease	Phase II (805) 447-1000 (800) 934-5556
fentanyl sublingual spray	INSYS Therapeutics <i>Phoenix, AZ</i>	cancer pain	Phase III (602) 910-2617
fentanyl sublingual (SRSS-001)	Sosei R&D <i>Tokyo, Japan</i>	cancer pain	Phase I
fentanyl transdermal patch	Lavipharm <i>East Windsor, NJ</i>	cancer pain	Phase III (609) 448-3001
<b>Fosamax</b> <sup>®</sup> alendronic acid	Merck <i>Whitehouse Station, NJ</i>	bone loss associated with androgen deprivation therapy in prostate cancer	Phase II (800) 672-6372
golotimod	SciClone Pharmaceuticals <i>Foster City, CA</i>	mucositis (prevention)	Phase II (650) 358-3456
In-111-DAC	Naviscan <i>San Diego, CA</i>	cancer diagnostic imaging	Phase I (858) 587-3641
LGD-4665	GlaxoSmithKline <i>Rsch. Triangle Park, NC</i>	treatment-induced thrombocytopenia	Phase II (888) 825-5249
morphine intranasal	MDRNA <i>Bothell, WA</i>	cancer pain	Phase II (425) 908-3600
MRX-1024	Molecular Therapeutics <i>Ann Arbor, MI</i>	mucositis	Phase I (734) 259-4574
<b>Nasalfent</b> <sup>®</sup> fentanyl intranasal	Archimedes Pharma <i>Reading, United Kingdom</i>	cancer pain	Phase III
<b>Neumega</b> <sup>®</sup> oprelvekin	Wyeth Pharmaceuticals <i>Collegeville, PA</i>	chemotherapy-induced mucositis	Phase II (800) 934-5556
		graft-versus-host disease	Phase I/II (800) 934-5556
<b>Neuprex</b> <sup>®</sup> opebacan	XOMA <i>Berkeley, CA</i>	graft-versus-host disease in patients undergoing allogeneic hematopoietic stem cell transplantation	Phase I/II (510) 204-7200
<b>Nipent</b> <sup>®</sup> pentostatin	Hospira <i>Lake Forest, IL</i>	graft-versus-host disease (see also leukemia, lymphoma)	Phase II/III (224) 212-2000
NP-2 gene therapy	Diamyd Medical <i>Pittsburgh, PA</i>	cancer pain	Phase I (412) 770-1310

## CANCER/CHEMOTHERAPY-RELATED CONDITIONS

Product Name	Sponsor	Indication	Development Status
<b>Nplate™</b> romiplostim	Amgen <i>Thousand Oaks, CA</i>	chemotherapy-induced thrombocytopenia (see also leukemia)	Phase II (805) 447-1000
ondansetron oral film	MonoSol Rx <i>Warren, NJ</i> Strativa Pharmaceuticals <i>Woodcliff Lake, NJ</i>	chemotherapy- and radiotherapy-induced nausea and vomiting	Phase III (219) 672-8112 (201) 802-4206
ondansetron oral spray	NovaDel Pharma <i>Flemington, NJ</i> Strativa Pharmaceuticals <i>Woodcliff Lake, NJ</i>	chemotherapy- and radiotherapy-induced nausea and vomiting	Phase III (908) 782-3431 (201) 802-4206
<b>Onsolis™</b> fentanyl transmucosal	BioDelivery Sciences <i>Morrisville, NC</i> Meda Pharmaceuticals <i>Somerset, NJ</i>	cancer pain	application submitted (919) 653-5160
<b>orBec®</b> beclometasone <b>(Orphan Drug)</b>	DOR BioPharma <i>Ewing, NJ</i> Sigma-Tau Pharmaceuticals <i>Gaithersburg, MD</i>	graft-versus-host disease	application submitted (609) 538-8200 (800) 447-0169
		----- graft-versus-host disease (prevention)	Phase II (609) 538-8200 (800) 447-0169
PF-4383119 (tanezumab)	Pfizer <i>New York, NY</i>	cancer pain	Phase II (860) 732-5156
PHY-906	PhytoCeutica <i>New Haven, CT</i>	chemoprotection	Phase I/II (203) 777-3462
<b>Phytosel®</b>	iBioPharma <i>Newark, DE</i>	chemoprotection	Phase I (302) 355-0650
PMI-150 (ketamine intranasal)	Javelin Pharmaceuticals <i>Cambridge, MA</i>	cancer pain	Phase III (617) 349-4500
<b>Prochymal®</b> human mesenchymal stem cell therapy <b>(Orphan Drug)</b>	Osiris Therapeutics <i>Columbia, MD</i>	graft-versus-host disease	Phase III (443) 545-1800
<b>Prograf®</b> tacrolimus	Astellas Pharma US <i>Deerfield, IL</i>	graft-versus-host disease	application submitted (800) 727-7003
<b>Rapamune®</b> sirolimus	Wyeth Pharmaceuticals <i>Collegeville, PA</i>	bone marrow transplant rejection (see also unspecified)	Phase II (800) 934-5556
<b>Rapinyl™</b> fentanyl sublingual (EN 3267)	Orexo <i>Uppsala, Sweden</i> ProStrakan <i>Galashiels, United Kingdom</i>	breakthrough cancer pain	Phase III

## CANCER/CHEMOTHERAPY-RELATED CONDITIONS

Product Name	Sponsor	Indication	Development Status
<b>Reviroc™</b> (Orphan Drug)	Kiadais Pharma <i>St. Laurent, Canada</i>	bone marrow transplant rejection	Phase II (514) 336-4886
		graft-versus-host disease	Phase I/II (514) 336-4886
<b>Sativex®</b> dronabinol/ cannabidiol	Otsuka America Pharmaceutical <i>Rockville, MD</i>	cancer pain	Phase II/III (800) 562-3974
SCH-58500 (p53 gene therapy)	Schering-Plough <i>Kenilworth, NJ</i>	myeloablation (see also bladder, head/neck, liver, lung)	Phase I (908) 298-4000
STS	Adherex Technologies <i>Durham, NC</i>	chemoprotection	Phase III (919) 484-8484
<b>Tavocept™</b> dimesna	BioNumerik Pharmaceuticals <i>San Antonio, TX</i>	chemoprotection	Phase III (210) 614-1701
<b>Telintra®</b> ezatiostat	Telik <i>Palo Alto, CA</i>	chemotherapy-induced neutropenia (see also leukemia)	Phase II (650) 845-7700
<b>Titragesia™</b> fentanyl patch	ZARS Pharma <i>Salt Lake City, UT</i>	cancer pain	Phase III (801) 350-0202
totrombopag	GlaxoSmithKline <i>Rsch. Triangle Park, NC</i>	thrombocytopenia	Phase I (888) 825-5249
<b>Urso Forte™</b> ursodeoxycholic acid	Axcan Pharma <i>Birmingham, AL</i>	chemoprevention (see also colorectal)	Phase II (205) 991-8085
veltuzumab (IMMU-106)	Immunomedics <i>Morris Plains, NJ</i>	chemotherapy-induced immune thrombocytopenic purpura (see also lymphoma)	Phase I/II (973) 605-8200
<b>Voraxaze™</b> glucarpidase	Protherics <i>Brentwood, TN</i>	chemoprotection	application submitted (615) 327-1027
xaliproden	sanofi-aventis <i>Bridgewater, NJ</i>	chemotherapy-induced neuropathies	Phase III (800) 633-1610
ZRx101	ZelleRx <i>Chicago, IL</i>	graft-versus-host disease (see also kidney, multiple myeloma, skin)	Phase I (312) 243-5200

## OTHER CANCERS

Product Name	Sponsor	Indication	Development Status
3F8 mAb	United Therapeutics <i>Silver Spring, MD</i>	central nervous system cancer (see also brain)	Phase II (301) 608-9292
Å6	Angstrom Pharmaceuticals <i>Solana Beach, CA</i>	advanced gynecological cancer (see also ovarian)	Phase I (858) 314-2356

## OTHER CANCERS

Product Name	Sponsor	Indication	Development Status
aflibercept (VEGF-trap)	sanofi-aventis <i>Bridgewater, NJ</i> Regeneron Pharmaceuticals <i>Tarrytown, NY</i>	symptomatic malignant ascites (see also colorectal, lung, pancreatic, prostate)	Phase III (800) 633-1610 (914) 345-7400
AMG 386	Amgen <i>Thousand Oaks, CA</i>	fallopian tube cancer, peritoneal cancer (see also breast, kidney, ovarian, stomach)	Phase II (805) 447-1000
<b>Armala™</b> pazopanib	GlaxoSmithKline <i>Rsch. Triangle Park, NC</i>	fallopian tube cancer, peritoneal cancer (see also brain, breast, cervical, kidney, liver, lung, ovarian, sarcoma)	Phase II (888) 825-5249
ARQ-501 (beta lapachone)	ArQule <i>Woburn, MA</i>	leiomyoma (see also head/neck, pancreatic, solid tumors)	Phase II (781) 994-0300
ATI-BC-1	Algeta <i>Oslo, Norway</i>	bone cancer (metastatic from hormone-refractory prostate cancer)	Phase I www.algeta.com
atiprimod	Callisto Pharmaceuticals <i>New York, NY</i>	carcinoid tumor	Phase II (212) 297-0010
<b>Avastin®</b> bevacizumab	Genentech <i>South San Francisco, CA</i>	fallopian tube cancer, peritoneal cancer (see also brain, colorectal, head/neck, kidney, liver, lung, lymphoma, multiple myeloma, ovarian, pancreatic, prostate, stomach)	Phase III (650) 225-1000
axitinib	Pfizer <i>New York, NY</i>	thyroid cancer (see also colorectal, kidney, lung, solid tumors)	Phase II (860) 732-5156
AZD6244	AstraZeneca <i>Wilmington, DE</i>	thyroid cancer (see also leukemia, liver, lung, multiple myeloma, ovarian, pancreatic, skin)	Phase II (800) 236-9933
<b>Azedra™</b> iodine-labeled metaiodobenzyl- guanidine <b>(Orphan Drug)</b>	Molecular Insight Pharmaceuticals <i>Cambridge, MA</i>	neuroendocrine tumors (see also brain)	Phase I/II (617) 492-5554
<b>Bonefos®</b> clodronic acid	Bayer HealthCare Pharmaceuticals <i>Wayne, NJ</i>	cancer metastases	application submitted (888) 842-2937
BSI-201	BiPar Sciences <i>Brisbane, CA</i>	fallopian tube cancer, peritoneal cancer, uterine cancer (see also brain, breast, ovarian)	Phase II (650) 635-6050
catumaxomab	Fresenius Biotech North America <i>Waltham, MA</i>	malignant ascites (see also ovarian)	Phase II www.fresenius-biotech.com

## OTHER CANCERS

Product Name	Sponsor	Indication	Development Status
CDB-4124	Repros Therapeutics <i>The Woodlands, TX</i>	uterine leiomyoma	Phase III (281) 719-3400
CS-7017	Daiichi Sankyo <i>Parsippany, NJ</i>	thyroid cancer (see also lung)	Phase I (973) 359-2600
CX-4945	Cylene Pharmaceuticals <i>San Diego, CA</i>	giant lymph node hyperplasia (see also multiple myeloma, solid tumors)	Phase I (858) 875-5100
D4064A	Genentech <i>South San Francisco, CA</i>	fallopian tube cancer, peritoneal cancer (see also ovarian)	Phase I (650) 224-1000
deforolimus (MK-8669)	ARIAD Pharmaceuticals <i>Cambridge, MA</i> Merck <i>Whitehouse Station, NJ</i>	endometrial cancer (see also breast, lung, prostate, sarcoma)	Phase II (617) 494-0400 (800) 672-6372
denosumab (AMG 162)	Amgen <i>Thousand Oaks, CA</i>	prevention of bone metastases (see also multiple myeloma, cancer-related)	Phase III (805) 447-1000
DM-CHOC-PEN	Dekk-Tec <i>New Orleans, LA</i>	central nervous system cancer	Phase I (504) 583-6135
E7080	Eisai <i>Woodcliff Lake, NJ</i>	thyroid cancer (see also solid tumors)	Phase II (888) 422-4743
EC-20	Endocyte <i>West Lafayette, IN</i>	diagnosis of folate receptor- positive cancers	Phase II (765) 463-7175
EC-145	Endocyte <i>West Lafayette, IN</i>	endometrial cancer (see also lung, ovarian)	Phase II (765) 463-7175
everolimus	Novartis Pharmaceuticals <i>East Hanover, NJ</i>	neuroendocrine tumors (see also kidney, pancreatic)	Phase III (888) 669-6682
<b>Herceptin</b> <sup>®</sup> trastuzumab	Genentech <i>South San Francisco, CA</i>	salivary gland cancer (see also colorectal, ovarian, pancreatic, prostate, stomach)	Phase II (650) 225-1000
<b>Hycamtin</b> <sup>®</sup> topotecan	GlaxoSmithKline <i>Rsch. Triangle Park, NC</i>	uterine cancer (see also breast, colorectal, head/neck, kidney, leukemia, lung, lymphoma, multiple myeloma, ovarian, pancreatic, prostate, stomach)	Phase II (888) 825-5249
idronoxil	Marshall Edwards <i>North Ryde, Australia</i>	fallopian tube cancer (combination therapy) (see also ovarian, prostate)	Phase I/II
ING 1	Aduro BioTech <i>Berkeley, CA</i>	adenocarcinoma	Phase I (510) 848-4400
MCS110	Novartis Pharmaceuticals <i>East Hanover, NJ</i>	bone cancer (see also prostate)	Phase I/II (888) 669-6682
MER-101	Merrion Pharmaceuticals <i>Wilmington, NC</i>	bone cancer	Phase II (910) 799-1847

## OTHER CANCERS

Product Name	Sponsor	Indication	Development Status
MK-0646	Merck <i>Whitehouse Station, NJ</i>	neuroendocrine tumors (see also breast, lung, pancreatic)	Phase II (888) 669-6682
MK-0822	Merck <i>Whitehouse Station, NJ</i>	bone cancer	Phase III completed (800) 672-6372
motesanib	Amgen <i>Thousand Oaks, CA</i> Millennium Pharmaceuticals <i>Cambridge, MA</i>	thyroid cancer (see also breast, colorectal, lung)	Phase II (805) 447-1000 (800) 390-5663
NBI-42902	Neurocrine Biosciences <i>San Diego, CA</i>	uterine leiomyoma (see also breast, prostate)	Phase I (858) 617-7600
<b>Norprolac</b> <sup>®</sup> quinagolide	Ferring Pharmaceuticals <i>Suffern, NY</i>	prolactinoma	Phase II www.ferring.com
<b>Opaxio</b> <sup>™</sup> paclitaxel poliglumex	Cell Therapeutics <i>Seattle, WA</i> Novartis Pharmaceuticals <i>East Hanover, NJ</i>	peritoneal cancer (see also lung, ovarian, stomach)	Phase II (800) 215-2355 (888) 669-6682
		----- fallopian tube cancer	Phase I/II (800) 215-2355 (888) 669-6682
pasireotide	Novartis Pharmaceuticals <i>East Hanover, NJ</i>	neuroendocrine tumors	Phase I completed (888) 669-6682
PX-12	Oncothyreon <i>Seattle, WA</i>	metastatic disease (see also pancreatic, stomach)	Phase I (206) 801-2100
<b>Quadramet</b> <sup>®</sup> samarium sm-153 lexidronam injection	Cytogen <i>Princeton, NJ</i>	cancer metastases (see also multiple myeloma, prostate, sarcoma)	Phase III (800) 833-3533
quarfloxin	Cylene Pharmaceuticals <i>San Diego, CA</i>	neuroendocrine tumors	Phase II (858) 875-5100
RAV-12	Raven Biotechnologies <i>South San Francisco, CA</i>	adenocarcinoma (see also pancreatic)	Phase I/II (650) 624-2600
relacatib (cathepsin K inhibitor)	GlaxoSmithKline <i>Rsch. Triangle Park, NC</i>	cancer metastases	Phase II (888) 825-5249
<b>Revlimid</b> <sup>®</sup> lenalidomide	Celgene <i>Summit, NJ</i>	central nervous system cancer (see also leukemia, lymphoma, multiple myeloma, prostate)	Phase II (908) 673-9000
saracatinib	AstraZeneca <i>Wilmington, DE</i>	metastatic bone cancer	Phase II (800) 236-9933
seliciclib	Cyclacel Pharmaceuticals <i>Short Hills, NJ</i>	nasopharyngeal cancer (see also lung)	Phase II (973) 847-5955
<b>Somatuline Autogel</b> <sup>®</sup> lanreotide	Tercica <i>Brisbane, CA</i>	neuroendocrine tumors	Phase III (650) 624-4900

## OTHER CANCERS

Product Name	Sponsor	Indication	Development Status
<b>Tarceva®</b> erlotinib	Genentech South San Francisco, CA OSI Pharmaceuticals Melville, NY	gynecological cancer (combination therapy) (see also bladder, brain, breast, colorectal, head/neck, liver, lung)	Phase II (650) 224-1000 (800) 572-1932
<b>Taxotere®</b> docetaxel	sanofi-aventis Bridgewater, NJ	pediatric cancer	Phase III (800) 633-1610
V503	Merck Whitehouse Station, NJ	vulvovaginal cancer prevention (see also cervical)	Phase III (800) 672-6372
XL-184	Bristol-Myers Squibb Princeton, NJ Exelixis South San Francisco, CA	medullary thyroid cancer (see also brain)	Phase III (212) 546-4000
<b>Yondelis®</b> trabectedin	Johnson & Johnson Pharmaceutical Research & Development Raritan, NJ	endometrial cancer (see also breast, ovarian, prostate, sarcoma)	Phase II (800) 817-5286
<b>Zactima®</b> vandetanib	AstraZeneca Wilmington, DE	medullary thyroid cancer (see also brain, breast, lung)	Phase III (800) 236-9933
<b>Zybrestat™</b> fosbretabulin (Orphan Drug)	OXIGENE Waltham, MA	thyroid cancer (combination therapy) (see also head/neck, lung, ovarian)	Phase II/III (781) 547-5900

## UNSPECIFIED CANCERS

(DRUGS THAT HAVE POTENTIAL FOR ONE OR MORE OF THE PREVIOUS CANCERS)

Product Name	Sponsor	Indication	Development Status
1059615	GlaxoSmithKline Rsch. Triangle Park, NC		Phase I (888) 825-5249
1120212	GlaxoSmithKline Rsch. Triangle Park, NC		Phase I (888) 825-5249
AFX-9901	Afecta Pharmaceuticals Irvine, CA		in clinical trials (949) 253-4688
AG-24322	Pfizer New York, NY		Phase I (860) 732-5156
AGS-16M18	Agensys Santa Monica, CA Astellas Pharma US Deerfield, IL		Phase I (310) 820-8029 (800) 477-6472
ALT-801	Altor BioScience Miramar, FL		Phase I/II (954) 443-8600
anti-HGF mAb	Schering-Plough Kenilworth, NJ		Phase I (908) 298-4000
ANX-514 (docetaxel emulsion)	ADVENTRX Pharmaceuticals San Diego, CA		Phase I (858) 552-0866

## UNSPECIFIED CANCERS

(DRUGS THAT HAVE POTENTIAL FOR ONE OR MORE OF THE PREVIOUS CANCERS)

Product Name	Sponsor	Indication	Development Status
ARRY-300	Array BioPharma <i>Boulder, CO</i>		Phase I (303) 381-6600
ARRY-380	Array BioPharma <i>Boulder, CO</i>		Phase I (303) 381-6600
ARRY-614	Array BioPharma <i>Boulder, CO</i>		Phase I (303) 381-6600
AVR-118	Advanced Viral Research <i>Yonkers, NY</i>		Phase II (914) 376-7383
belotecan	ALZA <i>Mountain View, CA</i>		Phase I (650) 564-5000
BIO-109	Evolve Oncology <i>New York, NY</i>		Phase II (646) 723-8941
BIO-113	Evolve Oncology <i>New York, NY</i>		Phase II (646) 723-8941
BIO-121	Evolve Oncology <i>New York, NY</i>		Phase I (646) 723-8941
BIO-128	Evolve Oncology <i>New York, NY</i>		Phase I (646) 723-8941
BLX-883	Biolex <i>Pittsboro, NC</i>		Phase I (919) 542-9901
carbendazim	Arisyn Therapeutics <i>Frederick, MD</i>		Phase I (301) 644-3921
CLT-001	Cellerant Therapeutics <i>San Carlos, CA</i>		Phase II (650) 232-2122
CNDO-101	Coronado Biosciences <i>San Diego, CA</i>		Phase I (510) 396-5709
CPI-613	Cornerstone Pharmaceuticals <i>Cranbury, NJ</i>		Phase I (609) 409-7050
EC-0225	Endocyte <i>West Lafayette, IN</i>		Phase I (765) 463-7175
ENMD-1198	EntreMed <i>Rockville, MD</i>		Phase I (240) 864-2600
EZN-2208	Enzon Pharmaceuticals <i>Bridgewater, NJ</i>		Phase I (866) 792-5172
F50035	Merck <i>Whitehouse Station, NJ</i> Pierre Fabre Medicament <i>Castres, France</i>		Phase II (800) 672-6372
<b>Fibrovox™</b> cancer vaccine	Cytokine PharmaSciences <i>King of Prussia, PA</i>		Phase I (610) 687-1776
GPX-150	Gem Pharmaceuticals <i>Birmingham, AL</i>		Phase I/II (205) 982-0320

## UNSPECIFIED CANCERS

(DRUGS THAT HAVE POTENTIAL FOR ONE OR MORE OF THE PREVIOUS CANCERS)

Product Name	Sponsor	Indication	Development Status
HuCAL fully human antibody	Centocor Horsham, PA MorphoSys Martinsried, Germany		Phase I (610) 651-6000
IAP antagonist	Genentech South San Francisco, CA		Phase I (650) 224-1000
IMC-18F1	ImClone Systems New York, NY		Phase I (212) 645-1405
<b>Imprime PGG™</b>	Biothera Eagen, MN		Phase I (651) 675-0300
JNJ-26483327	Johnson & Johnson Pharmaceutical Research & Development Raritan, NJ		in clinical trials (800) 817-5286
KX2-391	Kinex Pharmaceuticals Buffalo, NY		Phase I (716) 881-8984
LBY135	Novartis Pharmaceuticals East Hanover, NJ		Phase I (888) 669-6682
LOR-2501	Lorus Therapeutics Toronto, Canada		Phase I (416) 798-1200
LR-103	Genzyme Cambridge, MA		Phase I (617) 252-7500
LY2157299	Eli Lilly Indianapolis, IN		Phase I (800) 545-5979
LY2603618	Eli Lilly Indianapolis, IN		Phase I (800) 545-5979
MK-2461	Merck Whitehouse Station, NJ		Phase I/II (800) 672-6372
MK-4101	Merck Whitehouse Station, NJ		Phase I (800) 672-6372
MK-8033	Merck Whitehouse Station, NJ		Phase I (800) 672-6372
MKI833	Wyeth Pharmaceuticals Collegeville, PA		Phase 0 (800) 934-5556
NRX-4204	NuRx Pharmaceuticals Irvine, CA		Phase I (949) 336-7111
OSI-7904L	OncoVista San Antonio, TX		Phase II (210) 677-6000
oxaliplatin liposomal	Mebiopharm Tokyo, Japan		Phase I www.mebiopharm.com
PBI-05204	Phoenix Biotechnology San Antonio, TX		Phase I (877) 593-8945
PCI-27483	Pharmacyclics Sunnyvale, CA		Phase I (408) 774-0330

## UNSPECIFIED CANCERS

(DRUGS THAT HAVE POTENTIAL FOR ONE OR MORE OF THE PREVIOUS CANCERS)

Product Name	Sponsor	Indication	Development Status
PF-337210	Pfizer <i>New York, NY</i>		Phase I (860) 732-5156
PF-562271	Pfizer <i>New York, NY</i>		Phase I (860) 732-5156
PF-2341066	Pfizer <i>New York, NY</i>		Phase I (860) 732-5156
PF-3084014	Pfizer <i>New York, NY</i>		Phase I (860) 732-5156
PF-3446962	Pfizer <i>New York, NY</i>		Phase I (860) 732-5156
PF-3732010	Pfizer <i>New York, NY</i>		Phase I (860) 732-5156
PF-4217903	Pfizer <i>New York, NY</i>		Phase I (860) 732-5156
PF-4554878	Pfizer <i>New York, NY</i>		Phase I (860) 732-5156
PF-4856884 (CovX060)	Pfizer <i>New York, NY</i>		Phase I (860) 732-5156
PF-4929113	Pfizer <i>New York, NY</i>		Phase I (860) 732-5156
PHA-848125	Nerviano Medical Sciences <i>Nerviano, Italy</i>		Phase I <a href="http://www.nervianoms.com">www.nervianoms.com</a>
plasmid DNA cancer vaccine	Merck <i>Whitehouse Station, NJ</i> Vical <i>San Diego, CA</i>		Phase I (800) 672-6372 (858) 646-1100
QBI-139	Quintessence Biosciences <i>Madison, WI</i>		Phase I (608) 441-2950
R306465	Johnson & Johnson Pharmaceutical Research & Development <i>Raritan, NJ</i>		Phase I (800) 817-5286
<b>Rapamune®</b> sirolimus	Wyeth Pharmaceuticals <i>Collegeville, PA</i>	(see also cancer-related)	Phase I (800) 934-5556
RDEA-119	Ardea Biosciences <i>San Diego, CA</i>		Phase I/II (858) 652-6500
RDEA-436	Ardea Biosciences <i>San Diego, CA</i>		Phase 0 (858) 652-6500
SJG-136	Ipsen <i>Milford, MA</i>		Phase I (508) 478-8900
SNX-5422	Serenex <i>Durham, NC</i>		Phase I (919) 281-6001
SRT-501	Sirtris Pharmaceuticals <i>Cambridge, MA</i>		Phase II (617) 252-6920

## UNSPECIFIED CANCERS

(DRUGS THAT HAVE POTENTIAL FOR ONE OR MORE OF THE PREVIOUS CANCERS)

Product Name	Sponsor	Indication	Development Status
TAK-285	Millennium Pharmaceuticals <i>Cambridge, MA</i>		Phase I (800) 390-5663
taltobulin	Wyeth Pharmaceuticals <i>Collegeville, PA</i>		Phase I (800) 934-5556
TRC-102	TRACON Pharmaceuticals <i>San Diego, CA</i>		Phase I (858) 550-0780
TRC-105	TRACON Pharmaceuticals <i>San Diego, CA</i>		Phase I (858) 550-0780
V930 (cancer vaccine)	Merck <i>Whitehouse Station, NJ</i> Vical <i>San Diego, CA</i>		Phase I (800) 672-6372 (858) 646-1100
VTX-2337	VentiRx Pharmaceuticals <i>San Diego, CA</i>		Phase I (858) 436-1530

The content of this report has been obtained through industry sources and the Adis "R&D Insight" database based on the latest information. **Report current as of March 23, 2009.** The information may not be comprehensive. For more specific information about a particular product, contact the individual company directly or go to [www.clinicaltrials.gov](http://www.clinicaltrials.gov). The entire series of *Medicines in Development* is available on PhRMA's web site.

A publication of PhRMA's Communications & Public Affairs Department. (202) 835-3460

[www.phrma.org](http://www.phrma.org) | [www.innovation.org](http://www.innovation.org) | [www.pparx.org](http://www.pparx.org) | [www.buysafedrugs.info](http://www.buysafedrugs.info) | [www.sharingmiracles.com](http://www.sharingmiracles.com)

Provided as a Public Service by PhRMA. Founded in 1958 as the Pharmaceutical Manufacturers Association.

Copyright © 2009 by the Pharmaceutical Research and Manufacturers of America. Permission to reprint is awarded if proper credit is given.

**actinic keratoses**—Roughness and thickening of the skin caused by over-exposure to the sun's ultraviolet rays. It can degenerate into a skin cancer called squamous cell carcinoma.

**adenocarcinoma**—Malignant tumor derived from a gland or glandular tissue.

**adjunctive treatment**—An auxiliary treatment that is secondary to the main treatment.

**adjuvant**—A substance or drug that aids another substance in its action.

**allogeneic**—Refers to having cell types that are distinct and cause reactions in the immune system.

**application submitted**—An application for marketing has been submitted by the company to the Food and Drug Administration (FDA).

**ascites**—Excess fluid in the space between the tissues lining the abdomen and abdominal organs (the peritoneal cavity).

**basal cell cancer**—Cancer of the lower layers of the skin.

**B-cell**—A class of white blood cells important to the body's immune system.

**biliary**—Relating to bile.

**carcinoma**—A malignant tumor that arises from epithelial tissues, such as skin.

**cervical**—Relating to the neck of the uterus.

**chemoprotection**—A therapeutic technique in which bone marrow cells are removed from an individual with cancer and are genetically modified to withstand higher doses of chemotherapy before being returned to the donor.

**cholangiocarcinoma**—A malignancy of the biliary duct system that may originate in the liver and extrahepatic bile ducts. More than 90 percent are **adenocarcinomas**, and the remainder are squamous cell tumors. Cholangiocarcinomas tend to grow slowly and to infiltrate the walls of the ducts. Each year, approximately 2,500 cases

occur, and the average incidence is 1 case per 100,000 people per year.

**cutaneous**—Pertaining to the skin.

**dysplasia**—Abnormal tissue development.

**gastric**—Of or relating to the stomach.

**GISTs**—Gastrointestinal stromal tumors are uncommon tumors of the GI tract. Not all GISTs are cancerous; some are benign. Although these cancers can arise anywhere in the GI tract, they occur most often in the stomach (60% to 70%) and less commonly in the small intestine (20% to 30%). The rest are found in the esophagus, large intestine, rectum, and anus. About 80% of people diagnosed with GIST are older than 50. It is slightly more common in men. Blacks are more likely to develop GISTs than whites.

**glioblastoma**—A fast growing and highly malignant type of brain tumor arising from glial (supporting) cells within the brain. There are about five to 10 new cases per million population per year in the United States, and the cause is unknown.

**glioma**—A type of brain tumor arising from the supporting glial cells within the brain. Gliomas make up about 60 percent of all primary brain tumors and are frequently malignant.

**graft-versus-host disease (GVHD)**—A complication in bone marrow transplants where immune system cells attack the transplant recipient's tissues.

**head and neck cancer**—The term given to a variety of malignant tumors that develop in the mouth, throat, paranasal sinuses, nasal cavity, larynx, and salivary glands. Many authorities also include skin tumors of the face and neck and tumors of the cervical lymph nodes. There are more than half a million survivors of oral, head, and neck cancer living in the United States today.

**hematological malignancies**—Cancers of the blood or blood-forming tissues, such as **leukemia**, **Hodgkin's** and **non-Hodgkin's lym-**

**phomas**, AIDS-related malignancies, **multiple myeloma**, myelodysplasia and myeloproliferative disorders.

**hepatocellular cancer/carcinoma**—A cancer that begins in the liver cells.

**hyperuricemia**—An abnormally high uric acid level in the blood.

**imaging agent**—A substance used to enhance x-ray images of organs and spaces in the body.

**intraepithelial neoplasia, anal (AIN) & cervical (CIN)**—AIN is a consequence of chronic human papillomavirus infection in the anal canal and appears to be driven by high viral loads of human papillomavirus. What is known of its natural history resembles that of cervical intraepithelial neoplasia. **Dysplasia** and cervical intraepithelial neoplasia (CIN) are different terms or names for the same condition—it is a precursor to **cervical cancer**. CIN may be mild, moderate or severe.

**Kaposi's sarcoma**—A rare, malignant skin tumor that occurs in some AIDS patients. It can be accompanied by fever, enlarged lymph nodes and gastrointestinal problems.

**leiomyoma**—A benign neoplasm derived from smooth muscle.

**leukemia**—A form of cancer in which abnormally growing white blood cells are scattered throughout the body and bone marrow. They can take over the marrow and prevent it from making enough normal blood cells (white, red and platelets), leaving the patient highly susceptible to serious infections, anemia and bleeding episodes. The cells can also spill into the blood, infiltrating and interfering with the function of other organs. The four main types of leukemia are: **acute lymphoblastic leukemia (ALL)**, **acute myeloid leukemia (AML)**, **chronic lymphocytic leukemia (CLL)**, and **chronic myeloid leukemia (CML)**. The acute types have a rapid onset, and overwhelming infection or blood loss can cause death. The chronic forms progress much more slowly.

**lung cancer**—The leading cause of cancer deaths in both men and

women. There are several types of lung cancer, the most common being squamous cell carcinoma, small (oat) cell carcinoma, adenocarcinoma and large cell carcinoma. Each has a different growth pattern and response to treatment. The squamous cell, small cell and large cell types are all strongly associated with tobacco abuse.

**lymphoma**—Cancers in which the cells of lymphoid tissue, found mainly in the lymph nodes and spleen, multiply unchecked. Lymphomas fall into two categories: Hodgkin disease, characterized by a particular kind of abnormal cell, and **non-Hodgkin lymphomas**, which vary in their malignancy according to the nature and activity of the abnormal cells. **Mantle cell lymphoma** is a type of non-Hodgkin lymphoma.

**macroglobulinemia**—A disorder in which plasma cells produce an excessive quantity of macroglobulins (large antibodies) that accumulate in the blood. It results from a group of abnormal, cancerous lymphocytes and plasma cells. Men are affected more often than women, and the average age at onset is 65.

**mastocytosis**—A condition characterized by infiltration of mast cells into the tissues of the body. Mast cells are connective tissue cells which release chemicals including histamine that are very irritating and cause itching, swelling, and fluid leakage from cells.

**medullary**—Relating to the medulla (any soft marrow-like structure, especially the innermost part) or marrow.

**melanoma**—A cancer made up of pigmented (usually brown-colored) skin cells anywhere in the body.

**mesothelioma**—A tumor of the lining of the lung and chest cavity (the pleura).

**metastases/metastatic**—Areas of secondary cancer that have spread from the primary or original cancer site.

**mucositis**—The swelling, irritation, and ulceration of the mucosal cells that line the digestive tract. Mucositis

can occur anywhere along the digestive tract from the mouth to the anus. It can be a very troublesome and painful side effect of chemotherapy.

**multiple myeloma**—A malignant condition of middle to old age, characterized by the uncontrolled proliferation and disordered function of plasma cells in the bone marrow. The condition, which makes the patient particularly prone to infection, is rare, with about three new cases annually per 100,000 population.

**myeloablation**—A severe form of myelosuppression, a condition in which bone marrow activity is decreased, resulting in fewer red blood cells, white blood cells, and platelets. It is a side effect of some cancer treatments.

**myelodysplastic syndromes (MDS)**—Blood disorders that ultimately are fatal. Patients usually succumb to infections or bleeding. The term “preleukemia” has been used to describe these disorders.

**neoadjuvant therapy**—Chemotherapy, radiation therapy, or hormone therapy given before the primary or main treatment. Neoadjuvant therapy, like chemotherapy and radiation therapy, is often given before surgery to reduce the size of a tumor or to make surgery less complicated.

**neuroblastoma**—A tumor of the adrenal glands or sympathetic nervous system (the part of the nervous system responsible for certain automatic body functions, such as the control of heart rate). Neuroblastomas are the most common extracranial (outside the skull) solid tumors of childhood.

**osteosarcoma**—Cancer of the bone that occurs predominantly in adolescents and young adults. It accounts for 5 percent of cancer in children

**peritoneal**—Relating to the peritoneum, the membrane that lines the abdominal cavity and covers most of the abdominal organs.

**Phase 0**—First-in-human trials conducted in accordance with FDA’s 2006 guidance on exploratory Investigational New Drug (IND) studies designed to speed up development of promising drugs by establishing very early on whether the agent behaves in human subjects as was anticipated from preclinical studies.

**Phase I**—Safety testing and pharmacological profiling of new drugs in small numbers of humans.

**Phase II**—Effectiveness testing and identification of side effects of new drugs in humans.

**Phase III**—Extensive clinical trials in humans to verify effectiveness and monitor adverse reactions of new drugs.

**prolactinoma**—A noncancerous pituitary tumor that produces a hormone called prolactin, which results in too much prolactin in the blood.

**refractory**—Resistant to treatment or cure.

**sarcoma**—A malignant tumor that arises from deep body tissues, such as muscle, bone or fibrous tissue.

**T-cell**—One of two main classes of white blood cells called lymphocytes, which are important to the body’s disease-fighting immune system.

**thrombocytopenia**—A reduction in the number of platelet cells in the blood, which causes a tendency to bleed, especially from the smaller blood vessels.

**thymoma**—Although rare, thymomas are the most common tumor of the thymus, a small organ located in the upper chest just below the neck that produces certain types of white blood cells (lymphocytes) before birth and during childhood. Thymomas arise from thymic epithelial cells, which make up the covering of the thymus. Up to 40 percent of thymomas are invasive. They affect men and women equally and are usually diagnosed between the ages of 40 and 60. Thymomas are uncommon in children.

**unresectable**—Unable to be removed (resected) by surgery.

# SELECTED FACTS ABOUT CANCER IN THE UNITED STATES

---

## Overview<sup>1</sup>

- In 2008, more than 1.4 million new cancer cases are expected to be diagnosed. The National Cancer Institute estimates that approximately 10.1 million Americans with a history of cancer were alive in January 2002. The 5-year relative survival rate for all cancers diagnosed between 1996 and 2003 is 66 percent, up from 50 percent in the mid-70s.
  - Men have a little less than a 1 in 2 lifetime risk of developing cancer, and for women, the risk is a little more than 1 in 3. About 77 percent of all cancers are diagnosed in people ages 55 and older.
  - Scientific evidence suggests that about one-third of the cancer deaths expected this year will be related to overweight or obesity, physical inactivity, and nutrition, and thus could be prevented.
  - Cancer is the second leading cause of death by disease—1 of every 4 deaths—in the United States, exceeded only by heart disease. This year, an estimated 565,650 are expected to die of cancer, more than 1,500 people a day.
- 

## Costs<sup>1</sup>

- The National Institutes of Health estimate overall costs for cancer in 2007 at \$219.2 billion: \$89 billion for direct medical costs (total of all health expenditures); \$18.2 billion for indirect morbidity costs (e.g., cost of lost productivity due to illness); and \$112 billion for indirect mortality costs (cost of lost productivity due to premature death).
- 

## Bladder (Urinary) Cancer<sup>1</sup>

- Nearly 69,000 new cases of **bladder cancer** are expected in 2008. The incidence rate is nearly four times higher in men than in women and almost two times higher in whites than in African Americans.
  - **Bladder cancer** will cause more than 14,000 deaths in 2008. Mortality rates have continued to decrease since the late '70s, although the rate of decrease slowed in the most recent time period (0.2 percent a year from 1987-2004 compared with 2.1 percent a year from 1977-1987).
- 

## Breast Cancer<sup>1</sup>

- After continuously increasing for more than two decades, **female breast cancer** incidence rates decreased by 3.5 percent per year from 2001-2004. From 1992-2004, incidence rates decreased among American Indians/Alaska Natives (1.5 percent per year) and did not change significantly among Asian Americans/Pacific Islanders or Hispanics/Latinas.
  - Death rates from **breast cancer** have steadily decreased in women since 1990, with larger decreases in women younger than age 50 (a decrease of 3.3 percent per year) than in those age 50 and older (2 percent per year). From 1995-2004, female breast cancer death rates declined by 2.4 percent per year in whites and Hispanics/Latinas, 1.6 percent per year in African Americans, and remained unchanged among Asian Americans/Pacific Islanders and American Indians/Alaska Natives. The decrease in breast cancer death rates represents progress in both earlier detection and improved treatment.
- 

## Cervical Cancer/Uterine (Endometrial) Cancer<sup>1</sup>

- An estimated 11,070 cases of invasive **cervical cancer** are expected to be diagnosed in 2008. Incidence rates have decreased steadily over the past several decades in both white and African-American women. Mortality rates have also declined steadily; an estimated 3,870 cervical cancer deaths are expected in 2008.
  - More than 40,000 cases of **cancer of the uterine corpus** (body of the uterus), usually of the endometrium or lining of the uterus, are expected to be diagnosed in 2008.
- 

## Colorectal Cancer<sup>1</sup>

- An estimated 108,070 **colon** and 40,740 **rectal cancer** cases are expected to occur in 2008. **Colorectal cancer** is the third most common cancer in men and women. More than 90 percent of **colorectal cancer** cases are diagnosed in people over age 50.

# SELECTED FACTS ABOUT CANCER IN THE UNITED STATES

---

## Colorectal Cancer<sup>1</sup> (continued)

- Nearly 50,000 deaths from colorectal cancer are expected to occur this year, accounting for 9 percent of all cancer deaths. Mortality rates from colorectal cancer have declined in both men and women over the past two decades with a steeper decline in the most recent time period (1.8 percent per year from 1985-2002 compared to 4.7 percent from 2002-2004). That decrease reflects declining incidence rates and improvements in early detection and treatment.
- 

## Leukemia<sup>1</sup>

- An estimated 44,270 new **leukemia** cases are expected in 2008, with slightly more cases of chronic (19,940) than acute (18,720) forms of the disease.
  - Although often thought of as primarily a childhood disease, leukemia is diagnosed 10 times more often in adults than in children. **Acute lymphocytic leukemia** accounts for approximately 72 percent of the leukemia cases among children. In adults, the most common types are **acute myeloid leukemia** (about 13,290 cases) and **chronic lymphocytic leukemia** (about 15,110 cases).
- 

## Lung Cancer<sup>1</sup>

- The estimated 215,020 new cases of **lung cancer** expected in 2008 will account for about 15 percent of cancer diagnoses. The incidence rate is declining significantly in men, from a high of 102 cases per 100,000 in 1984 to 73.6 in 2004. In women, the rate is approaching a plateau after a long period of increase.
  - **Lung cancer** is the leading cause of cancer death in men and women. The estimated 161,840 deaths expected this year will account for about 29 percent of all cancer deaths. Death rates declined significantly in men from 1991 to 2002 by about 1.9 percent per year. Since 1987, more women have died each year from lung cancer than from breast cancer. Female lung cancer death rates are approaching a plateau after continuously increasing for several decades, reflecting the decrease in smoking rates over the past 30 years.
- 

## Lymphoma<sup>1</sup>

- Of the estimated 74,340 new cases of **lymphoma** this year, 8,220 will be **Hodgkin's lymphoma** and 66,120 will be **non-Hodgkin's lymphoma (NHL)**.
  - Since the early 1970s, incidence rates for **NHL** have nearly doubled. Although some of this increase is due to AIDS-related NHL, for the most part, the rise is unexplained. Since 1991, increasing NHL incidence has been confined to women.
  - Over the past 30 years, incidence rates for **Hodgkin's lymphoma** have decreased in men (0.7 percent per year) while they slightly increased in women (0.4 percent per year).
- 

## Ovarian Cancer<sup>1</sup>

- The estimated 21,650 new cases of **ovarian cancer** expected this year would account for about 3 percent of all cancers among women. It ranks second among gynecologic cancers, following cancer of the uterine corpus.
  - **Ovarian cancer** causes more deaths than any other cancer of the female reproductive system—15,520 deaths are expected in 2008.
- 

## Pain

- Most patients with cancer fear **pain** as their worst symptom. Indications are that 30 percent of those with newly diagnosed cancer and 80 percent with previously diagnosed cancer have complaints of pain.<sup>2</sup>
- Studies have shown that 90 percent of patients with advanced cancer experience severe **pain** and that pain occurs in 30 percent of all cancer patients, regardless of the stage of the disease. As many as 50 percent of patients may be undertreated for cancer pain, yet not all cancer patients feel pain, and pain is rarely a sign of early cancer. Pain usually increases as cancer progresses.<sup>3</sup>

# SELECTED FACTS ABOUT CANCER IN THE UNITED STATES

---

## Pain (continued)

- The most common **cancer pain** is from tumors that metastasize to the bone—as many as 60 percent to 80 percent of cancer patients with bone metastasis experience pain. The second most common cancer pain is caused by tumors infiltrating the nerve and hollow viscus. Tumors near neural structures may cause the most severe pain. The third most common pain associated with cancer occurs as a result of chemotherapy, radiation, or surgery. Cancer pain also may occur in different parts of the body. In one study, more than 80 percent of patients experienced two distinct pains, and more than 30 percent experienced three distinct pains.<sup>3</sup>
  - Fewer than half of cancer patients who experience pain receive adequate treatment for their pain. More than half of all hospitalized patients experienced pain in the last days of their lives, and although therapies are present to alleviate most pain for those dying of cancer, research shows that 50 percent to 75 percent of patients die in moderate to severe pain.<sup>4</sup>
  - African Americans and Hispanics are affected by racial profiling for diversion and under-treatment for **pain** by some physicians. This is compounded by a lack of research on pain across racial and ethnic differences as well as cultural attitudes toward pain care. One study found that more than 80 percent of African-American patients and 80 percent of Hispanic patients waited until their pain severity was a 10 on a 10-point scale before calling their healthcare provider or oncology clinic for assistance with pain management.<sup>4</sup>
  - **Chronic pain** has been said to be the most costly health problem in America. Estimated annual costs, including direct medical expenses, lost income, lost productivity, compensation payments, and legal charges, are about \$90 billion.<sup>5</sup>
- 

## Pancreatic Cancer<sup>1</sup>

- Nearly 38,000 new cases of **pancreatic cancer** are expected to occur in the United States in 2008. Incidence rates of pancreatic cancer have been stable in men since 1993 and in women since 1983.
  - More than 34,000 deaths from **pancreatic cancer** are expected this year. The death rate has continued to decline since 1975 in men, while it has leveled off in women after increasing from 1975-1984.
- 

## Prostate Cancer<sup>1</sup>

- **Prostate cancer** is the most frequently diagnosed cancer in men—more than 186,000 new cases will be diagnosed in 2008. Incidence rates are significantly higher in African-American men than in white men. Rates peaked in white men in 1992 (237.8 per 100,000 men) and in African-American men in 1993 (343.1 per 100,000 men).
  - **Prostate cancer** is a leading cause of cancer death in men, and an estimated 28,660 are expected to die this year. Although death rates have decreased more rapidly among African-American men than among white men since the early 1990s, rates in African-American men still remain more than twice as high as those in white men.
- 

## Skin Cancer<sup>1</sup>

- The most serious form of **skin cancer** is **melanoma**, which is expected to be diagnosed in more than 62,000 people in 2008. During the 1970s, the incidence rate for melanoma increased rapidly by about 6 percent annually. From 1981-2000, the rate of increase slowed to 3 percent per year, and since 2000, melanoma incidence has been stable. Melanoma is primarily a disease of whites—rates are more than 10 times higher in whites than in African Americans.
- **Skin cancer** will cause more than 11,000 deaths in 2008—8,420 from **melanoma** and 2,780 from other nonepithelial skin cancers. The death rate for melanoma has been decreasing rapidly in whites younger than age 50, by 3 percent a year since 1991 in men and by 2.3 percent a year since 1985 in women. In those older than age 50, rates have been stable since 1998 in men and since 1990 in women.

# SELECTED FACTS ABOUT CANCER IN THE UNITED STATES

## New Cancer Cases/Deaths<sup>1</sup>

Cancer Type	Estimated 2008 New Cases	Estimated 2008 Deaths
All Sites	1,437,180	565,650
Male	745,180	294,120
Female	692,000	271,530
Acute Lymphocytic Leukemia	5,430	1,460
Male	3,220	800
Female	2,210	660
Acute Myeloid Leukemia	13,290	8,820
Male	7,200	5,100
Female	6,090	3,720
Bladder Cancer	68,810	14,100
Male	51,230	9,950
Female	17,580	4,150
Bone Cancer (and joints)	2,380	1,470
Male	1,270	820
Female	1,110	650
Brain Cancer (and other nervous system)	21,810	13,070
Male	11,780	7,420
Female	10,030	5,650
Breast Cancer	184,450	40,930
Male	1,990	450
Female	182,460	40,480
Cervical Cancer/Uterine Cancer	51,170	11,340
Male	—	—
Female	51,170	11,340
Chronic Lymphocytic Leukemia	15,110	4,390
Male	8,750	2,600
Female	6,360	1,790
Chronic Myeloid Leukemia	4,830	450
Male	2,800	200
Female	2,030	250
Colorectal Cancer	148,810	49,960
Male	77,250	24,260
Female	71,560	25,700
Esophageal Cancer	16,470	14,280
Male	12,970	11,250
Female	3,500	3,030

# SELECTED FACTS ABOUT CANCER IN THE UNITED STATES

## New Cancer Cases/Deaths<sup>1</sup> (continued)

Cancer Type	Estimated 2008 New Cases	Estimated 2008 Deaths
Kidney Cancer (and renal pelvis)	54,390	13,010
Male	33,130	8,100
Female	21,260	4,910
Leukemia (all types)	44,270	21,710
Male	25,180	12,460
Female	19,090	9,250
Liver Cancer	21,370	18,410
Male	15,190	12,570
Female	6,180	5,840
Lung Cancer (and bronchus)	215,020	161,840
Male	114,690	90,810
Female	100,330	71,030
Lymphoma (all types)	74,340	20,510
Male	39,850	10,490
Female	34,490	10,020
Lymphoma (non-Hodgkin's)	66,120	19,160
Male	35,450	9,790
Female	30,670	9,370
Melanoma-Skin Cancer	62,480	8,420
Male	34,950	5,400
Female	27,530	3,020
Multiple Myeloma	19,920	10,690
Male	11,190	5,640
Female	8,730	5,050
Ovarian Cancer	21,650	15,520
Male	—	—
Female	21,650	15,520
Pancreatic Cancer	37,680	34,290
Male	18,770	17,500
Female	18,910	16,790
Prostate Cancer	186,320	28,660
Male	186,320	28,660
Female	—	—
Stomach Cancer	21,500	10,880
Male	13,190	6,450
Female	8,310	4,430

# SELECTED FACTS ABOUT CANCER IN THE UNITED STATES

---

## Sources:

1. *Cancer Facts & Figures 2008*, American Cancer Society ([www.cancer.org](http://www.cancer.org))
2. Journal of the American Osteopathic Association ([www.jaoa.org](http://www.jaoa.org))
3. Oncology Channel® ([www.oncologychannel.com](http://www.oncologychannel.com))
4. American Pain Foundation ([www.painfoundation.org](http://www.painfoundation.org))
5. Oregon Health and Science University ([www.ohsu.edu](http://www.ohsu.edu))

## THE DRUG DISCOVERY, DEVELOPMENT AND APPROVAL PROCESS

It takes 10-15 years on average for an experimental drug to travel from the lab to U.S. patients. Only five in 5,000 compounds that enter preclinical testing make it to human testing. One of these five tested in people is approved.

Discovery/ Preclinical Testing		Clinical Trials			FDA	Phase IV
		Phase I	Phase II	Phase III		
Years	6.5	1.5	2	3.5	1.5	
Test Population	Laboratory and animal studies	20 to 100 healthy volunteers	100 to 500 patient volunteers	1,000 to 5,000 patient volunteers	Review process/ approval	Additional post-marketing testing required by FDA
Purpose	Assess safety, biological activity and formulations	Determine safety and dosage	Evaluate effectiveness, look for side effects	Confirm effectiveness, monitor adverse reactions from long-term use		
Success Rate	5,000 compounds evaluated	5 enter trials			1 approved	

## THE DRUG DEVELOPMENT AND APPROVAL PROCESS

The U.S. system of new drug approvals is perhaps the most rigorous in the world.

It takes 10-15 years, on average, for an experimental drug to travel from lab to U.S. patients, according to the Tufts Center for the Study of Drug Development, based on drugs approved from 1994 through 1998. Only five in 5,000 compounds that enter preclinical testing make it to human testing. And only one of those five is approved for sale.

On average, it costs a company \$1.3 billion to get one new medicine from the laboratory to U.S. patients, according to a 2007 study by the Tufts Center for the Study of Drug Development.

Once a new compound has been identified in the laboratory, medicines are developed as follows:

**Preclinical Testing.** A pharmaceutical company conducts laboratory and animal studies to show biological activity of the compound against the targeted disease, and the compound is evaluated for safety.

**Investigational New Drug Application (IND).** After completing preclinical testing, a company files an IND with the U.S. Food and Drug Administration (FDA) to begin to test the drug in people. The IND becomes effective if FDA does not disapprove it within 30 days. The IND shows results of previous experiments; how, where and by whom the new studies will be conducted; the chemical structure of the compound; how it is thought to work in the body; any toxic effects found in the animal studies; and how the compound is manufactured. All clinical trials must be reviewed and approved by the Institutional Review Board (IRB) where the trials will be conducted. Progress reports on clinical trials must be submitted at least annually to FDA and the IRB.

**Clinical Trials, Phase I.** These tests involve about 20 to 100 normal, healthy volunteers. The tests study a drug's safety profile, including the safe dosage range. The studies also determine how a drug is absorbed, distributed, metabolized, and excreted as well as the duration of its action.

**Clinical Trials, Phase II.** In this phase, controlled trials of approximately 100 to 500 volunteer patients (people with the disease) assess a drug's effectiveness.

**Clinical Trials, Phase III.** This phase usually involves 1,000 to 5,000 patients in clinics and hospitals. Physicians monitor patients closely to confirm efficacy and identify adverse events.

**New Drug Application (NDA)/Biologic License Application (BLA).** Following the completion of all three phases of clinical trials, a company analyzes all of the data and files an NDA or BLA with FDA if the data successfully demonstrate both safety and effectiveness. The applications contain all of the scientific information that the company has gathered. Applications typically run 100,000 pages or more. The average review time for the 24 new therapeutics approved by the FDA in 2008 was 17.8 months.

**Approval.** Once FDA approves an NDA or BLA, the new medicine becomes available for physicians to prescribe. A company must continue to submit periodic reports to FDA, including any cases of adverse reactions and appropriate quality-control records. For some medicines, FDA requires additional trials (Phase IV) to evaluate long-term effects.

Discovering and developing safe and effective new medicines is a long, difficult, and expensive process. Pharmaceutical companies invested an estimated \$65.2 billion in research and development in 2008.

*Medicines in Development for Cancer* is presented by PhRMA in cooperation with the following organizations:

American Brain Tumor Association  
American Nurses Association  
Association of Community Cancer Centers  
Burger King Cancer Caring Center  
Chemotherapy Foundation  
Oncology Nursing Society  
PAACT (Patient Advocates for Advanced  
Cancer Treatments)

Being listed in this report in no way implies that the above-mentioned organizations endorse or recommend the use of any of the products in development contained in this publication. For further information, patients should consult their physicians or health care providers.



*New Medicines. New Hope.®*

Pharmaceutical Research and Manufacturers of America  
950 F Street, NW  
Washington, DC 20004